annual review troper launna enilkhtimsoxalg feel better live longer improving performance ever day wwwgskcom annual report glaxosmithkline mission global quest improve quality human life glaxosmithkline plc enabling people feel better live longer annual report year ended st december spirit undertake quest enthusiasm entrepreneurs excited constant search innovation value performance achieved integrity attain success world class global leader every one people contributing passion unmatched sense urgency strategic intent want become indisputable leader industry glaxosmithkline plc english public limited company shares listed london stock exchange new york stock exchange contents report annual report glaxosmithkline plc year ended st december prepared accordance report directors united kingdom requirements financial summary summary report year annual review joint statement chairman chief executive officer intended investor needing full detail description business annual report produced separate document corporate governance annual review includes joint statement chairman remuneration report chief executive officer summary review operations operating financial review prospects summary financial statements summary remuneration report financial statements directors statements responsibility annual review issued shareholders annual independent auditors report report issued shareholders elected receive consolidated statement profit loss documents available glaxosmithklines corporate consolidated statement total recognised gains losses website wwwgskcom consolidated statement cash flow consolidated balance sheet website reconciliation movements equity shareholders funds glaxosmithklines website wwwgskcom gives additional company balance sheet information group information made available notes financial statements website constitute part annual report investor information front cover living next welsh coastline uk naturally drew financial record young jack fraser sea chance develop shareholder return surfing skills however asthma symptoms shareholder information tightness chest meant could breathe properly share capital reluctant go outside mother catherine heard taxation information shareholders seretide friend eventually obtained glossary terms prescription son annual report approved board result jack seen practising surfing skills directors rd march published regular basis also developed keen interest golf th march contact details glaxosmithkline glaxosmithkline financial summary joint statement chairman chief executive officer growth statutory results cer fundamentally pharmaceutical industry bright future place debate rights wrongs turnover ageing populations developed world continuing unmet challenges pharmaceutical industrys traditional business medical need many diseases mean demand new model place us reassure shareholders trading profit better pharmaceutical products continue grow strongly every aspect model review order continue profit taxation years ahead development medicines basis reconciles earningsnet income responsibility society fair return shareholders industry however also faces formidable challenges determined change times imaginatively flexibly basic earnings per share p p threaten pharmaceutical industrys traditional business effectively fight believe best serve model shareholders reassured glaxosmithklines dividends per share p p long term interests glaxosmithkline one worlds management understands challenges company leading producers medicines making substantial progress responding merger restructuring disposal subsidiaries industry currently experiencing decline research robust financial performance trading profit development productivity glaxosmithkline tackled business performance earnings per share grew profit taxation radically redesigning rd organisation new structure per cent line guidance issued earningsnet income based seven centres excellence drug discovery trading profit rose nine per cent billion working well developing high quality compounds operating cash flow billion also raised dividend earnings per share p p ever december rd day able pence demonstrate progress made building business performance exceptionally strong product pipeline provide fuel total pharmaceutical turnover grew five per cent billion us sales also five per cent billion turnover future growth achievement confirms underlying strength resilience trading profit also seeing increasingly aggressive generics industry business particularly given continued generic erosion profit taxation eroding period medicine patent year sales augmentin introduction generic protected protection crucial enabling competition paxil september adjusted earningsnet income pharmaceutical industry sustain huge investment rd adjusted earnings per share p p consumer healthcare business also well making trading glaxosmithkline course continue defend intellectual profit million year per cent property vigorously meanwhile mitigating impact business performance primary performance measure used management presented excluding merger items generic competition introducing improved versions integration restructuring costs disposal businesses management believes exclusion items provides better year transition returning growth established medicines driving growth key reflection way business managed gives indication performance group terms elements particularly challenging year see full products enabled glaxosmithkline deliver robust revenue expenditure local management able influence information provided addition statutory impact generic competition paxil introduction financial performance despite generic competition results prepared uk gaap given assist shareholders gain clearer understanding underlying performance business generic wellbutrin together products us sales important products last two years increase comparability periods presented billion last year companies threat sales pricing pressures also continue usa come scale would catastrophic expect able weather merger integration items represent items arisen result merger glaxo wellcome smithkline beecham pressure cut pharmaceutical prices senior citizens efforts impact well partly size partly acquisition block drug restructuring costs arise merger acquisition manufacturing restructuring allow unregulated import lower priced drugs introduction improved versions medicines partly programmes already agreed glaxo wellcome smithkline beecham date merger items abroad glaxosmithkline played leading role discussions driving growth key products broad portfolio nature considered outside normal business expenditure glaxosmithkline expected occur regular basis us government others address issues fact expect able deliver earnings per share statutory results appear pages include items costs associated restructuring activities arise outside ensuring patient safety protected pleased us eps least line business performance eps specific restructuring programmes treated exceptional items government passed medicare prescription drug benefit constant exchange rates returning growth group multinational business operates many countries earns revenues incurs costs many currencies results bring much needed help patients purchasing represent solid achievement glaxosmithkline many group reported sterling therefore affected movements exchange rates sterling overseas currencies prescription drugs europe situation complex pharmaceutical companies faced similar loss group uses average exchange rates prevailing year translate results overseas companies sterling currencies government healthcare budgets coming increasing cost sales result generic competition seen earnings influence translations us dollar euro japanese yen average sterling exchange rates restraints means continual squeeze returns fall significantly stronger us dollar japanese yen nine per cent two per cent respectively weaker euro even greater need us continue demonstrating year transition glaxosmithkline end nine per cent compared value medicines companys profile transformed well order illustrate underlying performance groups practice discuss results terms constant exchange rate cer growth finally developing world ongoing challenge one broadlybased product portfolios represents growth calculated exchange rates used determine results overseas companies sterling remained intellectual property rights belief pharmaceutical industry onwards also one unchanged used previous year cer represents growth constant exchange rates represents growth actual industrys contribution persistent health crises include lowest exposures patent expiries measured percentage exchange rates pricing medicines near cost glaxosmithkline led way turnover time expect see big increase pioneering availability preferentially priced medicines number major new compounds entering phase iii trials vaccines believe remain pharmaceutical company promising pipeline cautionary statement regarding forwardlooking statements group 's reports filed furnished us securities exchange commission sec including document written information released conducting research prevention treatment oral statements made public future behalf group may contain forwardlooking statements forwardlooking statements give world health organizations three priority diseases broad product portfolio drives growth group 's current expectations forecasts future events investor identify statements fact relate strictly historical developing world hivaids tb malaria pleased glaxosmithklines ability continue delivering robust current facts use words anticipate estimate expect intend project plan believe words terms similar meaning agreement reached world trade organization august pharmaceuticals sales growth despite generic challenges connection discussion future operating financial performance particular include statements relating future actions prospective allows countries unable manufacture medicines import primarily due exceptionally broad product portfolio products product approvals future performance results current anticipated products sales efforts expenses outcome contingencies generics compulsory licences gives assurances fastgrowing highvalue products glaxosmithkline global legal proceedings financial results group undertakes obligation update forwardlooking statements whether result new information future events otherwise abused nevertheless external pressure amend leader several therapeutic areas including respiratory antiviral trips agreement protects intellectual property remains central nervous system diabetes vaccines forwardlooking statements involve inherent risks uncertainties group cautions investors number important factors including strong document could cause actual results differ materially contained forwardlooking statement factors include limited discussed risk factors pages annual report bases business performance results cer growth rates explained glaxosmithkline joint statement chairman chief executive officer glaxosmithkline description business company major products accounting time healthcare way delivered billion sales growing strong double digits include funded provoke much debate third corporate responsibility seretideadvair asthma chronic obstructive pulmonary report sets issues face area explains disease copd grew per cent year addressing possible performance description business discusses activities billion one top pharmaceutical brands measures included show progress resources operating environment business world diabetes treatments avandiaavandamet also identifies developments achievements significant achievements year include progress continue perform well sales billion per cent following headings making programmes developing world products like valtrex herpes lamictal epilepsy growing strongly approaching blockbuster status efforts eliminate lymphatic filariasis lf elephantiasis business also vaccines hivaids businesses sales debilitating disease affecting million people world health history development company billion organization target eliminate lf time glaxosmithkline strategy expect donated six billion treatments medicine products albendazole worth around billion one new product launches pharmaceutical industrys largest ever donation programmes operating environment several new important products introduced competition highlights included us launches wellbutrin xl new reduced notforprofit prices hiv treatments twice regulation improved version antidepressant levitra erectile taking price combivir dysfunction approval received lexiva hivaids advair cents day however much needs done tackle operating activities copd lamictal bipolar disorder usa enormous hivaids crisis real progress made marketing distribution avandamet diabetes europe responsibility shared sectors global society manufacture supply governments international agencies companies plan make several significant product launches filings research development glaxosmithkline include solifenacin overactive bladder developed partner yamanouchi pharmaceuticals ltd proud global community investment operating resources japan avandaryl fixeddose combination treatment million per cent groups pretax profit intellectual property extend avandia family treatments type included million groups patient assistance information technology diabetes epivir plus ziagen first oncedaily combination programs initiatives lowincome groups glaxosmithkline people hivaids treatment available single tablet usa million humanitarian product donations property plant equipment building strong diverse rd pipeline governance business society provided clearest evidence yet success creating financial reporting councils new combined code corporate responsibility productive rd organisation industry rd corporate governance published board supports responsibility environment health safety day december demonstrated redesigned rd new code moved quickly bring glaxosmithklines access healthcare developed world operation delivering product pipeline exceptional diversity governance procedures substantially line best practices access healthcare developing world quality quantity drive future growth flow code global community investment company discussion groups management structures corporate acknowledgements projects clinical development span governance procedures set corporate governance year number changes board variety therapeutic areas encompass number pages board benefits direct presence dr tachi yamada pioneering approaches treating patients including exciting new great knowledge experience medical practice remuneration report gives details groups policies compounds areas oncology cardiovascular disease well pharmaceutical industry three new nonexecutive directors remuneration amounts earned directors projects include new chemical entities nces directors joined board year larry culp president senior management pages product line extensions ples vaccines nces danaher corporation crispin davis chief executive reed discussion groups operating financial performance clinical phases ii iiiregistration expect make elsevier plc sir robert wilson chairman bg group plc financial resources given operating financial record number filings next five years many bring many years experience successful track review prospects pages compounds potential reach blockbuster status records different industries undoubted skills strengthen board report glaxosmithkline group means glaxosmithkline included many promising compounds highlighted plc subsidiary undertakings company means december first kind dual kinase inhibitor sir roger hurn paul allaire left board june dr michle glaxosmithkline plc glaxosmithkline share means ordinary share treatment breast lung cancer cervarix vaccine barzach john mcarthur donald mchenry step glaxosmithkline plc p american depositary share ads potential prevent per cent cervical cancers board agm may express appreciation represents two glaxosmithkline shares nextgeneration antidepressant lppla inhibitors contribution company target newly identified risk factor heart disease odiparcil dedicated effective service board throughout report figures quoted market size market share market growth rates relate months ended th novel antiblood clotting treatment first dual action conclusion behalf board corporate executive september later available glaxosmithkline cox inhibitor targeting inflammatory neuropathic pain team thank shareholders continued support estimates based recent data independent external building strong heritage respiratory medicine challenging time sources valued sterling relevant exchange rates figures quoted also developing nextgeneration seretideadvair oncedaily product market share reflect sales glaxosmithkline licensees combination new longacting corticosteroid brand names appearing italics throughout report trade marks longacting selective beta agonist developed glaxosmithkline associated companies exception theravance inc amaryl nicoderm trade marks aventis baycol levitra trade marks bayer bexxar trade mark corixa corporation corporate responsibility hepsera trade mark gilead services micropump trade mark corporate responsibility particular resonance flamel technologies natrecor trade mark scios navelbine trade pharmaceutical sector business creating medicines treat sir christopher hogg j p garnier mark pierre fabre mdicament pritor trade mark prevent disease something society needs values chairman chief executive officer boehringer ingelheim used licence group glaxosmithkline description business description business glaxosmithkline business history development company building strong diverse rd pipeline products pharmaceuticals group aiming create productive discovery therapeutic area trade mark compound mechanism indication may vary country glaxosmithkline plc subsidiary associated pipeline industry benefit patients consumers central nervous seroxatpaxil paroxetine selective serotonin reuptake depression panic anxiety undertakings constitute major global healthcare group society includes developing focused portfolio strategy system inhibitor engaged creation discovery development manufacture support pipeline manage full life cycle compounds wellbutrin bupropion noradrenaline reuptake inhibitor depression marketing pharmaceutical consumer healthrelated launch overthecounter products strategy imigranimitrex sumatriptan ht agonist migraine cluster headache products includes selective inlicensing efficient execution naramigamerge naratriptan ht agonist migraine development commercialisation supply chain processes lamictal lamotrigine sodium channel modulator epilepsy bipolar disorder glaxosmithkline corporate head office london requip ropinirole dopamine dd agonist parkinsons disease glaxosmithklines rd organisation measures productivity zyban bupropion sr noradrenaline reuptake inhibitor smoking addiction great west road number innovation products creates brentford respiratory flixotideflovent fluticasone propionate inhaled antiinflammatory asthma copd also commercial value products ability middlesex tw gs serevent salmeterol xinafoate bronchodilator asthma copd address unmet needs consumers including patients seretideadvair salmeterol fluticasone bronchodilatorantiinflammatory asthma copd england healthcare professionals budget holders regulators propionate tel perspective constitutes valuable new product flixonaseflonase fluticasone propionate intranasal antiinflammatory hayfever perennial rhinitis glaxosmithkline also operational headquarters philadelphia details given pages ventolin salbutamolalbuterol bronchodilator bronchospasm research triangle park usa operations becotidebeclovent beclomethasone dipropionate inhaled antiinflammatory asthma countries products sold countries principal product commercialisation beconase beclomethasone dipropionate intranasal antiinflammatory hayfever perennial rhinitis research development rd facilities uk usa glaxosmithkline links research commercial operations closely antivirals trizivir lamivudine zidovudine reverse transcriptase inhibitor hivaids japan italy belgium products currently manufactured order maximise value portfolio compounds abacavir countries developed tested innovative marketing campaigns combivirbiovir lamivudine zidovudine reverse transcriptase inhibitor hivaids epivirtc lamivudine reverse transcriptase inhibitor hivaids powerful focused sales efforts planned major markets groups products usa japan retrovirazt zidovudine reverse transcriptase inhibitor hivaids appropriate within markets group aims build strong france germany uk italy ziagen abacavir reverse transcriptase inhibitor hivaids relationships patients ultimate consumers agenerase amprenavir protease inhibitor hivaids glaxosmithkline plc public limited company incorporated medicines details given lexiva fosamprenavir protease inhibitor hivaids th december english law th december valtrexzelitrex valaciclovir dna polymerase inhibitor shingles genital herpes company acquired glaxo wellcome plc smithkline global competitor zovirax aciclovir dna polymerase inhibitor herpes infections shingles beecham plc english public limited companies way glaxosmithkline operates increasingly global environment chicken pox cold sores scheme arrangement merger two companies scale offers significant advantages group leverages zeffixheptavir lamivudine reverse transcriptase inhibitor chronic hepatitis b infection glaxo wellcome smithkline beecham major global scale building interdependent businesses share heptodinepivir hbv healthcare businesses successful practices across business boundaries geographic antibacterials augmentin amoxicillinclavulanate broad spectrum oralinjectable bacterial infections borders common approaches management processes antimalarials antibiotic st october glaxo wellcome plc changed name business functions used internationally diverse zinnatceftin cefuroxime axetil oral antibiotic bacterial infections glaxosmithkline services plc th march became talented management team order create sustain fortumfortaz ceftazidime injectable antibiotic severe life threatening infections glaxosmithkline services unlimited historical references glaxo bactroban mupirocin topical antibiotic skin infections competitive advantage markets addition glaxosmithkline wellcome plc document changed amoxil amoxicillin broad spectrum oralinjectable bacterial infections continues demonstrate commitment corporate antibiotic responsibility helping improve access better medicines business segments malarone atovaquoneproguanil electron transport inhibitor treatment prophylaxis malaria developing world details given glaxosmithkline operates principally two industry segments lapdap chlorproguanil hydrochloride antifolate antimalarial treatment malaria pages dapsone pharmaceuticals prescription pharmaceuticals vaccines metabolic avandia rosiglitazone ppargamma agonist type diabetes consumer healthcare overthecounter medicines oral care consumer healthcare avandamet rosiglitazone metformin ppargamma agonist type diabetes nutritional healthcare glaxosmithkline consumer healthcare recognises clear hydrochloride antihyperglycemic agent understanding needs expectations consumers metformin glaxosmithkline strategy fundamental success business traditional method vaccines havrix hepatitis communicating customers television advertising engerixb hepatitis b glaxosmithklines business goal become indisputable although newer channels internet gaining twinrix hepatitis b leader pharmaceutical industry achieving goal importance whichever method chosen challenge make infanrix diphtheria tetanus acellular pertussis require meeting three key challenges face glaxosmithkline products stand competition oncology zofran ondansetron ht receptor antagonist nausea vomiting cancer industry society whole emesis therapy new products come many sources importantly hycamtin topotecan topoisomerase inhibitor ovarian cancer small cell lung cancer improving productivity research development consumer healthcare partners pharmaceutical business navelbine vinorelbine cytotoxic nonsmall cell lung cancer breast ensuring patients access new medicines maximise groups assets opportunities cancer reaching consumers beyond traditional healthcare pharmaceutical products overthecounter market bexxar iodine tositumomab radioimmunotherapy follicular nonhodgkins lymphoma professional cardiovascular coreg carvedilol alphabeta blocker congestive heart failure people glaxosmithkline developed strategies focus urogenital lanoxin digoxin cardiac antiarrhythmic congestive heart failure number key business drivers order meet challenges single greatest source competitive advantage cardiac arrhythmia company people groups ambition make flolan epoprostenol inhibitor blood clotting primary pulmonary hypertension place great people apply energy passion make lacipil lacidipine calcium channel blocker hypertension difference world skills intellect key pritor telmisartan angiotensin ii antagonist hypertension components successful implementation groups levitra vardenafil pde inhibitor erectile dysfunction strategy work environment supports informed empowered avodart dutasteride selective inhibitor type ii benign prostatic hyperplasia isoforms ar resilient workforce group values draws diverse knowledge perspectives experience styles zantac ranitidine histamine h antagonist duodenal ulcers stomach ulcers global community details given reflux dyspepsia copromoted glaxosmithkline description business description business glaxosmithkline glaxosmithklines principal pharmaceutical products presently antivirals infanrix range paediatric vaccine combinations infanrix major products necessarily sold markets directed nine therapeutic areas analysis sales combivir combination retrovir epivir consolidated provides protection diphtheria tetanus pertussis therapeutic areas description principal products position two reverse transcriptase inhibitors whooping cough infanrix pentapediarix provides additional category product set cornerstone many multiple antihiv product regimens physician protection hepatitis b polio infanrix hexa acceptance clearly demonstrated value placed adds protection haemophilus influenzae type b overthecounter medicines turnover therapeutic area minimising pill burden faced patients causes meningitis analgesics panadol dermatologicals zovirax central nervous system ziagen reverse transcriptase inhibitor products potency glaxosmithkline also markets priorix measles mumps abreva respiratory ease use resistance profile allow play significant role rubella vaccine typherix vaccine protection typhoid gastrointestinal tums antivirals variety highly active well tolerated simplified hiv fever varilrix vaccine varicella chicken pox citrucel antibacterialsantimalarials treatment regimens addition group markets range vaccines prevent respiratory tract contac metabolic vaccines trizivir combination combivir ziagen combining three meningitis umbrella name mencevax beechams oncology emesis antihiv therapies one tablet twice daily administration smoking control commit oncology emesis nicorette cardiovascular urogenital agenerase protease inhibitor treatment hiv zofran used prevent nausea vomiting associated nicoderm cq first medicine class brought market chemotherapy radiotherapy cancer available niquitin cq glaxosmithkline agenerase twice daily dosing regimen oral injectable forms also approved use nicabate cq significant food drink restrictions prevention treatment postoperative nausea vomiting natural wellness support abtei central nervous system cns lexiva also protease inhibitor treatment hiv hycamtin second line treatment ovarian cancer oral care aquafresh seroxatpaxil selective serotonin reuptake inhibitor ssri new combination tolerability convenience lexiva small cell lung cancer corega approved depression panic obsessive compulsive disorder may dosed daily boosted ritonavir dr best navelbine approved first line treatment nonsmall cell post traumatic stress disorder social anxiety disorder premenstrual macleans zeffix approved marketing usa europe china lung cancer combination cisplatin single agent dysphoric disorder general anxiety disorder paxil cr odol markets treatment chronic hepatitis b controlled release version launched usa bexxar treatment patients follicular nonhodgkins odol med valtrex treatment chicken pox zoster shingles cold sores lymphoma whose disease refractory rituximab polident wellbutrin antidepressant available usa normal episodic genital herpes well long term suppression relapsed following chemotherapy poligrip sustainedrelease sr tablet formulations oncedaily genital herpes valtrex supersedes zovirax also widely sensodyne version wellbutrin xl launched usa september used treat herpes infections cardiovascular urogenital nutritional healthcare horlicks coreg alphabeta blocker proven lucozade imigranimitrex ht receptor agonist used treatment antibacterials antimalarials effective treating hypertension heart attack patients ribena severe frequent migraine cluster headache augmentin broadspectrum antibiotic suitable mild moderate severe heart failure glaxosmithkline sole become reference product sector naramigamerge treatment wide range common bacterial infections marketing rights usa canada generic versions newer migraine product particularly effective respiratory tract infections augmentin product became available canada overthecounter medicines es extra strength suspension specifically designed treat leading products panadol widely available lamictal well established treatment epilepsy also levitra pde inhibitor indicated male erectile dysfunction children recurrent persistent middle ear infections paracetamolacetominophen analgesic nicorette gum indicated bipolar disorder glaxosmithkline copromotion rights worldwide except nicoderm niquitin cq nicabate range smoking control augmentin xr extra strength tablet form adults combat japan levitra launched usa requip specific dopamine dd receptor agonist indicated products tums calcium based antacid citrucel laxative contac growing problem bacterial resistance community european markets treatment parkinsons disease treatment colds influenza abtei natural medicines zinnat oral antibiotic used primarily communityacquired avodart ari inhibitor currently indicated benign prostatic vitamin range zovirax abreva treatment zyban nicotinefree prescription medicine available infections lower respiratory tract fortum used hypertrophy large clinical outcome study underway examining cold sores sustainedrelease tablet treating problem hospitalbased injectable antibiotics market efficacy prevention prostate cancer smoking addiction flixonase allergy nasal spray airborne allergies malarone oral antimalarial used treatment launched uk product glaxosmithklines respiratory prophylaxis malaria caused plasmodium falciparum programme appropriate switching prescription category includes groups principal dermatological seretideadvair combination serevent flixotide offers medicines overthecounter products betnovate higher potency dermovate newer longacting bronchodilator antiinflammatory single metabolic cutivate antiinflammatory steroid products used treat skin inhaler seretide approved treatment chronic avandia potent insulin sensitising agent acts oral care diseases eczema psoriasis relafen nonsteroidal obstructive pulmonary disease copd eu may underlying pathophysiology type diabetes avandamet leading oral care products toothpastes mouthwashes antiinflammatory drug treatment arthritis zantac combination avandia metformin hci first medicine aquafresh sensodyne macleans odol brand serevent longacting bronchodilator used treat asthma treatment peptic ulcer disease range gastric acid targets insulin resistance decreases glucose production names range toothbrushes sold aquafresh copd ventolin selective shortacting bronchodilator used related disorders continues play major role number one convenient pill dr best names addition denture care products available treat bronchospasm markets even patent protection lost principally polident poligrip corega brand names flixotideflovent becotidebeclovent inhaled steroids vaccines products consumer healthcare treatment inflammation associated asthma copd glaxosmithkline markets range hepatitis vaccines havrix nutritional healthcare protects hepatitis engerixb hepatitis b glaxosmithklines principal consumer healthcare products leading products category lucozade glucose energy flixonaseflonase beconase intranasal preparations twinrix combined hepatitis b vaccine protecting three major areas analysis sales areas set sports drinks ribena blackcurrantbased juice drink rich treatment perennial seasonal rhinitis diseases one vaccine available adult vitamin c horlicks range milkbased malted food paediatric strengths chocolate drinks overthecounter medicines oral care nutritional healthcare glaxosmithkline description business description business glaxosmithkline operating environment competition pharmaceuticals major respiratory competitors singulair merck especially competition consumer healthcare grant marketing authorisation affords group protection usa europe symbicort astrazeneca spiriva period competitor rely confidential data pharmaceutical industry highly competitive main competitors groups consumer healthcare markets pfizerboehringer ingelheim regulatory file basis marketing authorisation glaxosmithklines principal competitors large international include major international companies colgatepalmolive data protection period begins date authorisation pharmaceutical companies substantial resources johnson johnson pfizer procter gamble unilever wyeth antivirals first granted european union expires ten years companies major products mentioned addition many companies compete major competitors hiv market bristol myers squibb authorisations granted via centralised procedure ten six glaxosmithkline selected markets pharmaceuticals may subject competition merck pfizer amongst others years authorisations granted via mutual recognition products period patent protection major competitor products overthecounter otc procedure depending country concerned glaxosmithkline pioneering role hiv market patent generic versions manufacturers generic medicines retrovir epivir acting cornerstone combination may european union expanded products typically bear significant research development therapy available combivir single tablet launches usa metamucil laxative clearasil acne treatment member states anticipation enlargement european costs consequently able offer products ziagen agenerase trizivir lexiva broadened pepcid indigestion private label smoking control regulatory legislation currently undergoing review impact considerably lower prices branded competitors research groups portfolio hiv products valtrex helped products changes regulatory procedures data protection periods development based pharmaceutical company normally strengthen groups position antiherpes area although uk lemsip cold remedy nurofen anadin remains seen seek achieve sufficiently high profit margin sales volume zovirax faces competition generic aciclovir valtrex analgesics nicorette nicotinell smoking control period patent protection repay original usa drug price competition patent term zovirax compete novartis famvir zeffix first antiviral remedies investment generally substantial fund research restoration act hatchwaxman established current market treat hepatitis b gileads hepsera second future competition generic products generally occurs oral healthcare major competitors colgatepalmolives framework approval generic drugs including related patent approved us food drug administration fda patents major markets expire increasingly patent challenges colgate procter gambles crest data protection provisions hatchwaxman sponsor september made prior patent expiry claiming innovator patent abbreviated new drug application anda receive nutritional healthcare major competitors horlicks valid andor infringed generic product marketing approval without submitting safety efficacy data antibacterials antimalarials ovaltine milo malted food chocolate drinks following loss patent protection generic products rapidly rely pioneer companys extensive preclinical generic versions augmentin ceftinzinnat competitors ribena primarily local fruit juice products capture large share market particularly usa clinical development data provided proposed generic drug introduced usa following successful legal challenges lucozade competes energy drinks demonstrated bioequivalent pioneer product glaxosmithkline undertakes range activities maximise generic manufacturers see note financial statements glaxosmithkline holds leading global positions key however generic drug approvals subject data protection value intellectual property including introducing innovative legal proceedings augmentin already lost patent protection consumer product areas worldwide second largest periods five years new chemical entities three years products many markets possible accelerating process various countries europe augmentin xr augmentin es oral care third largest otc medicines nutritional modifications supported new clinical studies moreover bring new products market developing improved patent compete broad range branded generic healthcare holds leading position uk india provisions hatchwaxman filing anda protected versions older products increasing brand antibiotics malarones safety profile convenient dosing ireland trigger procedures may allow patent holders initiate patent recognition among customers regimen helped put product strong position versus infringement litigation significant procedural advantage mefloquine following recent launch malaria prophylaxis glaxosmithkline believes competitive position dependent regulation pharmaceuticals assured fdas approval proposed generic upon discovery development new products together product stayed months pending resolution metabolic international pharmaceutical industry highly regulated effective marketing existing products within litigation procedures generated litigation major competitor avandia takeda chemicals actos national regulatory authorities administer panoply laws pharmaceutical industry introduction new products controversy particularly currently applied copromoted eli lilly usa regulations governing testing approval manufacturing processes competitors may affect pricing levels result resulted multiple nonconcurrent month stays labelling marketing drugs also review safety product replacement assurance products proposed generic products june fda issued new vaccines efficacy pharmaceutical products regulatory may become outmoded notwithstanding patent trade mark regulations clarify certain aspects procedures glaxosmithklines major competitors vaccine market include requirements major factor determining whether protection addition increasing government pressure generated controversy addition november new laws aventis pasteur ap merck wyeth engerixb havrix substance developed marketable product physicians patients use generic pharmaceuticals rather enacted us congress modified hatch compete vaccines produced ap merck comvax amount time expense associated development brandname medicines may increase competition waxman laws modifications eliminated grant recombivax hb hepatitis b vaqta avaxim hepatitis products longer protected patent particular importance requirement many countries additional month stays patents issued anda infanrixs major competitor aps range dtpabased products authorised registered prior marketing filed limited grant month stay one per anda combination vaccines cns disorders authorisation registration maintained subsequently applicant circumstances major competitors usa paxil generic forms oncology emesis national regulatory authorities many jurisdictions including usa second reauthorisation prescription drug launched september fluoxetine generic form zofran presently provides glaxosmithkline leadership position usa european union japan australia high user fee act came effect st october pdufa iii eli lillys prozac zoloft pfizer forest laboratories celexa antiemetic market competition includes standards technical appraisal consequently introduction remains seen substantial additional resources funded lexapro principal competitors usa wellbutrin rochechugai aventis recently merck major competitors new pharmaceutical products generally entails lengthy pdufa iii result reduction overall approval times ssris effexor xr wyeth product limited generic diverse cytotoxic market include bristol myers squibb approval process drugs biologicals however one requirements competition wellbutrin began usa january aventis pfizer novartis glaxosmithklines cytotoxic portfolio pdufa iii calls fda initiate review first action european union currently two procedures success seroxatpaxil wellbutrin made led hycamtin navelbine holds relatively small market approvals compared approvable nonapprovable decisions obtaining marketing authorisations medicinal products target generic manufacturers glaxosmithkline position report back findings review continues respond appropriately see note financial centralised procedure applications made direct fda also completed previously announced statements legal proceedings recent launches paxil cr cardiovascular urogenital european medicines evaluation agency leading consolidation review activities certain biologicals oncedaily wellbutrin xl expected help retain glaxosmithkline markets coreg usa major authorisation valid member states compulsory vaccines center drug evaluation research strong presence antidepressant market given recent competitors toprol xl generic betablockers products derived biotechnology optional new cder consolidation also entailed shifting resources entry generic paroxetine usa generic competition group launched two urogenital products levitra avodart active substances innovative medicinal products center biologics evaluation research cber also commenced uk number markets avodart competes directly mercks proscar within bph mutual recognition procedure applicable cder impact shift resources remains seen market levitra marketed male erectile dysfunction faces majority conventional medicinal products operates respiratory competition pfizers viagra lillys cialis mutual recognition national marketing authorisations glaxosmithklines respiratory franchise driven growth agreement reached resolved seretideadvair gaining patients competitor products procedure binding arbitration cannibalisation serevent flixotide ventolin becotide faced generic competition years maintained significant sales glaxosmithkline description business description business glaxosmithkline operating activities along pdufa iii first action review consolidation value money marketing distribution pharmaceuticals stakeholder initiatives cber review activities cder fda also becoming increasingly necessary demonstrate value company launched several initiatives improve announced sponsorship commissioner money new products particular impact upon drug budget analysis total pharmaceutical turnover geographic region abilities deliver important information physicians renewed focus innovation drug development hopefully expenditure burden disease treated set patients diseases therapies treat allowing rapid development needed medicines markets need satisfy healthcare purchasers initiative investigate use pharmacogenomics turnover geographic region sales force excellence value money becoming additional hurdle product surrogate markers efficacy among things tools acceptance regulatory tests safety efficacy usa worldwide sales force excellence initiative focuses rapidly developing safe effective drugs unmet medical quality delay bringing effective improved europe increasing glaxosmithkline sales representatives skills providing needs medicines market reduce effective patent international value healthcare professionals around globe centrepiece project global framework training raise across international markets countries outside usa protection time asia pacific standards representatives knowledge diseases europe regulatory environment continues extremely japan varied challenging glaxosmithkline anticipates many markets becoming increasingly difficult even latin america role glaxosmithkline medicines treating training introduction new products continue require substantial significantly improved therapy obtain premium price middle east africa also address answer central questions effort time expense comply regulatory requirements existing medication valuebased pricing may difficult follow canada physician faces deciding patients treatment circumstances although usa still possible use glaxosmithkline medicine use price products reflect value use price controls many countries prices pharmaceutical products possible predict whether extent glaxosmithkline sells prescription medicines primarily initiative aims build good reputation controlled law governments may also influence prices groups business may affected future legislative wholesale drug distributors independent chain retail glaxosmithkline sales forces already enjoy among physicians control national healthcare organisations may bear regulatory developments relating specific pharmaceutical pharmacies physicians hospitals clinics government entities worldwide surveys physicians major world markets large part cost supplying products consumers products price institutions products ordinarily dispensed recently rated glaxosmithkline sales representatives public pharmacies prescriptions written doctors industry uk germany france spain recent government healthcare reforms countries france regulation consumer healthcare hospitals doctors surgeries us among pulmonologists allergistsimmunologists paediatricians spain germany may restrict pricing reimbursement neurologists ear nose throat specialists infectious disease consumer healthcare industry subject national regulation usa worlds largest pharmaceutical market usa recent legislation healthcare reform crossborder specialists testing approval manufacturing labelling marketing pressure contain healthcare costs encouraged growth trade acceleration generics market increased patient products many countries high standards technical managed care organisations pharmacy benefit managers source rankings taylor nelson sofres healthcare europe contributions increased focus pricing currently appraisal entail lengthy approval process new product intermediaries use range methods lower costs verispan usa government price controls private sector launched including substitution generic products cheaper purchases federal legislation requires pharmaceutical therapies branded products prescribed doctors result marketing excellence manufacturers pay prescribed rebates certain drugs order national regulatory authorisation also required approve increasing importance supplier healthcare goals global marketing excellence initiative first eligible reimbursement medicaid federal switch products prescription otc requirements community glaxosmithkline contracts managed care help undiagnosed patients seek physicians help second healthcare programmes include longterm experience quality safety efficacy sector small number wholesalers ensure receive appropriate treatment example product wide patient population data confirm uk officials estimate million people suffer type medicare relevant condition selflimiting easily market glaxosmithkline deploys sales forces diabetes yet per cent remain undiagnosed us medicare prescription drug improvement diagnosed consumer representatives supporting medical staff promote diagnosed another per cent remain untreated modernization act provides limited immediate benefits prescription products medical prescribers healthcare treated significant number undertreated medicare patients form government sponsored discount purchasers personal visits way patients achieve level health cards replaced comprehensive outpatient drug promotion glaxosmithklines products supplemented treatments could provide optimal circumstances benefit benefit intended administered scientific seminars advertising medical journals glaxosmithklines marketing initiative explores barriers proper number private organisations construct benefit television advertising provision samples direct mailing diagnosis treatment implements programmes structures consistent federal law market benefit information contained groups website overcome programmes begin show effects medicare patients societal costs disease decrease extent physicians directtoconsumer dtc advertising major component law provides strong incentives manufacturers choose glaxosmithkline product patients treatment product marketing usa dtc advertisements negotiate prices plan sponsors bill provide company benefit well primary source information patients requesting specific explicit government price controls seniors already brand name products physicians usa sort outpatient drug coverage increases demand may patient advocacy limited drugs required low income seniors outside usa dtc either prohibited limited third worldwide initiative seeks achieve higher level past able arrange private coverage low role informing patients european union dtc intimacy glaxosmithkline ultimate consumer income seniors receive larger subsidies deductible prescriptiononly products currently prohibited australia products patient already us glaxosmithkline copayments associated comprehensive benefit government allows dtc advertising pharmacyonly products hosted two patient advocacy leaders summits subject certain safeguards new zealand dtc allowed brought many leaders patient groups together law also changes way drugs administered physician selfregulated industry collaboration advertising seek areas common interest among offices clinics hospital outpatient departments standards agency markets allow dtc date glaxosmithkline plan actions around working reimbursed instead reimbursement based prices published impact limited together groups strive continued open access independent pricing services new law provides appropriate medicines constituencies increasing reimbursement based actual market prices addition direct marketing products subsidiaries challenge time tightening budgets champion reported manufacturers audited government glaxosmithkline entered agreements continued investments development new medicines addition beginning physicians option pharmaceutical companies comarketing copromotion choosing purchase claim reimbursement products products many markets example levitra bayer similar approach launched europe patient instead allowing drug distributors provide drugs doctors advocacy groups becoming increasingly organised offices submit claims medicare patients contributions distributors earn ability provide products services competitive bidding process glaxosmithkline description business description business glaxosmithkline marketing distribution consumer healthcare secondary supply chain consumer healthcare supply chain rd processes discovery commercialisation delivery european region consumer healthcare manufacturing sites spread principal markets consumer healthcares otc medicines sites european region spread across eight across countries consumer healthcare supply chain diagram shows relationship various usa uk germany australia argentina italy mexico countries european sites manufacture nearly diverse includes manufacturing supply otc stages rd japan canada france principal markets oral care major pharmaceutical products marketed globally medicines oral care nutritional healthcare smoking control products usa germany uk nutritional drinks glaxosmithkline wide variety finished dosage forms products well internal facilities contract suppliers business particularly strong uk ireland india although used worldwide research development commercialisation range products available markets north america region otc oral care products primarily distributed six pharmaceutical manufacturing sites north research development pharmaceuticals pharmacy mass market outlets either directly america region located puerto rico canada usa global biological pharmaceutical research wholesalers nutritional healthcare products distributed development rd function glaxosmithkline responsible genetics preclinical similar extensive retail wholesale network international region discovering developing registering commercialising research development international region comprises manufacturing sites supporting effective marketing innovative prescription project future countries spread across six distinct areas five sites medicines vaccines delivery systems treatment discovery worldwide fundamental review undertaken consumer middle eastafrica sites spread across asia pacific prevention human disease research development healthcare business model product innovation marketing australia area four sites china one japan five latin aimed increase competitiveness thereby sales growth america fundamental goal thorough understanding review termed project future transitioned glaxosmithklines diseases investigation facilitated pioneering work consumer healthcare geographically based structure glaxosmithkline integration genetics range technologies well traditional global strategic support one brands developed longterm integrated change programme implemented research disciplines addition work create new rd processes appropriate place result responsibility time merger called global supply network gsn medicines vaccines extensive efforts made gain clear line glaxosmithkline 's strategic intent become taken centrally develop global brands autonomy structured deliver benefits five major streams understanding unmet needs patients healthcare indisputable leader industry rd set goal afforded local markets manage local brands activity providers payers guide overall direction rd becoming industrys productive rd organisation using entrepreneurial skills full reduction abovesite infrastructure costs glaxosmithkline invested nearly billion fundamental prerequisite approach crucial procurement initiatives pharmaceuticals rd rd organisation benefits rd also focuses needs patient benefits manufacture supply continued network rationalisation insights top scientists around world employs may derived new medicines innovative glaxosmithkline large portfolio products ranging logistics improvements staff biological pharmaceutical rd activities formulations existing medicines available need tablets toothpaste inhalers complex capsules operational excellence leansigma improvements sites worldwide including recover health quality life different pack sizes presentations part network rationalisation plan production ceased uk beckenham brentford cambridge dartford rd measures productivity number innovation manufacture medicines begins development eight sites countries included uk india greenford harlow stevenage tonbridge ware products creates also commercial value therapeutic active ingredient bulk active selected formulation romania usa programme met merger welwyn product 's ability address unmet needs customers global manufacture supply gms develops manufacturing commitments one year ahead plan usa bristol tennessee philadelphia upper merion including patients healthcare professionals budget holders processes full scale volume production active compounds upper providence pennsylvania research triangle regulators perspective constitutes 'primary ' manufacturing sites converting active compounds external suppliers park north carolina valuable new product rd positioned ensure finished dosage formulation responsibility procurement global function supporting functions belgium rixensart generates right safety efficacy quality information 'secondary ' manufacturing sites areas glaxosmithkline business manufacturing one canada mississauga respond different perspectives data largest areas billion spent many external france les ulis evreux demonstrating overall social benefits new medicine gms operates single global network sites suppliers every year including purchase active ingredients italy verona increased length quality life increased workplace countries year gms produces around tonnes bulk chemical intermediates partfinished finished products gms japan tsukuba science city takasaki productivity actives four billion packs packaged taken appropriate steps protect supply chains spain tres cantos madrid delivered sale countries throughout world one historical contradictions pharmaceutical industry also supports approximately new product line extension disruption resulting interrupted external supply rd delivered wide range products need lever advantages large organisation launches year appropriate stock levels contracting alternative registered market achieved significant success bringing several without losing creative spirit research environment suppliers new compounds earlier stages research past glaxosmithkline rd structured balance areas gms focused delivering critical proof concept poc decision point extensive benefit large scale take advantage secure source supply high quality products vaccines supply chain inlicensing programme slowed small enhance productivity c e b l peo x e ra opm cte ip unc inl rt gi eaa c mtn ei lo ac ee sn g ns e tw c apoit nrsh cr e inig c eu osl ta hat eo n rr g p lr oe e bq rf au li rr fme um na cne tn c ioets n sa n td sc itu es st im n er v bn un pa pc p sb ec p oi dlln w yg e oi ccou nhhm j ao fta ooi n n nw r u et bi ni cf evta avh e c nt tt blu svh lu e er r fi r n e eg os n ii mn tih c e hl co e e ephrc ds n flt iit ae fn ue f g c es rnp ui en dr n tm f tr ir r ok mua ner n asi tsl c ry ne ia k n e e e tg dm sd er e ami rx n nm ae aa dnn ng ds n fidina rur g tsa h tna n oh en g sd e h v e w u rfl scn ra e ec fgv x rnar obe r e mly e p p e vh anr r iso e ls uc g uo p eu r rv oe ac nes rt nr gtsi e fv oi ti n hl eno l e vr f eret nh c rv da oee nll lo ep iy n wp po vm ops e mt r u e tm n en c sd tte ii itcr c sg n nle r ea er p sn sro oe io tr v un og r e rc clt por ee ap si aas mt isa ei oi ot n e ni ng ts n ca n h hnh u ia eda v e b e lt tsa r hn r eo b e gf ed ec pe mot tno im anp u f oou c fn u ss c h cca hh igrp ae e hi et nk la yn e l r oy ni en g ta gt hr e u e etn la h ras ai ev rt e eh e smt hr flb ah oe ii ngn ur lehe ryq fi st au ht h r rf ter oho u em tg c hh l eb rp ice reu e r btn e eg k n sc tl lt da l av r og fe n atsa hd n r e te tu h gt c oh eh eso v ea ies f se l hc ht paoh emtma st ea tp nr ra eo utr ue ct n ud r al health authorities mass vaccination campaigns unit remains small units respond quickly changing organisation december rd presentations made uk environment opportunity scientists interact optimised bulk filling packaging carefully balanced stocking us glaxosmithklines pipeline future products need return investment focused primary supply chain vaccines helps manage shortterm increases demand unveiled analysts featured promising compounds selected fostering entrepreneurial accountable culture global organisation sites spread across five increases prompted disease outbreaks increased demand novelty impact disease commercial potential countries broad range active ingredients antibiotic public owing disease awareness campaigns included nextgeneration noradrenalinedopamine nonantibiotic products manufactured packaged reuptake inhibitor depression cyclooxygenase inhibitor sites located australia ireland singapore uk pain lipoproteinassociated phospholipase usa majority active ingredients manufactured inhibitor atherosclerosis dual kinase inhibitor primary supply chain supplied secondary pharmaceutical cancer thirdgeneration inhaled corticosteroid sites europe north america international offering oncedaily treatment greater efficacy compared current compounds glaxosmithkline description business description business glaxosmithkline addition established centres excellence drug many diseases arise complex interactions product development pipeline discovery cedd discussed number partnerships number gene variants environmental factors product development pipeline set shows considerable breadth depth february glaxosmithkline forged companies extend glaxosmithklines challenge involved significant identifying genes pharmaceutical vaccine projects development clinic includes new chemical entities nce capability screen compounds generated research predispose patients particular disease understanding phase iii registration phase ii phase product line extensions vaccines competitive reasons new function effectively extends cedd concept ensure role progression lead finding new ways intervene projects preclinical development disclosed project types may identified efficient rapid validation maximum number lead diseases key candidates preclinical testing clinical studies programme initiated identify tractable targets proof concept criteria handing v vaccine phase evaluation clinical pharmacology usually conducted genetically associated human diseases interest p pharmaccine volunteers compound worldwide development organisation large already identified genetic associations several major compounds shionogiglaxosmithkline pharmaceuticals scale clinical trials diseases several clinical studies started investigate inl l lic ce j si en v tt hu ere r alliance relationship third party phase ii efe fit ce ar cm yin ca ot nio dn u co tf e ne sn md nia ul e bva el ru oa ft io pn io ef n ts worldwide development wwd function integrates presence genetic markers efficacy susceptibility adverse date first submission clinical regulatory activities necessary bring new medicine events enhance ability focus development date first regulatory approval maa first phase iii large comparative study compound versus placebo marketplace past year clinical development new medicines patients likely benefit eu approval letter andor established treatment patients al approvable letter establish clinical benefit safety process significantly shortened improvements ultimately providing reassurance prescriber maa marketing authorisation application europe associated processes enabling seamless transition data patient nda new drug application usa estimated filing dates clinical testing final report implementation compoundproduct type indication phase maa nda integrated document management system reduced discovery research cardiovascular metabolic urogenital time required collate thousands pages data necessary discovery research dr produces lead compounds form submission regulatory agencies around world basis drug discovery efforts cedds dr peroxisome proliferatoractivator receptor ppar dyslipidaemia provided cedds many high quality new lead compounds alpha agonist beginning accommodate unprecedented lppla inhibitor atherosclerosis activity defined targets investment dr focused number compounds moving pipeline group p kinase inhibitor atherosclerosis also rheumatoid arthritis copd increasing quality quantity lead compounds angiotensin converting enzyme neutral hypertension transformed changing scale structure latestage available central theme investment focus peptidase acenep dual inhibitor development enable stronger focus patients coreg cr beta blocker hypertension congestive heart failure daily na delivery products creating six therapeutically aligned medicine automation odiparcil indirect thrombin inhibitor prevention thrombotic complications ii cardiovascular disease development centres mdcs residing within wwd centres rd opened new automation facilities high lppla inhibitor atherosclerosis ii discussed detail accountable throughput screening tres cantos spain high throughput adenosine aa agonist dyslipidaemia also neuropathic pain generation life cycle management marketed medicines chemistry harlow uk construction new combined facility ppar delta agonist dyslipidaemia ii compounds reaching proof concept poc cedds also started upper providence usa ppar alpha agonist dyslipidaemia ii piboserod ht antagonist atrial fibrillation new product supply organisation bridges traditional divide another focus high throughput biology techniques talnetant nk antagonist overactive bladder also irritable bowel syndrome ii ibs schizophrenia development manufacturing ensuring robust developed rapid screening new compounds avodart alpha reductase inhibitor benign prostatic hyperplasia combination iii manufacturing processes developed global commercial cell based whole animal model systems many cases alpha blocker strategy gcs organisation provides integrated global efforts supported sophisticated imaging avodart alpha reductase inhibitor reduction risk prostate cancer lll noratak nesiritide recombinant type natriuretic peptide acute heart failure submitted ssep na commercialisation strategic direction rd maximise systems enhanced understanding disease solifenacin ym muscarinic antagonist overactive bladder approvable na aloct portfolio value full product life cycle crucial models levitra pde inhibitor erectile dysfunction approved amar aaug success rd capacity embrace develop new metabolic projects technologies streamline drug discovery process resources available exploit opportunities within group beta adrenergic agonist type diabetes overactive bladder always limited overall productivity enhanced dipeptidyl peptidase dpp iv inhibitor type diabetes technology development organisation keeps abreast emerging attrition reduced better value money achieved dpp iv inhibitor type diabetes technologies may advance creation new medicines sodium dependent glucose transport type diabetes following annual portfolio prioritisation review cedds evaluates provides investment knowledge sglt antagonist able select programmes fund internally excess assets avandamet xr ppar gamma agonist plus metformin type diabetes extended release required ensure glaxosmithklines access appropriate may developed novel partnership scheme known ccka agonist obesity ii technologies rd generates modifies technologies ppar pan agonist type diabetes ii alternative drug discovery initiative adi key philosophy focus groups internal goals also avandaryl ppar gamma agonist plus sulphonylurea type diabetes fixed dose combination submitted soct behind adi concept shared risk reward avandia amaryl maximise return rd assets sales spinouts partners consequently many different business avandamet ppar gamma agonist plus metformin type diabetes fixed dose combination approved aoct aoct outlicensing arrangements adi partnerships established avandia ppar gamma agonist type diabetes combination insulin approved na afeb academic institutions supplement target validation provide infectious diseases early research role genetics early stages finding new medicines requires essentially better access tissue samples patient populations clinical augmentin daily beta lactam antibiotic respiratory tract infections studies rd also formed adi partnerships biotechnology phospholipid antiendotoxin emulsion sepsis ii two components targets shown affect mechanisms companies pharmaceutical companies explore topical pleuromutilin bacterial skin infections important pathological processes human disease chlorproguanil dapsone antifolate artemisinin treatment uncomplicated malaria na compounds typically small molecules also including different approaches drug discovery artesunate cda augmentin es beta lactam antibiotic acute otitis media incl penicillinresistant pneumoniae iii na macromolecules protein therapeutics vaccines able chewable highdose chewable tablet modulate behaviour specific targets part target sitamaquine aminoquinoline treatment visceral leishmaniasis iii na validation process glaxosmithkline aims identify genes etaquine tafenoquine aminoquinoline malaria prophylaxis adults iii relevant common diseases large unmet medical lapdap antifolate treatment uncomplicated malaria approved ajul na antivirals needs major patient burdens asthma noninsulin miv nucleoside reverse transcriptase inhibitor hiv infections dependent diabetes osteoarthritis copd early onset heart aspartyl protease inhibitor hiv infections disease alzheimers disease nonnucleoside reverse transcriptase inhibitor hiv infections valtrex xr nucleoside analogue management genital herpes modified release l ono ccr antagonist hiv infections ii ziagenepivir reverse transcriptase inhibitors hiv infections combination tablet submitted snov soct lexiva protease inhibitor hiv infections approved sdec aoct valtrex nucleoside analogue herpes simplex virus hsv suppression approved na aapr immunocompromised patients valtrexzelitrex nucleoside analogue prevention hsv transmission approved aaug aaug glaxosmithkline description business description business glaxosmithkline estimated filing dates estimated filing dates compoundproduct type indication phase maa nda compoundproduct type indication phase maa nda neurology gastrointestinal psychiatry endothelin antagonist stroke dual acting cox inhibitor schizophrenia also acute chronic pain conditions endothelial cell adhesion molecule inhibitor inflammatory bowel disease including neuropathic pain selective inos inhibitor acute migraine nk antagonist depression anxiety selective inos inhibitor migraine also asthma copd allergic rhinitis ht antagonist schizophrenia also alzheimer 's disease noradrenalinedopamine reuptake inhibitor restless leg syndrome rls neuropathic pain mixed htdopaminergic antagonist schizophrenia also depression nk antagonist depression anxiety gap junction blocker migraine epilepsy noradrenalinedopamine reuptake inhibitor depression also rls neuropathic pain ii gap junction blocker migraine epilepsy n triple htnoradrenalinedopamine depression attention deficit hyperactivity ii dual acting cox inhibitor acute chronic pain conditions including reuptake inhibitor disorder neuropathic pain also schizophrenia glycine antagonist smoking cessation ii dual alpha integrin antagonist vla multiple sclerosis inflammatory bowel disease nk antagonist depression anxiety also functional dyspepsia ii endothelin antagonist stroke chemotherapy induced nausea vomiting benzodiazepine partial inverse agonist alzheimer 's disease vascular dementia talnetant nk antagonist schizophrenia also ibs overactive bladder ii ht antagonist alzheimer 's disease also schizophrenia lamictal sodium channel inhibitor bipolar disorder acute treatment iii na alvimopan peripheral muopioid antagonist irritable bowel syndrome l wellbutrin xl noradrenalinedopamine reuptake inhibitor seasonal affective disorder iii lamictal xr sodium channel inhibitor neuropathic pain epilepsy daily l paxil cr selective serotonin reuptake inhibitor ssri premenstrual dysphoric disorder intermittent treatment approved ajan dual acting cox inhibitor acute chronic pain conditions including ii lamictal sodium channel inhibitor bipolar disorder longterm prophylaxis approved amar ajun neuropathic pain migraine paxil cr ssri premenstrual dysphoric disorder continuous treatment approved aaug adenosine aa agonist neuropathic pain also dyslipidaemia ii paxil cr ssri social anxiety disorder approved aoct nk antagonist functional dyspepsia also chemotherapy induced ii wellbutrin xl noradrenalinedopamine reuptake inhibitor depression approved aaug nausea vomiting depression anxiety alvimopan peripheral muopioid antagonist chronic opiate induced bowel dysfunction ii respiratory constipation chemokine il receptor antagonist oral chronic obstructive pulmonary disease copd avandia ppar gamma agonist alzheimer 's disease ii long acting beta agonist copd also copd asthma combination talnetant nk antagonist ibs also schizophrenia overactive bladder ii glucocorticoid agonist sumatriptan mt ht agonist naproxen migraine fixed dose combination ii na p kinase inhibitor oral copd also rheumatoid arthritis atherosclerosis alvimopan peripheral muopioid antagonist post operative ileus iii glucocorticoid agonist allergic rhinitis asthma also asthma copd lamictal sodium channel inhibitor neuropathic pain iii na combination long acting beta agonist requip cr nonergot dopamine agonist parkinsons disease controlled release formulation iii long acting beta agonist copd also copd asthma combination requip nonergot dopamine agonist restless legs syndrome submitted sjul aldec glucocorticoid agonist imigranimitrex ht agonist adolescent migraine nasal formulation approved aapr aldec selective inos inhibitor oral asthma copd allergic rhinitis also migraine imigranimitrex ht agonist migraine fast disintegratingrapid release formulation approved ajul ajun long acting beta agonist copd also copd asthma combination oncology musculoskeletal inflammation glucocorticoid agonist glucocorticoid agonist allergic rhinitis ii grot cxc chemokine prevention chemotherapyinduced cytopaenias glucocorticoid agonist asthma also asthma copd combination calcium antagonist osteoporosis long acting beta agonist cathepsin k inhibitor osteoporosis osteoarthritis chemokine ccr antagonist oral asthma allergic rhinitis ii recombinant human il immunologicallysensitive cancers pde iv inhibitor inhaled asthma copd ii immunomodulator melanoma renal cell mepolizumab antiil monoclonal antibody asthma also hypereosinophillic syndrome ii thrombopoietin agonist thrombocytopenia serevent beta agonist asthma copd noncfc inhaler iii na p kinase inhibitor rheumatoid arthritis also atherosclerosis copd seretide beta agonistinhaled corticosteroid asthma initial maintenance therapy iii na vascular endothelial growth factor solid tumours seretideadvair beta agonistinhaled corticosteroid copd mortality claim iii tyrosine kinase inhibitor ariflo pde iv inhibitor oral copd approvable aloct elacridar oral bioenhancer cancer flixotideflovent inhaled corticosteroid asthma noncfc inhaler approved aapr aldec nk antagonist chemotherapy induced nausea vomiting ii seretideadvair beta agonistinhaled corticosteroid asthma noncfc inhaler approved ajun aloct also functional dyspepsia depression anxiety oct kinesin spindle protein ksp inhibitor nonsmall cell lung cancer also solid tumours ii seretideadvair beta agonistinhaled corticosteroid copd approved amay anov ethynylcytidine selective rna polymerase inhibitor solid tumours ii hepatitis vaccines mepolizumab antiil monoclonal antibody hypereosinophillic syndrome also asthma ii erbb egfr dual kinase inhibitor breast cancer also lung bladder gastric head iil hepatitis e recombinant hepatitis e prophylaxis ii neck cancers fendrix extra strength recombinant extra strength hepatitis b prophylaxis submitted smay hycamtin topoisomerase inhibitor small cell lung cancer first line therapy ill hepatitis b prehaemodialysis haemodialysis patients hycamtin topoisomerase inhibitor nonsmall cell lung cancer second line therapy iii na hycamtin topoisomerase inhibitor small cell lung cancer second line therapy iii paediatric vaccines oral formulation n meningitidis conjugated meningitis prophylaxis ii hycamtin topoisomerase inhibitor ovarian cancer first line therapy iii combinations bonivabonviva bisphosphonate treatment prevention postmenopausal iii ibandronate osteoporosis monthly oral dosing priorixtetra mmrvaricella live attenuated measles mumps rubella varicella prophylaxis iii rotarix live attenuated oral rotavirus prophylaxis iii bonivabonviva bisphosphonate treatment prevention postmenopausal iii ibandronate osteoporosis intermittent iv dosing streptorix conjugated pneumoniae disease prophylaxis children iii navelbine vinca alkaloid advanced tumours iii na vaccines breast cancer oral formulation nelarabine u guanine arabinoside prodrug acute lymphoblastic leukaemia lymphomas iii dengue fever attenuated tetravalent vaccine prophylactic use avandia ppar gamma agonist psoriasis iii hiv recombinant hiv prophylaxis bexxar radiolabelled antib monoclonal nonhodgkin 's lymphoma approved na ajun new influenza subunit influenza prophylaxis new delivery antibody pneumoniae elderly recombinant pneumoniae disease prophylaxis bonivabonviva bisphosphonate treatment prevention postmenopausal approved sjun amay varicella zoster recombinant varicella zoster prevention ibandronate osteoporosis daily oral regimen cervarix recombinant prophylaxis human papillomavirus hpv infections ii hycamtin topoisomerase inhibitor small cell lung cancer second line therapy approved anov epsteinbarr virus ebv recombinant ebv prophylaxis ii mosquirix recombinant malaria prophylaxis ii staphylococcal antibodies monoclonal antibody prevention staphylococcal infections ii simplirix recombinant genital herpes prophylaxis iii boostrix polio subunit adolescentadult booster diphtheria tetanus submitted sjul pertussis polio boostrix subunit adolescentadult booster diphtheria tetanus approved aoct pertussis pharmaccines breast cancer therapeutic recombinant treatment breast cancer l neu mage recombinant treatment lung cancermelanoma ii glaxosmithkline description business description business glaxosmithkline product approvals approvals received number new products including several significant new indications formulations existing compounds progressed phase clinical development products summarised table number discovery projects listed table progressed nonclinical safety testing early phase countryregion clinical development compounds continuing rigorous nonclinical clinical commercial assessments leading proof product approval date description concept decisions next months augmentin usa may convenient tablet formulation breakline amoxicillin betalactam antibiotic clavulanate betalactamase inhibitor bacterial infections compoundproduct mechanism indication avandamet eu october fixed dose combination avandia metformin type diabetes endothelial cell adhesion molecule inhibitor inflammatory bowel disease avandiainsulin combination usa march combined use avandia insulin type diabetes selective inos inhibitor acute migraine bexxar usa june radiolabelled antib monoclonal antibody inlicensed corixa aa topical pleuromutilin bacterial skin infections treatment nonhodgkins lymphoma chemokine il receptor antagonist oral copd boniva usa may ibandronate bisphosphonate oral daily treatment osteoporosis inlicensed gap junction blocker migraine epilepsy roche gap junction blocker migraine epilepsy imigranimitrex eu july fast dissolve tablet formulation sumatriptan ht antagonist calcium receptor antagonist osteoporosis usa june nk antagonist depression anxiety lamictal eu march lamotrigine sodium channel blocker longterm prophylaxisprevention bipolar ppar alpha agonist dyslipidaemia usa june disorder cox inhibitor nd generation pain lamictal usa january lamotrigine addon therapy paediatric epilepsy lppla inhibitor atherosclerosis lapdap eu july combination chlorproguanil dapsone treatment malaria longacting beta agonist copd levitra eu march pde v inhibitor treatment male erectile dysfunction inlicensed nk antagonist chemotherapyinduced nausea vomiting usa august bayer ag ht antagonist alzheimers disease schizophrenia lexiva usa october fosamprenavir protease inhibitor hiv mixed htdopaminergic antagonist schizophrenia paxil cr usa august controlled release formulation paroxetine selective serotonin reuptake inhibitor acenep dual inhibitor hypertension continuous treatment premenstrual dysphoric disorder glucocorticoid agonist asthmacopd inhaled allergic rhinitis intranasal paxil cr usa october paroxetine controlled release social anxiety disorder dipeptidyl peptidase iv inhibitor type diabetes requip usa ropinirole nonergot dopamine agonist restless legs syndrome dipeptidyl peptidase iv inhibitor type diabetes seretideadvair diskus eu may combination salmeterol longacting betablocker fluticasone nk antagonist depression anxiety usa november corticosteroid dry powder diskus device treatment copd dipeptidyl peptidase iv inhibitor type diabetes valtrex usa april valaciclovir dna polymerase inhibitor suppression herpes simplex virus sodiumdependent glucose transporter type diabetes immunocompromised patients sglt inhibitor valtrex eu usa august valaciclovir suppression transmission herpes simplex virus ccr antagonist hiv wellbutrin xl usa august extended release formulation bupropion treatment depression augmentin daily formulation amoxicillin clavulanate respiratory tract infections approvable letter january avandamet xr extended release fixed dose combination avandia type diabetes metformin centres excellence drug discovery cedd responsible identifying optimal drug phase started january two essential steps creating drug candidates candidate desired biological effect assessing optimising lead compound potency efficacy safety safety development characteristics preclinical screens submissions intrinsic characteristics molecule ii demonstrating achieved cedds responsible proving number significant dossiers submitted regulatory authorities major regions summarised validity therapeutic hypothesis early clinical compound safe efficacious patients smallscale table trials resulting candidate cedds focused specific clinical trials proof concept decision point disease areas designed nimble entrepreneurial product countryregion description decision made whether information available range skills resources required drive midstage abacavirlamivudine eu usa fixed dose combination reverse transcriptase inhibitors treatment development projects lead optimisation key date justifies compounds progression latestage drug hiv infections decisionpoint demonstration proof concept major development necessary largescale clinical trials advair diskus usa labelling paediatric twicedaily dosing combination salmeterol investments made fund largescale clinical trials conducted register commercialise product longacting betablocker fluticasone corticosteroid dry powder device cedds accelerated progress new new biopharmaceuticals cedd formed avandaryl usa combination rosiglitazone sulphonylurea type diabetes compounds first dosing humans see table extend rds current efforts discover develop recombinant augmentin usa convenient tablet formulation breakline amoxicillin clavulanate compounds progressed phase initial therapeutic proteins monoclonal antibodies certain bacterial infections evaluation efficacy patients addition adjustments therapeutic vaccines imigranimitrex eu usa fast dissolve tablet formulation sumatriptan ht antagonist processes involved stage development enabling paxil cr usa controlled release formulation paroxetine selective serotonin reuptake seven cedds based usa europe reduction development times inhibitor intermittent treatment premenstrual dysphoric disorder paxil japan paroxetine obsessive compulsive disorder biopharmaceuticals centred stevenage uk result substantial number new compounds achieved requip eu usa ropinirole nonergot dopamine agonist restless leg syndrome cardiovascular urogenital diseases centred upper merion critical milestone proof concept potential new seretide mdi eu dose counter pressurised aerosol containing salmeterol fluticasone usa medicines shown sufficient effect target seretide eu use pressurised aerosol containing salmeterol fluticasone metabolic viral diseases centred research triangle park patient group justify transition later stages paediatric asthma usa development microbial musculoskeletal proliferative diseases including serevent diskus eu salmeterol longacting betablocker dry powder diskus device major partnership announced imperial cancer centred upper providence usa treatment copd college london develop major clinical imaging centre neurology gastrointestinal diseases centred harlow uk glaxosmithkline imperials hammersmith hospital site psychiatry centred verona italy respiratory inflammation centred stevenage uk glaxosmithkline description business description business glaxosmithkline first partnership world highly described tasts replaced beginning since group formed december signed latestage projects terminated interactive relationship clinical service ongoing six mdcs responsible creating value major external collaborations products clinical development oxibendazole helminth intestinal infections biomedical chemical research worldclass academic delivery full product development plans includes managing development products preclinical stage phase iii phase ii asthma centre medical school imaging centre provide unique daytoday operational activities postpoc portfolio compounds subject inlicensing copromotion treatment hiv new capabilities required drive clinical portfolio forward delivery medicines patients maximising global commercial deals potential products ensuring strong partnerships vaccines rd part glaxosmithklines major response challenges pulsatile drug delivery system advancis use cedds global commercial strategy gcs project vaccines rd conducted glaxosmithklines biologicals diseases affecting developing world microbial controlled delivery antimicrobials management function integrated mdc centre rixensart belgium including related activities musculoskeletal proliferative diseases cedd responsibility controlled release micropump technology flamel framework order provide direct expertise planning clinical development regulatory strategy commercial strategy drug discovery unit based tres cantos dedicated technologies use developing new formulations execution development activities mdcs therapeutically scaling production packaging support functions finding new medicines diseases research projects nucleoside reverse transcriptase inhibitor medivir aligned follows research scientists employed devoted tres cantos focus malaria tb together work treatment hiv infections discovering new vaccines developing costeffective elsewhere group hivaids vaccines address cardiovascularmetabolic fixeddose combination tablet containing combinations convenient combination products prevent infections cause prevention treatment three world health infectious diseases including ddw long acting nonsteroidal antiinflammatory drug serious medical problems worldwide discovery work identifies organizations top priority diseases group also works musculoskeletalinflammationgastrointestinalurology pozen glaxosmithklines range antimigraine therapies new vaccines candidates expressed yeast numerous external partners worldwide search new neuroscience psychiatryneurology imigranimitrex naramigamerge improve patient bacteria mammalian cells purified high level treatments diseases developing world ddw oncology benefits migraine respiratory solifenacin muscarinic antagonist copromotion followed formulation vaccine involves preclinical development yamanouchi treatment overactive bladder mixing antigens selected adjuvants ultimately matrix teams responsible maximising worldwide preclinical development pcd participates wide range atriple monoamine reuptake inhibitor attentiondeficit stimulate good immune response humans next step development opportunities product within remit activities within drug development process optimising hyperactivity disorder ns part broad evaluate safety efficacy candidate vaccine invivo information needed support registration safety selection compounds potential development alliance covering number research programmes central models preclinical proof concept established programmes pricing formulary negotiations available launch marketplace enhancement existing products nervous system diseases neurosearch candidate vaccine tested clinical trials healthy required commercial input gcs ensures early devising convenient formulations early individuals evaluate safety effective vaccine stage regional marketing needs fully integrated current collaborative adi partnerships cytokinetics inc development process metabolic rate safety compounds inducing immune response protect body disease development plans careful prioritisation across phases oncology mitotic kinesin inhibitors shionogi co hiv evaluated laboratory animals prior testing humans encountered later natural setting largescale field trials development ensures high potential integrated portfolio neurology programmes potential broad based discovery healthy individuals follow establish safety efficacy testing required animals humans mandated achieved collaboration antimicrobials oncology metabolic cross section population results obtained clinical highly regulated government agencies neurology tanabe seiyaku co ltd broad based neurology mdcs collaborate early stage cedds define trials development quality production process gastrointestinal urology diabetes respiratory exelixis inc pcd researchers investigate dosage form eg tablet inhaled target product profiles new molecules integrated facilities combined regulatory file oncology inflammation theravance inc asthma ranbaxy develop formulations enhance drugs effectiveness technical development manufacturing functions ensure submitted authorities various countries laboratories ltd broad based pcd also responsible development drug formulations rapid effective launch delivery product innovative vaccine made available used clinical trials processes supporting analytical methods clinical programmes lead molecules cedds glaxosmithkline one academic adi partner uk drug synthesis product formulation delivery scaled developed using crossfunctional project teams two usa long term collaborative relationships animals research meet increasing supply requirements ultimately leading group committed funding two years ethical regulatory scientific reasons research using animals crossfunctional input extends focused life cycle management technical transfer processes methods option renew additional three years addition remains vital part research development new products deliver new indications new presentations manufacturing glaxosmithkline already entered number agreements medicines vaccines animals used initial regulatory approval commercial launch examples third parties codevelop comarket certain alternative available glaxosmithkline constantly aims new product supply process partnership rd life cycle management include extended release formulation compounds arrangements range milestone payments reduce numbers used group strives exceed industry global manufacturing supply ensures robust product wellbutrin xl development programmes designed deliver third parties acquire rights intellectual property standards care welfare animals uses laboratory developed large scale commercial manufacturing launch new indications use lamictal bipolar disorder joint ventures develop commercialise specified compounds animals usually bred specifically research well cared key technology areas provide ways improve rds first products gold pass initiative started many agreements group obligations throughout lives qualified trained staff productivity include drug delivery systems predictive technologies levitra wellbutrin xl launched make payments future specified milestones achieved animals used research unnecessary pain suffering particle engineering process innovation use particle designation agreed rd regional markets financial commitments summarised note scrupulously avoided glaxosmithkline actively engaged engineering process innovations enhances ability manufacturing key component portfolio resource financial statements commitments research develop validate experimental methods manufacture consistently highquality products efficiently prioritisation management process ensure provide better alternatives use animals resources placed behind key emerging assets yield optimum discontinuations research worldwide development commercial benefit well maximum medical benefit research development carries risk failure provide focus development process major patients gold pass assets high value strategic commensurate extension scientific knowledge glaxosmithkline acknowledges use animals research functional components clinical medical biomedical data importance glaxosmithkline require specific organisational compound effects lead compounds purposes subject rightly commands high level public regulatory safety integrated single visibility urgency meet patients needs consequently identified possess positive activity validated target interest full glaxosmithkline public policy position 'the care management organisation worldwide development small number assets receive gold pass status one time prove safe enough introduce humans feasible ethical use animals research ' available website six crossfunctional therapeutic area strategy teams enabling full focus organisation aligned two manufacture commercial scale glaxosmithkline rd wwwgskcom secretariat tasts covering one following groups diseases products depression cancer endeavours ensure far possible risks received gold pass designation year ameliorated extensive predictive testing early possible research development consumer healthcare cardiovascular urogenital metabolic diseases development process despite efforts ultimate test infectious diseases including ddw principal centres consumer healthcare rd uk inlicensing research collaborations product remains point administered neurology gastrointestinal diseases usa focus rd identification glaxosmithkline continued identify compounds would large numbers patients disease oncology musculoskeletal diseases inflammation rapid development novel products bring benefits enhance portfolio create innovative collaborations glaxosmithkline merck kgaa reviewed progress psychiatry consumers otc oral care nutritional healthcare ensure group regarded partner choice development programme ssri hta receptor partial respiratory markets consumer healthcare liaises closely pharmaceuticals large small companies agonist vilazodone result companies agreed maximise groups assets finding applications development programme terminated prescription products otc marketplace glaxosmithkline description business description business glaxosmithkline operating resources intellectual property levitrad group copromotion rights us patent trade marks significant cost savings achieved consolidation active ingredient vardenafil due expire glaxosmithklines pharmaceutical products protected simplification standardisation basic infrastructure glaxosmithkline regards intellectual property key business usa pfizer initiated legal action usa registered trade marks major markets general mark networks email business application hosting number asset effective legal protection intellectual property certain countries bayer glaxosmithkline used product market around world new central infrastructure services introduced including critical ensuring reasonable return investment rd alleged infringement patent broad method may local variations example usa trade mark hosting web based applications information storage intellectual property protected patents trade marks treatment claim e paxil used instead seroxat advair used instead document management registered designs copyrights domain name registrations seretide patent trade mark rights regarded particularly valuable lexiva glaxosmithkline exclusive licensee patent proactive attention management computer virus threats active ingredient fosamprenavir due expire trade mark protection may generally extended long resulted minimal impact continuity business operations patents usa europe trade mark used renewing necessary risk mitigation plans established several important glaxosmithklines policy obtain patent protection glaxosmithklines trade marks pharmaceutical products computing risk areas including externally facing systems data paxilseroxat patent active ingredient paroxetine significant products discovered developed rd generally assume increasing importance patent privacy business continuity plans outsourced business applications due expire usa europe litigation activities patent protection new active ingredients available product expired particular country generic compliance concerning validity infringement patents protecting significant markets protection also obtained new versions product become available products ongoing usa e generic competition pharmaceutical formulations manufacturing processes transforming extending business activities commenced usa uk certain markets consumer healthcare business trade marks particularly new medical uses special devices administering insights gained genomics proteomics transforming important business brand orientated many products retrovir patents active ingredient zidovudine way disease targets identified validated products patent protection patents covering pharmaceutical formulations containing information obtained external sources may integrated basic patent position respect significant products zidovudine medical use due expire internally generated information rapid flexible follows information technology usa europe manner subjected analysis provide insights augmentin basic patent key active ingredient information technology plays three strategic roles support decisionmaking full advantage taken advances seretideadvair patents specific combination active potassium clavulanate expired markets except italy glaxosmithkline computer technology increased processing power ingredients salmeterol fluticasone propionate due c generic competition exists markets litigation expire usa b europe challenge supporting key business processes local regional access information regulatory agencies clinical opinion concerning clavulanic acid production strain ongoing made patent uk e functional global levels leaders healthcare professionals patients public usa e enabling transformation extension key business enhanced steps taken reduce reliance paper serevent patents active ingredient salmeterol xinafoate avandia avandamet basic patent active ingredient activities based processes clinical trials registration new medicines due expire b europe b france rosiglitazone due expire usa b facilitating collaboration access information use wireless handheld technologies internet c italy usa europe patents commercial form active ingredient global basis many administrative processes including human resources rosiglitazone maleate due expire usa trizivir patents specific combination lamivudine addition computer infrastructure hardware software procurement technology support streamlined b europe litigation concerning validity zidovudine abacavir due expire organisation responsible voice video technologies moving selfservice model enables employees infringement patents protecting products ongoing usa b europe monitoring business technology trends could selfsufficient reduces time effort required usa e valtrex patents active ingredient valaciclovir impact glaxosmithkline preparing group risks complete basic transactions major elearning programme avodart patents active ingredient dutasteride due expire usa b europe associated latest information technology allows employees choose learn new skills normal expiry usa europe requests litigation concerning validity infringement patents reducing training costs significantly introduced focused delivering increased value group extension term patents pending expected protecting product ongoing usa e sales force technology training almost basic services improved quality whilst extend dates usa b europe wellbutrin sr zyban patents basic active ingredient time cost services reduced return introduction extranet capabilities enable secure combivir patents specific combination lamivudine expired various formulation patents protect currently investment increased introduction new interaction partners suppliers increased zidovudine due expire usa marketed sr sustained release formulations latest rapid low cost methodology improving business processes effectiveness supply chain collaboration rd b europe due expire usa europe regulatory without requiring major technology investments establishing alliance partners prescribers data exclusivity provides protection least process ensure business application projects pay coreg glaxosmithkline exclusive licensee us patent countries litigation concerning validity within one year collaborating assessing information active ingredient carvedilol due expire infringement patents protecting products ongoing enabling glaxosmithklines staff productive remains usa e generic competition one dosage forms supporting key business processes high priority adoption standard global tools support epivir patents active ingredient lamivudine due already commenced usa expected shortly developed web based tools provide scientists collaboration information access critical enablers expire usa b europe dosage forms information need candidate medicines way early achieving phase rd teams draw shortlists molecules flixotideflovent flixonaseflonase usa patent ziagen basic patents active ingredient abacavir standard intranet portal adopted consideration possible treatments specific diseases faster active ingredient fluticasone propionate initial expiry due expire usa b europe primary communication channel employees retrieval confidence quality shortlist areas date extended virtue paediatric important information made easier faster zofran basic patents active ingredient ondansetron rd playing important role highthroughput exclusivity may european countries protection provision standard intranet searching capability due expire usa b europe biology laboratory automation imaging electronic data capture due expire b c france c italy patents use treating emesis document management clinical data management uptake groups standard collaboration product suite imigranimitrex patents active ingredient sumatriptan expire litigation concerning validity infringement enables employees work collaboratively across multiple implementation groups enterprise resources planning due expire usa b europe patents protecting products ongoing usa e geographic time zones increased significantly included strategy continued common applications use c italy litigation concerning validity infringement product suite highquality videoconferencing facilities manufacturing plants commercial units patents protecting products ongoing usa e instant messaging online meeting services implemented number sites standard transactions lamictal patents active ingredient lamotrigine middleware used enable efficient movement across progress made global implementation standard due expire usa b countries including extension term supply chain whilst allowing independent optimisation desktop provides employees improved access b including extension term supplementary protection certificates europe litigation concerning validity infringement commercial units regional functional level well information business applications lower cost lightweight c including extension term national supplementary protection certificate patents protecting product ongoing usa e notified following recent change italian law subject legal challenges manufacturing web based desktop also development registered trademark bayer ag e see note financial statements glaxosmithkline description business description business glaxosmithkline business society glaxosmithkline people last year marked first annual multicultural marketing corporate responsibility ehs management diversity awards entrants five countries event glaxosmithkline takes systematic approach managing ehs glaxosmithkline people fundamental success glaxosmithkline committed connecting business decisions highlighted activities serve diverse employees customers risks impacts framework information programmes business skills intellect key components ethical social environmental concerns solid financial stakeholders across glaxosmithklines global community based global ehs standards guides management successful implementation sound business strategy performance closely connected ethical business practices key aspects impacts risks throughout organisation human capital maximises potential groups group committed employment policies free group understands much profit scientific commercial financial assets outcome effective discrimination potential existing staff grounds makes matters stakeholders want know profit ehs assurance improvement human resources policy glaxosmithklines solid reputation age race ethnic national origin gender sexual orientation made reassured sound ethical basis part governance responsibility glaxosmithkline conducts international employer choice faith disability particular glaxosmithkline committed business glaxosmithkline identified broad issues ehs audits sites key contract manufacturers suppliers offering people disabilities access full range generated interest stakeholders reports achieve group initiated candidate care processes based assessing performance recruitment career opportunities every effort made retain year corporate responsibility report available commitment seeking acquiring best employment ehs standards include quantitative performance measurement support staff become disabled secretariat website wwwgskcom candidates reflect diversity background experience sites audited three followup reviews perspective contribute success glaxosmithkline corporate responsibility committee performed part continuous improvement process talent management leadership development glaxosmithkline nonexecutive directors oversight corporate progress monitored actions arising issues raised development planning key element performance planning responsibility matters advises board social ethical audits employees year reviews conducted performance reward environmental issues potential impact seriously business function ensure diverse talent pool fully pilot exercise conducted global manufacturing importance people must translate employment glaxosmithklines business reputation corporate developed meet future business needs successors supply investigate obtaining group wide third party practices demonstrate value individual executive team directs groups corporate responsibility identified key positions certification international standards environmental compensation benefit packages glaxosmithklines total activities general counsel responsible managing health safety management systems iso ohsas reward aim competitive innovative either comprehensive leadership development opportunities available overall programme five sites achieved certification standards part global local orientation depending best drives managers levels opportunities targeted help corporate responsibility issues dialogue stakeholders process addition sites business performance rewards individual contribution leaders meet challenges face complex global managed appropriate functions within glaxosmithkline previously individually certified iso pilot organisation ensure leaders motivate teams individuals compensation philosophy programme development rather central department ensures confirmed feasibility approach programme best work underscore glaxosmithklines commitment performance remain integrated part everyday operation continue voluntary basis global certification culture performance based pay base variable share business facilitate policy development implementation achieved three four years human resources services information systems awards share options performance development planning communication however crossfunctional team established glaxosmithklines human resource delivery strategy designed part commitment corporate social responsibility evaluation contribute retention key talent superior beginning ensure coordinated make technology human resources services proactive management glaxosmithkline manufacturing performance accomplishment business targets comprehensive approach team made representatives information delivered low cost highly effective supply base key contract manufacturers key business areas ensures policies place commitment flexible working flexitime channels make easy job candidates employees suppliers also assessed process evaluated mechanisms exist implementation monitoring teleconferencing remote working flexible work schedules retirees access information employment compensation management ehs risks impacts based groups ehs recognises employees work best environment benefits policies programmes include intuitive crossfunctional team developed set requirements contract manufacturers generally good helps integrate work personal lives personalised web based tools available employees many corporate responsibility principles glaxosmithkline sets performance identified recommendations made locations approach ten areas standards ethical conduct improvements needed communication involvement leadership advocacy research innovation products stimulate employee engagement daily news service property plant equipment customers access medicines employment practices human objectives targets place business unit intranet sites includes daily group rights community investment caring environment objectives focused theme reducing key risks glaxosmithkline invested billion property news announcements online news magazine service engagement stakeholders risks identified significant based past performance carrying value financial statements almost billion chief executive officers home qa online driver safety ergonomics chemical exposures process safety billion carrying value invested plant instances caring environment access information resource encourage employees serve company resilience well emergency response equipment assets construction glaxosmithkline medicines performance measures already place ambassadors appropriate publication media invested million new renewal property plant support demonstration progress principles progress made issues work continue clippings also accompanied group position statement equipment mainly related large number projects potential developing performance indicators support objectives centre around emerging issues ensure employee access key messages important issues improvement expansion facilities various worldwide effective management communication explored pharmaceuticals environment chemicals policy climate employee survey undertaken determine sites property mainly held freehold new investment financed aim strike balance desires change theme responding external ehs challenges employee satisfaction communications channels content group liquid resources st december group stakeholders greater transparency operations numerical targets ehs improvements set per cent employees expressed satisfaction capital contractual commitments future expenditure glaxosmithkline realities costs running accomplished five years health safety target employee broadcast hosted ceo million operating lease commitments business reduction lost time injury illness rate per cent per chairman pharmaceuticals rd held december million information issues may found corporate year environmental targets include reductions energy usage recognise performance remind employees rd pipeline glaxosmithklines business sciencebased technologyintensive responsibility report overview three key associated greenhouse gas emissions reductions solvent information reiterate global strategy share highly regulated governmental authorities allocates corporate areas environment health safety access emissions amount waste wastewater disposed ownership schemes encourage participation owners significant financial resources renewal maintenance healthcare community investments follow progress toward meeting targets tracked every year business increasing awareness short long term business property plant equipment minimise risks interruption published wwwgskcom date significant progress objectives global local employee opinion surveys allow production achieve compliance regulatory responsibility environment health safety made towards achieving ehs targets employees opportunity express views perspectives standards research development manufacture important group issues environment health safety ehs key element corporate pharmaceuticals uses chemicals hazardous materials performance improvement measures responsibility group high priority responsibility group observes stringent procedures uses specialist skills glaxosmithkline measures impact health safety diversity ehs highest level corporate group reporting manage environmental risks activities environmental people work sites impact environment glaxosmithkline diversity initiative continued focus general counsel overall responsibility providing issues sometimes dating operations modified measure impact people lost time injury illness creating inclusive work environment aiming enhance governance leadership ehs issues head group discontinued referenced responsibility environment rate enough result lost time per hours worked employee innovation productivity measurably improve makes regular reports corporate executive team cet health safety note financial impacts air water land measured metric tonnes employee attraction development retention audit committee within operations line managers statements legal proceedings glaxosmithkline believes material emitted waste disposed impact natural responsible ehs supported sitebased ehs facilities adequate current needs resources measured cubic metres water used gigajoules occupational health professionals energy consumed glaxosmithkline description business description business glaxosmithkline glaxosmithkline selects measures performance improvement access healthcare developing world preferential pricing improving access group global community investment based risk risks determined part evaluation arrangements covering worlds poorest countries access healthcare developing countries remains unique glaxosmithklines global community investment activities impacts impacts considered potential supply arvs preferential prices customers include governments challenge global community problem rooted valued million included million adverse impact people environment business nongovernmental organisations ngos hospitals academic poverty demands significant mobilisation resources groups patient assistance programs medicine donations continuity business reputation measures selected institutions private employers true spirit partnership must tackled shared low income groups usa million similar reported companies responsibility sectors global society group offer notforprofit prices requires sustainable framework humanitarian product donations total equivalent recommended global reporting initiative longterm mandate expertise resources address underlying combining groups commitment preferential pricing per cent group profit tax included million multistakeholder international undertaking develop problems exist however glaxosmithkline continues play commitments governments avoid price referencing costs manage deliver community programmes disseminate globally applicable sustainability reporting guidelines vital role commitment rd diseases preferentially priced medicines help prevent product countries particularly prevalent developing world diversion glaxosmithkline taken steps minimise threat product stewardship many programmes long term commitments help programme preferential pricing antiretrovirals arvs diversion able supply countries combivir glaxosmithkline global standard product stewardship bring sustainable change underserved communities antimalarials vaccines community investment special access pack similar efforts underway secure establishes requirements responsible ethical groups community investment activities mainly focused activities partnerships widespread regulatory approval trizivir epivir access packs management ehs aspects products throughout life health education include colour differentiate product packaging cycles product stewardship provides systematic way identify rd diseases developing world product process risks early may mitigated however alone fully deter illegal traders public health programmes growing antiinfective resistance current treatments inadequate managed ultimately eliminated integrating product experts repackaging medicines glaxosmithkline therefore global alliance eliminate lymphatic filariasis healthcare infrastructure poor patient compliance complex stewardship business activities protects people welcomed political commitment prevent diversion arose glaxosmithklines flagship community programme aims treatment regimens continues drive need investment environment enhances compliance local regulatory g summit june european union eliminate disfiguring mosquitoborne disease world rd new drugs vaccines diseases affect requirements avoids interruption product supply antidiversion regulation may countries company committed provide much developing world encouraged take similar steps ensure introduction antiparasitic drug albendazole required estimated billion environmental sustainability glaxosmithkline believes industrys extensive strict enforcement measures counter trade main preventative treatments treat one billion people risk concept sustainable development central groups portfolio products rd projects diseases beneficiaries illegal importers countries environmental programmes work started towards eventual developing world undertakes rd prevention october glaxosmithkline extended voluntary licence glaxosmithkline founders global alliance environmental sustainability mitigating environmental impacts treatment three world health organizations granted aspen pharmacare subsaharan africas largest generics eliminate lymphatic filariasis lf unique partnership looking ways improve production efficiency use priority diseases developing world hivaids tuberculosis company manufacture sale combivir epivir includes ministries health endemic countries non renewable resources overall balance consumption tb malaria retrovir licence previously limited public sector governmental organisations communitybased organisations resources generation waste investigated addition rd hivaids glaxosmithkline rd south africa zimbabwe group extended academic institutions international organisations private future group standard sustainable development team based spain uk dedicated treatments licence cover public private sectors across sector defines approach discovery manufacturing diseases developing world projects prioritised primarily subsaharan africa sales environmental sustainability starts rd part fifth year programme million tablets socioeconomic public health benefits rather support rd toolkit developed assist worth almost million wholesale acquisition cost commercial returns group currently rd success partnership selection green chemistries processes donated countries part ongoing preventative projects programmes relevance developing world glaxosmithkline continues build history community programme glaxosmithkline shipped million albendazole nine aimed producing vaccines medicines investment programmes support better healthcare delivery access healthcare developed world tablets sri lanka ministry health mobilised diseases disproportionally affect developing countries education underserved communities developing healthcare workers volunteers treat million people glaxosmithkline plays active part improving healthcare world group active engagement group increasingly involved publicprivate partnerships single day july one largest community treatment people limited access medicines orange card external stakeholders consulted worked enable wide range projects undertaken saw one programmes type take place developing world scheme helped senior american citizens governments developed developing world first tangible outputs partnerships launch addition group gave grants almost million staff low incomes save medicines buy un ngos investment community antimalarial lapdap result collaboration expertise support activities global alliance group reinforced commitment programme least uk government university liverpool much achieved specifically around hivaids funding eliminate lf including advocacy research community mobilisation london school hygiene tropical medicine support thanks initiatives global fund president bushs educational initiatives brings companysponsored savings programmes single initial grant wellcome trust lapdap already emergency plan aids relief however significant increase card extending possible savings pharmacy counter launched number african countries resources still needed also important maintain glaxosmithklines positive action hivaids widely prescribed medicines easy use incentives rd protection intellectual property marked th year positive action glaxosmithklines card together rx participants able save per cent preferential pricing arrangements example neither cure vaccine hivaids pioneering global programme hiv education care usual amount paid prescriptions end glaxosmithkline offered vaccines public health community support positive action supported glaxosmithkline continue vital contribution approximately million people joined programme programmes significant discounts years group programmes countries partners positive action improving healthcare developing world however real also sets single sustainable notforprofit price focus subsaharan africa magnitude progress occur significant barriers stand arvs antimalarials wide range customers least hivaids pandemic programme also supports way better access healthcare tackled shared developed countries subsaharan africa well projects affected communities countries around world responsibility sectors global society governments fullyfunded global fund fight aids tb malaria international agencies charities academic institutions support included grant movement men means notforprofit prices offered total pharmaceutical industry others aids kenya mmaak encourage mens engagement countries glaxosmithkline committed contributing involvement aspects hivaids crisis since men health improvements sustainable manner commonly decisionmakers workplace government preferential prices glaxosmithkline arvs antimalarials religious institutions another example support therefore set levels profit made direct vulnerable communities grant uk costs covered allowing supply sustained long based ngo develop lowcost health education resource required group undertaken reduce prices hiv hepatitis sexual health use uk prisons whenever possible able meet commitment twice glaxosmithkline description business description business glaxosmithkline help address growing hivaids problem china education programmes included science groups efforts improve public education included grant employee involvement group provided british red cross australian across world international education programme uses science summer free librarybased glaxosmithkline employees encouraged contribute red cross threeyear programme prevent spread web based resources promote discussion science issues within science education programme philadelphia area teaching local communities employee volunteering schemes hiv training young people drug users hiv schools almost countries seventh year basic scientific concepts children th year support varies around world includes employee time prevention life skills group sponsored royal institution christmas lectures children participated programme cash donations charities employees completed broadcast channel four television give young people voluntary work matching gifts programme many russia ukraine rapidly increasing incidence university north carolina chapel hill received opportunity inspired eminent scientists countries glaxosmithkline offers taxefficient options employee hivaids glaxosmithkline provided funding establish part overall million grant travelling science giving accordance local taxation guidelines support national networks positive people help part glaxosmithklines commitment environment laboratory help improve science teaching encourage advocate hiv education prevention care treatment group sponsored gowild oneoff living festival royal underserved students pursue careers science usa group matched services addition group granted million two botanic gardens kew received visitors employee gifts value million us pharmaceuticals group launched glaxosmithkline healthy years support work two hivaids clinics malawi may september communities health education outreach group also matched million employee donations uganda programme advance healthy living among african americans federal united way campaign usa giving combined europe congressional black caucus foundation date received contribution million addition glaxosmithklines glaxosmithkline african malaria partnership corporate programmes europe focused improving part grant four year period investment volunteer excellence give programme provided glaxosmithkline african malaria partnership supports three childrens health total funding million supporting help support high school graduates college students interested grants charitable organisations usa behavioural development programmes working seven african range longterm programmes addition glaxosmithkline pursuing careers science medicine employees partners volunteered least hours countries group disbursed first grants companies europe provided million regional year million commitment partners freedom hunger community activities international amref plan international programmes expected glaxosmithklines making difference programme uk european forum families children living hivaids groups corporate public health programmes benefit nearly two million people focus particularly young provided grants nonprofit organisations received three year programme works young developing countries corporate programmes children pregnant women encouraging effective prevention registered charities based employee involvement people italy portugal romania russia spain alleviate international region addressed health education mobilisation measures prompt treatment antenatal malaria management hivassociated stigma discrimination providing funding million foundations regional community initiatives barretstown ireland lenvol france support group provided phase initiative personal glaxosmithkline operate single charitable foundation united kingdom european children cancer lifethreatening illnesses hygiene sanitation education kenya zambia nicaragua community investment programmes number glaxosmithkline contributed million continuing rediscover inner strength selfesteem received peru last four years phase provided education countrybased foundations canada czech republic france corporate programme charitable activities uk respectively school children reduce diarrhoearelated disease italy romania spain usa support projects within areas health medical death glaxosmithkline continued support charity healthprom last five years glaxosmithkline france foundation research science education arts environment azerbaijan health ministry investing ethiopia group provided integrated supported programmes african countries improve addition glaxosmithkline companies uk provided fourth year safe childbirth initiative benefit management childhood illnesses imci partnership hivaids prevention education training care million community purposes giving combined total refugees unicef enables families improve key household people expected benefited million support projects uk practice behaviours significant impact foundation provided funding zippys friends school programme run partnership medical research total provided child survival rates growth development ongoing initiatives part five year commitment children teach coping skills young children denmark epilepsy research foundation international spinal research trust lithuania continued receive funding extended pakistan national commission human development north carolina glaxosmithkline foundation usa national osteoporosis society tommys baby charity reach uk india nchd received focus improving maternal health endowed selffunding organisation operates separate glaxosmithklines annual uk impact awards recognise excellence rural areas entity foundation publishes annual report work voluntary community health organisations across north america available request uses asset base support uk uk charities received unrestricted corporate programmes north america focused improving product donations mathematics science health education north carolina award work dealing issues diverse public education access better healthcare children glaxosmithkline donates essential products antibiotics foundation made donations totalling sexual abuse mental health elderly day care disability seniors funding million million humanitarian relief efforts donations made request million included groups total community donated groups us based businesses regional governments major charitable organisations may investment figure donation almost made charity beating community activities manufactured specifically meet requirements bowel cancer national awareness campaign bowel glaxosmithkline works partnership charitable organisations cancer uks second deadly cancer aimed highlighting examples glaxosmithklines contribution improving deliver relief including americares interchurch medical symptoms promoting early diagnosis save lives healthcare include threeyear grant million assistance map international project hope ensure helped expand childrens health funds referral glaxosmithkline hopes encourage next generation right product reaches right person right time management initiative rmi seven us states ensuring scientists supporting science education programmes example group donated vital medicines first airlift continuity specialist medical care highrisk children give science context enhance science teaching group iraq april aid flight kosovo organised often homeless committed million four years support phase two americares glaxosmithkline also provided relief following new darwin centre natural history museum glaxosmithkline share recognition awards recognised earthquakes india flooding nicaragua london glaxosmithkline continued support inspire work small communitybased organisations aim total value groups international humanitarian innovative scheme postdocs research education improve health older people across diverse cultures product donations million excludes albendazole scheme developed partnership imperial college london six organisations received total providing extra donated part groups commitment lymphatic specialist schools trust million donation support launch new programmes strengthen ongoing filariasis elimination programme product donations valued four years inspire aims raise achievement science placing initiatives wholesale acquisition cost wholesale list price postdoctoral researchers specialist science schools assist annual usa impact awards acknowledge reward including discounts standard industry method science teaching study teaching qualification excellence nonprofit healthcare sector greater philadelphia area nine charities received unrestricted award work dealing issues diverse child abuse breast cancer sexual reproductive health glaxosmithkline glaxosmithkline corporate governance section discusses glaxosmithklines management structures governance procedures contains companys reporting disclosures corporate governance required combined code corporate governance uk listing authority code including required statement compliance also gives details principles provisions new combined code corporate governance financial reporting council code glaxosmithkline required comply st january report annual report measures implemented achieve described section company reports compliance relevant us laws regulations apply board corporate executive team governance policy dialogue shareholders annual general meeting internal control framework committee reports combined code us law regulation glaxosmithkline corporate governance corporate governance glaxosmithkline board john mcarthur aged corporate executive team cet david pulman appointed rd may president sir christopher hogg aged jp garnier nonexecutive director mr mcarthur formerly nonexecutive global manufacturing supply appointed rd may chief executive officer director glaxo wellcome plc nonexecutive director dr pulman responsible global manufacturing supply nonexecutive chairman sir christopher formerly chief executive officer dr garnier responsible bce inc bce emergis inc cabot corporation hca corporation chain network joined glaxo responsible nonexecutive director smithkline beecham plc management group oversees operational aspects koc holdings rohm haas company telsat canada north american supply network manufacturing strategy nonexecutive chairman reuters group plc member including establishing policies objectives initiatives aes corporation also senior advisor president logistics current appointment supervisory board air liquide sa chairman directs longterm strategy formerly chief executive officer world bank royal national theatre smithkline beecham joined group david stout donald mchenry aged president dr jeanpierre garnier aged rupert bondy appointed rd may pharmaceutical operations appointed rd may senior vice president general counsel nonexecutive director mr mchenry formerly nonexecutive mr stout responsible global pharmaceuticals vaccines chief executive officer dr garnier appointed executive mr bondy responsible legal matters across group director smithkline beecham plc nonexecutive businesses joined smithkline beecham head director smithkline beecham plc became chief together environmental health safety issues insurance directorships include cocacola company fleetboston us sales marketing president us pharmaceuticals executive officer april nonexecutive director security lawyer private practice joining financial corporation international paper company att current appointment january united technologies corporation member board smithkline beecham corporation trustees eisenhower exchange fellowships holds chris viehbacher ford calhoun phd pharmacology university louis pasteur sir ian prosser aged president chief information officer france mba stanford university usa appointed rd may us pharmaceuticals dr calhoun responsible information technology global nonexecutive director sir ian formerly nonexecutive mr viehbacher responsible us pharmaceuticals since john coombe aged function enables key business processes across parts director smithkline beecham plc chairman six january joined wellcome became director appointed rd may group doctoral postdoctoral training microbiology continents plc world travel tourism council continental europe glaxo wellcome chief financial officer mr coombe formerly executive genetics biomathematics computer science joined smith nonexecutive deputy chairman bp plc member responsible glaxosmithklines european pharmaceuticals director glaxo wellcome plc responsible kline french cbi presidents committee business current appointment finance investor relations member supervisory john coombe board siemens ag code committee uk dr ronaldo schmitz aged andrew witty chief financial officer takeover panel appointed rd may president head finance function mr coombe responsible nonexecutive director dr schmitz formerly nonexecutive pharmaceuticals europe dr michle barzach aged activities financial reporting control tax treasury director glaxo wellcome plc nonexecutive director mr witty responsible groups pharmaceuticals appointed rd may investor relations finance systems internal audit real estate legal general group plc member board directors operations europe since january joined glaxo nonexecutive director dr barzach formerly nonexecutive joined glaxo group financial controller rohm haas company cabot corporation glaxosmithkline senior vice president asia pacific director glaxo wellcome plc member appointed group finance director current appointment international cooperation high council chairman board dr lucy shapiro aged marc dunoyer equilibres et populations director board project appointed rd may tachi yamada president hope international consultant health strategy formerly nonexecutive director dr shapiro formerly nonexecutive chairman pharmaceuticals japan french minister health family director smithkline beecham plc ludwig professor research development mr dunoyer appointed president pharmaceuticals japan cancer research department developmental biology dr yamada leads groups complex business drug discovery lawrence culp aged march joined group senior vice director beckman center molecular genetic development creating new medicines research appointed st july president regional director japan current medicine stanford university school medicine joined smithkline beecham nonexecutive member nonexecutive director mr culp president chief executive appointment nonexecutive director anacor pharmaceuticals inc holds board became chairman rd pharmaceuticals officer danaher corporation prior joining danaher held phd molecular biology albert einstein college russell greig appointed board directors st january positions accenture previously andersen consulting medicine president jennie younger crispin davis aged pharmaceuticals international sir robert wilson aged senior vice president appointed st july dr greig leads pharmaceutical operations outside usa appointed st november corporate communications community partnerships nonexecutive director mr davis chief executive reed elsevier europe covering countries joined nonexecutive director sir robert nonexecutive chairman mrs younger responsible groups internal external plc prior chief executive aegis group plc group senior vice president worldwide bg group plc economist group previously communications image partnerships global joined guinness plc group business development rd prior current appointment executive chairman rio tinto plc communities joined glaxo wellcome director managing director united distillers member main march investor relations board guinness plc spent early career procter dr tachi yamada aged dan phelan gamble appointed st january jack ziegler senior vice president chairman research development dr yamada formerly president sir peter job aged human resources nonexecutive director subsequently executive director consumer healthcare appointed rd may mr phelan responsible benefits compensation recruitment smithkline beecham plc prior joining smithkline beecham mr ziegler head global consumer healthcare business nonexecutive director sir peter formerly nonexecutive organisation development leadership development succession chairman department internal medicine produces oral healthcare overthecounter medicines director glaxo wellcome plc nonexecutive director planning human resource information systems employee university michigan medical school physicianinchief nutritional healthcare products joined smithkline beecham schroders plc shell transport trading company plc tibco health management lawyer private practice university michigan medical center member appointed president consumer software inc instinet group inc also member joining smith kline french appointed board directors diadexus inc trustee healthcare business supervisory boards deutsche bank ag bertelsmann ag senior vice president director human resources smithkline rockefeller brothers fund beecham members directors mr pien left group st march pursue another role sir roger hurn nonexecutive deputy chairman mr paul pharmaceutical industry mr ingram continues work part allaire nonexecutive director retired board time vice chairman pharmaceuticals acting special th june advisor group attends cet meetings capacity details membership board committees may found glaxosmithkline corporate governance corporate governance glaxosmithkline governance policy board reviews companys internal controls risk audit committee evaluation board board committees directors management policies approves governance structure audit committee reviews financial internal reporting board initiated systematic approach evaluation board executive code ethics board reviews also approves major process system internal control management risks performance evaluation board committees directors listed board financing investment contractual decisions excess external internal audit process committee also directors undertaken chairman implemented defined thresholds addition items board evaluates proposes shareholders appointment external auditors collaboration committee chairmen support board responsible groups system corporate monitors performance group whole directly responsible remuneration oversight company secretary governance ultimately accountable groups activities includes work committee consists entirely independent strategy financial performance evaluation conducted way private discussion nonexecutive directors meets least four times year engaging board meetings ceo executive chairman directors chairman board comprises three executive eleven nonexecutive report audit committee given directors members cet appropriate assisted preparing conducting evaluation directors whilst board considers nonexecutive directors financial operating performance glaxosmithkline external adviser conducted separate interviews independent character judgement accordance remuneration committee external issues material groups prospects directors enabled directors perspectives code determined four nonexecutive remuneration committee determines terms service chairmans performance fed back chairman directors chairman dr barzach mr mchenry dr shapiro evaluating progress toward achievement groups remuneration executive directors members cet full board performance evaluations board committees considered independent code financial business objectives annual plans assistance external independent advisors conducted behalf chairman chairmen case chairman mr mchenry due evaluates makes recommendations board overall monitoring reports received directly various respective board committees length service glaxosmithkline predecessor executive remuneration policy committee consists entirely committees key significant risks facing group companies case drs barzach shapiro due independent nonexecutive directors meets least four times corporate executive team remuneration received group board overall responsibility succession planning year otherwise necessary information remuneration cet assists ceo executive management capacities four nonexecutive directors resigned ceo position board given ceo broad authority directors given remuneration report pages group cet meets times per year members positions board committees independence operate business group ceo accountable responsibilities listed corporate executive team required code reports board business performance nominations committee board considers mr mcarthur dr schmitz mr culp board met six times director attended every nominations committee reviews structure size mr davis sir peter job sir ian prosser sir robert wilson meeting held tenure dialogue shareholders composition board appointment members independent code board noted board recognises may occasions one board cet makes recommendations board dr schmitz mr mcarthur associated nonexecutive financial results announced quarterly directors feel necessary take independent legal appropriate committee also monitors planning directors public companies rohm haas company andor financial advice companys expense succession board senior management committee company reports formally shareholders twice year cabot corporation consider associations agreed procedure enable consists entirely nonexecutive directors majority halfyear fullyear results announced ceo cfo sufficient economic significance compromise independent meets least year consider succession give presentations final year end results institutional independence company secretary responsible board available planning otherwise necessary report investors analysts media london new york individual directors respect board procedures date publication majority board members nominations committee given addition teleconferences release first company secretary simon bicknell appointed may excluding chairman independent nonexecutive second third quarter results institutional investors analysts barrister joined group directors accordance recommendations financial results committee media presentations may also accessed secretary board committees code financial results committee reviews approves behalf companys website board annual report form f annual dr barzach mr mcarthur mr mchenry retiring board committees agm takes place london formal notification sent review convening annual general meeting board conclusion annual general meeting agm shareholders least one month advance meeting together preliminary quarterly statements trading th may following retirement assuming board established number committees provides business presentation made shareholders directors able results director member committee directors seeking election reelection agm sufficient resources enable undertake duties attend available formally meeting informally quorum meeting three members quorate elected reelected board comprise three executive current membership committees given table afterwards questions details agm set meeting must include chairman chairman audit directors eight nonexecutive directors majority pb eolfo bwoar committees indicated following table section annual general meeting committee ceo cfo committee meets board excluding chairman independent nonexecutive directors ggoh reinrag ebmooc hcazrab pluc sivad boj ruhtracm yrnehcm ressorp ztimhcs oripahs nosliw adamay necessary ensure nonexecutive directors aware understand views major shareholders company sir christopher hogg nonexecutive chairman dr garnier corporate responsibility committee board place process focusing sector specific issues audit c chief executive officer ceo chairman leads board corporate administration corporate responsibility committee formerly corporate well general shareholder preferences respect transactions represents board ceo cet members social responsibility committee consists entirely nonexecutive general perspectives shareholders year nonexecutive corporate responsibility c necessary board meetings ceo manages group financial results directors provides board level forum regular review directors receive external review shareholder opinion implements strategy policies adopted board nominations c external issues potential serious impact upon presented may october full board chairman chairmen board committees remuneration c groups business reputation committee also received presentation leading financial analyst specialising communicate regularly ceo cet members key c chairman member responsible annual governance oversight groups pharmaceutical sector division responsibilities role chairman worldwide donations community support committee ceo cfo maintain dialogue institutional ceo set writing agreed board meets formally twice year meetings following summary role terms reference shareholders performance plans objectives appears full companys website sir ian prosser consultations required committee full terms reference committee programme regular meetings speak regularly appointed senior independent director effect obtained company secretary corporate external conferences presentations st january sir roger hurn senior independent director corporate administration transactions committee governance section companys website st january th june corporate administration transactions committee reviews groups investor relations department offices london approves matters connection administration philadelphia acts focal point contact investors board process groups business certain corporate transactions throughout year board authority accountable shareholders committee consists directors corporate executive team companys website gives access current financial ensuring company appropriately managed members company secretary committee meets business information group achieves strategic objectives agreed board board necessary discharges responsibilities supervising overall budgetary planning treasury planning business strategy glaxosmithkline corporate governance corporate governance glaxosmithkline share buyback programme biographical details director given number risk areas specific standards meet exceed legal intellectual property october following completion billion share board requirements applicable law established specialist product liability intellectual property antitrust litigation buyback programme announced company audit compliance groups example corporate environment government investigations related private litigation dr barzach mr mcarthur mr mchenry retire announced plans billion share buyback health safety worldwide regulatory compliance assist significant potential risks glaxosmithkline group board conclusion agm programme programme covers purchases company dissemination implementation audit standards involved various legal administrative proceedings shares cancellation held treasury shares areas outcome proceedings predicted reappointment auditors internal control framework also relies risk oversight accordance authority given shareholders level certainty resolutions proposed reappoint compliance council rocc reports cet companys annual general meeting total million pricewaterhousecoopers llp auditors authorise audit committee well business unit risk also potential risk third parties may allege spent audit committee determine remuneration management compliance boards rmcb help identify risks marketing groups products infringe intellectual may company authorised purchase provide guidance risk management compliance property rights third parties maximum million shares million shares may special business initiatives corporate business unit levels rocc million shares purchased cancellation company seek renew authority chaired corporate compliance officer cco meets finance see note financial statements share capital share regularly review assess significant risks mitigation plans potential risks uncertainties surrounding groups make donations eu political organisations incur premium account exact amount timing future directed risks rocc oversight ability forecast future thus meet financial targets eu political expenditure purchases determined company dependent risks deemed significant group rmcb oversees risks group invests new products ventures based give directors authority disapply preemption rights market conditions factors important business function thus increasing active assumptions success may prove inaccurate allotting new shares connection rights issues management risks across group corporate ethics also potential risks around groups treasury otherwise maximum five per cent donations political organisations eu political compliance department cec responsible supporting operations including tax liabilities transfer pricing current issued share capital expenditure development implementation practices facilitate possibility trading losses counterparty fraud compliance obtain authority purchase ordinary shares agm may shareholders employees compliance laws group policy cco evolving financial disclosures legal reporting maximum ten per cent current issued authorised company make donations eu political also manages cec assists coordination risk requirements constitute risks including appropriateness share capital organisations incur eu political expenditure management activities among various compliance audit effectiveness controls place support financial statement provisions political parties elections referendums act functions across group reporting groups pension liabilities represent area internal control framework year although company potential risk discussed note financial details risks affecting group see note intended make donations political parties statements employee costs board recognises responsibility present balanced financial statements legal proceedings risk factors within normal meaning expression definition understandable assessment groups position prospects pages areas potentially significant risk subject legislation eu political organisation extend bodies manufacturing structure accountability audit operated regular reporting rocc include following including concerned policy review law reform maintaining supply key glaxosmithkline products potentially glaxosmithkline follows representation business community special interest significant risk groups policy take reasonable measures human resources groups concerned environment board accountability reviewing approving ensure uninterrupted supply product including legal requirements regarding discrimination harassment company subsidiaries might wish support adequacy effectiveness internal controls operated manufacturing accordance applicable laws regulations integrity workforce including preemployment group made donations noneu political organisations totalling company including financial operational compliance controls well corporate standards may exceed screening control use contractors temporary donations made eu political risk management board delegated responsibility requirements group takes efforts minimise single staff risks inherent group employees organisations review audit committee receives reports sourcing key products rationalising supply chain individuals identified committees report balancing manufacturing capacity present risks could research development annual general meeting responsibility management cet potentially disrupt supply important products safety marketed products potentially significant risk implement board policies risk control cet matter great concern glaxosmithkline conduct agm held pm monday th may responsible identifying approving enforcing key policies information technology laboratory practices clinical practices trials rd must queen elizabeth ii conference centre broad sanctuary go heart group conducts business protecting information technology assets increasing risk accordance applicable laws regulations well westminster london swp ee business transacted internal control framework includes central direction resource businesses extend networks systems data third parties corporate standards may exceed requirements meeting include allocation risk management key activities research dependency internet communications increases pharmaceutical products bring benefits risks development manufacturing marketing sales legal ensuring proper systems validation electronic records including potential side effects preclinical clinical trials receiving adopting glaxosmithkline 's annual human resources information systems financial practice signatures key regulatory issues matters potential risk conducted development potential products report part framework comprehensive planning group web systems accessible public must comply determine safety efficacy products use humans system annual budget approved board results legal regulatory requirements represent potential following approval regulatory bodies spite efforts approving remuneration report operating units reported monthly compared risks potential risks include use personally identifiable drugs introduced marketplace unanticipated remuneration report pages sets budget forecasts prepared regularly year information electronic record retention outsourced business side effects may become evident group views use remuneration policies operated glaxosmithkline applications susceptibility viruses outside incursions extensive financial controls procedures selfassessment exercises animals human tissue testing required develop new disclosures directors remuneration including required much groups business dependent upon electronic risk mitigation activities reviewed groups internal products another risk companies act directors remuneration means disaster recovery also poses potential risk auditors commercial financial responsibility however report regulations resolution proposed clearly delegated local business units supported regional marketing sales approve remuneration report security environment safety management structure principles designed provide group operates globally complex legal regulatory threats security well groups employees environment central leadership coupled local operating environments often vary among jurisdictions groups retirement election reelection directors property environment present significant risks autonomy framework exercise accountability policy conduct marketing accordance applicable laws mr lawrence culp mr crispin davis sir robert wilson appropriate safeguards precautions continually reviewed control within group regulations well corporate standards may dr tachi yamada appointed directors since upgraded employee injury ill health due occupational exceed requirements failure observe applicable last agm offer election board group also attaches importance clear principles conditions plant management potential impact marketing codes rules regarding government pricing management procedures designed achieve appropriate accountability plants environment potential risks group addresses sir christopher hogg retire offer reelection samples legal restrictions sale marketing practices control corporate policy risk management legal process sets targets provides guidance board article companys articles may create significant risks commercial sectors compliance mandates business units establish processes results may achieved association group failure comply may result legal proceedings managing risks significant businesses group glaxosmithkline corporate governance corporate governance glaxosmithkline effectiveness controls dr schmitz also member executive board committee primary responsibility making committee met full session audit committee receives regular reports areas directors deutsche bank ag retired board recommendation shareholders appointment quorate basis members present full meeting significant risk group related internal controls charge investment banking dr schmitz reappointment removal external auditors annually following consideration reports committee reports formerly member executive board directors assessing qualifications expertise resources independence remuneration report annually board effectiveness controls basf including cfo external auditors effectiveness audit process remuneration report found pages controls may mitigate eliminate risks addition holds mba insead sir peter job ceo reuters plc making assessment committee considers papers areas groups business necessary brings considerable industrial experience combined code detail relevant regulatory requirements required external take risks achieve satisfactory return shareholders role member committee sir ian prosser auditors evaluates reports external auditors investment acquiring new products businesses cfo later ceo six continents plc member throughout company complied code provisions stated compliance requirements external cases companys objective apply expertise institute chartered accountants england wales combined code except follows auditors provide nonaudit services committee ensures prudent management rather elimination risk directors sir robert wilson began professional career economist auditor objectivity independence safeguarded policy board appoint one independent review relates company subsidiaries held senior management positions rio tinto plc culminating requiring preapproval audit committee services nonexecutive directors senior independent director extend material associated undertakings joint ventures appointment executive chairman expenditure audit nonaudit services set sir roger hurn senior independent director investments committee supported company secretary st january th june remainder considered audit committee report effectiveness attends committees meetings available year nonexecutive directors remained available guidelines set companys policy engaging controls board believes system internal controls financial resources take independent professional advice shareholders raise concerns could addressed external auditors provide nonaudit services include ascertaining provides reasonable although absolute assurance considered necessary meetings committee attended chairman ceo cfo december skills experience external auditors make material misstatement loss process accords chairman ceo cfo general counsel head global following nominations committee review boards suitable supplier nonaudit services adequate safeguards guidance internal control issued turnbull committee internal audit gia cco external auditors structure composition board announced place objectivity independence audit appointment sir ian prosser senior independent director committee worked structured programme compromised fee levels relative annual audit effect st january activities agenda matters focused coincide key events fee within limits set committee criteria committee reports annual financial reporting cycle together standing govern compensation individuals performing b schemes performance related remuneration items committee required consider meeting annual audit appropriate neither annual bonuses benefits kind audit committee report pensionable pension contributions solely determined audit committees role flows directly boards external auditors reported committee critical company also wellestablished policies including code basis basic salary companys position described oversight function authorised board investigate accounting policies practices used company ethics available website helpline facility remuneration report pages activity within terms reference committee alternative accounting treatments discussed reporting investigation unlawful conduct written terms reference approved management resultant conclusion external b notice contract periods service contracts committee met full session four times four board committee reports regularly board auditors material written communications management one year less companys position described times quorate basis full session attended performance activities assigned restrictions access information remuneration report pages members committees main responsibilities include reviewing corporate cfo reported financial performance company b compensation commitments event early accounting financial reporting process monitoring technical financial accounting matters nominations committee report termination directors contract companys position integrity companys financial statements evaluating nominations committees terms reference include respect mr coombes previous contract described system internal control management risks general counsel reported material litigation responsibility proposing appointment board remuneration report pages overseeing compliance laws regulations ethical codes company secretary reported corporate governance committee members three new nonexecutive practice committees oversight role requires address company required comply combined directors one executive director appointed regularly relationships management internal head gia reported effectiveness system code st january report compliance external auditors understand monitor reporting internal controls steps taken improve companys case nonexecutive directors committee annual report issued regard relationships tiers accountability parties risk management framework considered particular skills knowledge experience measures described implemented would benefit board significantly appointment committee entirely composed independent nonexecutive cco reported activities undertaken rocc annual report contains statement broad selection criteria focused achieving balance directors sir christopher hogg resigned member board operates decisions taken company secretary chairman disclosure representation uk us markets committee effect st january sir robert delegated management manner committee reported matters affect quality individuals ceo experience skills developed various wilson appointed place date performance board committees timely disclosure financial material information sectors board engaged professional search agency individual directors evaluated committee members bring considerable financial accounting board public markets shareholders specialising recruitment high calibre nonexecutive experience committees work members past enabled committee review clarity completeness directors dossier potential nonexecutive appointees board also recorded division employment experience either finance accounting roles disclosures published annual financial statements provided committee candidates shortlisted responsibilities chairman ceo comparable experience corporate activities interim reports quarterly preliminary results interview considering relevant qualifications new company determined independence announcements formal announcements relating nonexecutive directors selected appointed offer board determined combined qualifications nonexecutive directors stated reasons financial performance prior release board election companys agm experience committee members taken together independence notwithstanding existence relationships appointments announced publicly modus operandi gives committee collectively financial audit committee management internal audit full circumstances likely affect could appear expertise necessary discharge responsibilities accordingly board work together ensure quality companys customised induction process conducted affect independence board chosen nominate one committee member corporate accounting financial reporting committee new nonexecutive directors focusing particular board appointed effect st january recent relevant financial experience serves primary link board external experience taking account different backgrounds one independent nonexecutive directors senior internal auditors facilitates necessary independence process included meeting key members cet arriving conclusion board considered following independent director management encourages external internal key executives cases visiting particular points dr ronaldo schmitz chairman auditors communicate freely regularly committee operational facilities group b c annual report contains committee since april prior appointment committee met collectively separately required statements work nominations nonexecutive director company nonexecutive committee also recommended board consider external auditors head gia remuneration audit committees director glaxo wellcome plc served audit appointing dr tachi yamada executive responsible committee pharmaceutical rd within group executive director new directors received full formal tailored dr yamada subsequently appointed board customised induction joining board effect st january glaxosmithkline corporate governance glaxosmithkline remuneration report b c composition positions held accounting periods ending th april sarbanes members remuneration audit oxley requires companys annual report contain report nominations committees comply combined stating responsibility management establishing code committees also amended terms maintaining adequate internal control financial reporting reference comply requirements assessing effectiveness companys internal control combined code available shareholders financial reporting although company required remuneration report sets remuneration policies companys website report compliance annual report management operated glaxosmithkline respect directors undertaken process ensure position c c c audit committee complied corporate executive team cet members together report compliance due date requirements reviewing arrangements disclosures directors remuneration including required staff company raise confidence concerns sarbanesoxley introduced requirement ceo directors remuneration report regulations improprieties matters financial reporting cfo complete formal certifications confirming regulations accordance regulations following monitoring reviewing effectiveness internal audit sections remuneration report subject audit annual reviewed annual report form f activities provision nonaudit services remuneration nonexecutive directors remuneration share companys external auditors contains material misstatements omissions options incentive plans pensions remaining sections subject audit neither pages referred within financial statements financial information fairly us law regulation auditable sections presents material aspects financial condition results operations cash flows period covered report submitted shareholders board approval number provisions us law regulation apply annual report annual general meeting referenced chairmans glaxosmithkline companys shares quoted letter notice annual general meeting sent new york stock exchange nyse form adss responsible establishing maintaining disclosure shareholders controls procedures ensure material information nyse rules made known evaluating effectiveness throughout remuneration report executive directors nyse rules permit company follow home country uk controls procedures yearend results cet members referred executives corporate governance practices instead apply evaluation contained annual report disclosing references glaxosmithkline shares adss mean respectively usa provided company explains significant variations annual report changes controls ordinary shares glaxosmithkline plc p american explanation provided companys website reasonably likely material effect controls depositary shares glaxosmithkline plc ads represents disclosed external auditors audit two glaxosmithkline shares sarbanesoxley act committee significant deficiencies material weaknesses following number corporate accounting scandals design operation internal control financial introduction usa congress passed sarbanesoxley act sarbanes reporting fraud regardless materiality involving remuneration policy oxley sarbanesoxley established new enhanced standards persons significant role companys internal executive director terms conditions remuneration corporate accountability usa although companys control financial reporting nonexecutive directors terms conditions fees corporate governance structure believed robust directors senior management remuneration line best practice certain changes necessary ensure indicated annual report whether annual remuneration compliance sarbanesoxley significant changes internal control nonexecutive directors remuneration financial reporting recommended securities exchange commission directors interests sec glaxosmithkline established disclosure committee ceo cfo completed certifications share options committee reports ceo cfo audit filed sec part groups form f incentive plans committee chaired company secretary pensions members consist senior managers finance legal evaluation disclosure controls procedures directors senior management compliance corporate communications investor relations group carried evaluation supervision directors interests contracts participation groups management including external legal counsel external auditors invited ceo cfo effectiveness design operation attend meetings responsibility considering groups disclosure controls procedures inherent materiality information timely basis determining limitations effectiveness system disclosure controls disclosure treatment information also procedures including possibility human error responsibility timely filing reports sec circumvention overriding controls procedures formal review annual report form f accordingly even effective disclosure controls procedures committee met eight times provide reasonable assurance achieving control sarbanesoxley requires annual report contains objectives based upon groups evaluation ceo cfo statement whether member companys audit concluded st december disclosure committee audit committee financial expert controls procedures effective provide reasonable asurance information required disclosed reports board reviewed qualifications backgrounds group files submits us securities exchange act members audit committee determined although amended recorded processed summarised one member companys audit committee audit reported required committee financial expert combined qualifications experience audit committee members taken significant changes internal control financial together modus operandi give audit committee reporting collectively financial expertise necessary discharge changes groups internal control responsibilities explanation basis boards financial reporting year materially affected judgement refer reasonably likely affect materially groups internal control financial reporting glaxosmithkline remuneration report remuneration report glaxosmithkline remuneration report introduction committee met times member remuneration policy pay performance comparators attending follows following table sets companies used pay remuneration committee committee responsible principles performance comparison making recommendations board companys number meetings number meetings committee considered findings established three core market cap held whilst attended remuneration policy within terms agreed policy name committee member committee member principles underpin new remuneration policy company country determining total individual remuneration packages mr j mcarthur glaxosmithkline abbott laboratories usa executives chairman th june pay performance performance astrazeneca uk committee reviewed developed mr p allaire robust transparent governance structures aventis france remuneration policy align executive remuneration chairman th june commitment leader good remuneration practice bristolmyers squibb usa interests shareholders whilst meeting imperative recruiting dr barzach pharmaceutical industry eli lilly usa retaining executive talent essential leadership mr c davis glaxosmithkline uk company sir roger hurn formulating policy committee also decided johnson johnson usa sir peter job remuneration structure must support business merck usa remuneration policy set report finalised mr mchenry securing retaining motivating key talent novartis switzerland undertaking extensive consultation process shareholders pfizer usa competitive market place institutional bodies course two quorate meetings held effect formal grant roche holdings switzerland uk shareholder guidelines would followed maximum year chairman glaxosmithkline chairman share options performance share awards give effect sanofisynthelabo france extent consistent needs business committee met shareholders representing nearly half committees decisions scheringplough usa company would maintain regular dialogue shareholders glaxosmithklines share capital ensure committee takeda chemical industries japan exception company secretary employees global pharmaceutical companies primary pay obtained clear understanding shareholder expectations wyeth usa company involved conduct committee comparator group communicate competitive issues facing company meetings dr garnier ceo senior vice president human performance conditions would based measurable benchmarking committee derived considerable benefits resources invited attend part meetings delivery strong financial performance delivery benchmarking purposes total remuneration incorporates base process consultation result instigated major shift committee required superior returns shareholders compared salary annual bonus longterm incentives setting pay way glaxosmithkline sets remuneration pharmaceutical companies towers perrin leading firm remuneration benefit committee due regard executives pension senior executives high proportion total remuneration opportunity would consultants provides strategic advice glaxosmithkline arrangements based performancerelated remuneration revised remuneration policy designed establish general remuneration benefit planning also provides delivered medium longterm global pharmaceutical industry continue used framework remuneration consistent market data towers perrin appointed committee remuneration would determined using projected value primary pay comparator executives appropriate companys scale scope operations meets separate mandate advise remuneration method see explanation marketplace companys senior executive talent recruitment needs business closely aligned uk senior executive management one remuneration structure executive directors first instance pay benchmarked publicly available shareholders guidelines st december company cet particular performance conditions apply remuneration data companies second largest pharmaceutical company world independent review executive remuneration equally longterm incentive awards revenue operations five continents covering indicated remuneration report committee provide context information reference made exgratia payments would made countries around per cent sales generated appointed deloitte touche llp deloitte conduct towers perrin annual global pharmaceutical pay survey pay structures would simple consistent usa comprehensive review remuneration executives pharmaceutical human resources association phra business needs glaxosmithkline deloitte reported exclusively committee ensure global pharmaceutical industry benchmark remuneration committee chairman company overall policy intended provide median total remuneration subject scrutiny review committee also consider composition committee changed year median performance poor performance result total pay data global businesses primarily consumer deloitte provided consulting services glaxosmithkline early part saw departure mr allaire remuneration significantly pay comparator group manufacturing sectors year provide advice executive sir roger hurn mr mcarthur appointed interim chairman median opportunity earn upper quartile total remuneration matters committee prior determining annual longterm incentive opportunity committee led committee conduct remuneration exceptional performance committee considers range vesting levels may policy review members committee deloitte reviewed aspects remuneration policy strong alignment performance demonstrably achieved based different assumptions share price dr barzach mr davis appointed st july sir peter job element remuneration performance measures used interests shareholders provides executives growth performance levels etc performance line appointed th june mr mchenry pending terms conditions executives contracts review unambiguous signals importance delivering success expectations total remuneration targeted median embodiment higgs report combined code also included consideration relevant comparator companies companys shareholders comparator group longterm incentive opportunity set board deemed members committee performance measurement pay benchmarking way provides positioning total remuneration independent nonexecutive directors senior roles commitment median consequence revised definition independence set deloittes independent review produced following key findings committee apply policy consistent ensure stable benchmark developed reduce combined code dr barzach mr mchenry transparent basis significant changes measures used link pay performance needed strengthening impact shortterm fluctuations incentive policies global retired committee st january implications assess performance discussed shareholders potential payment failure needed addressing pharmaceutical companies assessed number years combined code set corporate use comparators pay benchmarking committee stronger alignment uk best practice shareholder governance section use discretion ensure remuneration levels reasonable guidelines needed valuation method believes changes may cause concern amongst sir robert wilson mr culp appointed members global pharmaceutical companies primary market projected value method used benchmark total shareholders position discussed shareholders committee st january mr mcarthur retire talent remuneration method projects future value prior implementation board conclusion annual general meeting longterm incentive opportunity uncompetitive remuneration package different performance scenarios th may role chairman committee represents major change method hitherto applied assumed sir robert wilson date pay comparison based solely estimated present value using mathematical model committee believes new approach moderate impact market fluctuations short term greatly strengthen focus performance glaxosmithkline remuneration report remuneration report glaxosmithkline individual elements remuneration longterm incentives tsr measured sterling performance period setting eps targets committee consider balance fixed base salary variable annual executives eligible performance share awards share change value share together value companys internal projections analysts forecasts bonus longterm incentive elements remuneration changes options remuneration policy provides annual longterm reinvested dividends paid order remove impact glaxosmithklines eps performance well analysts forecasts performance chart shows normal range incentive awards normally made performance share varying tax treatments dividends different jurisdictions pharmaceutical industry variability ceo dr garnier cfo mr coombe award share option award new remuneration policy dividends reinvested gross committee agreed following key principles govern increases emphasis use performance shares glaxosmithkline ranked median performance use eps performance measure ceo cfo committee considers performance shares provide comparator group per cent shares vest adjustments considered major items stronger alignment shareholder value therefore new glaxosmithkline one top two companies adjustments judgement committee remuneration policy increases emphasis use shares vest determining vesting levels committee purpose adjustments ensure performance shares longterm incentive awards determined regard companys underlying financial performance performance measurement fair reasonable target performance half participants shareholders base salary annual bonus longterm incentives longterm incentive reward derived performance shares tsr rank companies percentage discretion exercised committee disclosed glaxosmithkline award vesting grant annual awards using one plan consistent shareholders annual report base salary practice pay comparator group leading committee set basis decision considers base salaries set reference median relevant uk companies longterm incentives cet appropriate make adjustment market executives pharmaceutical pay comparator basis executive directors group actual salary levels reviewed annually may vary departure previous policy share options granted cet prior share options granted executive depending executives experience responsibility market members subject performance conditions directors subject performanc e condition order value changes usually take effect st april increase applied share options granted executive directors options vest full business per formance eps growth arose independent review provides closer alignment uk best practice represents excluding currency exceptional ite ms average major step change global pharmaceutical pay practice median least three percentage points per annum increase annual bonus typically apply performance conditions median uk retail prices index threeyear performance bonuses determined basis formal review vesting options period tsr measured prorata basis glaxosmithklines annual performance stretching financial targets based part review process committee considered performance falls two comparators level vesting grant vesting increases straight line basis business performance profit interest tax subject performance conditions applied longterm determined actual relative level tsr rather simple eps performance hurdles set table detailed assessment individual business unit group incentives committee concluded appropriate ranking achievements objectives bonus payable financial annualised percentage measure performance using combination absolute financial performance less per cent target performance provide closer link shareholder returns payments growth eps award vesting results based earnings per share eps delivery bonuses subject upper limits executives superior value shareholders based total shareholder executives notional dividends reinvested rpi ceo range per cent per cent return tsr paid proportion vesting award receipt rpi base salary ceos limit per cent dividends incorporated benchmarking rpi annual bonus paid basis target business committee concluded eps key measure award levels addition performance shares earned rpi performance business also fully reflected executives sold except meet related tax performance together base salary provides annual cash business measures extended throughout group ensuring liabilities two years following end vesting performance condition substantially consistent uk line median pay comparator group organisational alignment period committee believes aligns interests shareholder guidelines expectations considerably case ceo bonus targets set executives longterm interests shareholders demanding operated global comparative performance previously measured reference committee following end financial year committee pharmaceutical companies change consistent ftse committee concluded prior performance share awards two parts half reviews ceos performance determines bonus payable new policy providing pay performance measurement performance performance comparator could earned reference glaxosmithkline 's tsr ceo makes recommendations committee regarding performance group pharmaceutical companies see would provide performance compared ftse company performance level achieved objectives better assessment companys performance tsr chosen constituent half award deliverable executives onwards performance executives recommendations considered appropriate comparative measure since focuses companys business performance eps growth excluding measured three financial years following grant committee determine resultant bonus return shareholders well understood tested currency exceptional items average least three option committee decided grant executives also choose invest bonus glaxosmithkline mechanism measure performance allows comparison percentage points per annum increase uk performance condition met full three year shares minimum three years annual investment companies operating different countries retail prices index threeyear performance period period performance measured four financial plan end threeyear holding period executives years following date grant option extent performance share awards share options delivered pre awards glaxosmithkline delivers returns entitled matching award per cent deferred option performance conditions met end us resident executives form adss awards delivered would rank top ftse based tsr shareholding match subject performance four years option lapse form ordinary shares executives resident uk performance shares part award conditions plan open approximately senior countries awards made plans vest th position ftse per cent committee considers remeasurement important executives terms committee believes incorporate dilution limits consistent guidelines provided shares vest glaxosmithkline ranked th position feature grant light imposition arrangements encourage shareholding amongst senior executives association british insurers national association none shares subject part award vest performance conditions industry major considers appropriate executives participate pension funds shareholder representative bodies th th positions vesting occur competitors apply options committee terms current estimated dilution existing awards made since sliding scale consider prior annual grant options whether bonus awards reflected committees belief merger approximately four per cent companys share remeasurement permitted company produced superior results year taking capital st december b share options account factors outside control management notably pensions share options allow holder buy shares future date exchange rate changes launch generic competition performance shares executives participate glaxosmithkline senior executive share price prevailing time grant share options paxil usa pension plans pension arrangements structured executives level performance shares vesting granted managers glaxosmithkline accordance plans operated executives country based companys tsr relative performance including executives share options granted executives likely retire benefits normally comparator group threeyear measurement period executives linked achievement compound annual payable age details individual arrangements eps growth performance period executive directors set glaxosmithkline remuneration report remuneration report glaxosmithkline share ownership requirements key aspects new contractual framework thereafter however dr garnier leaves prior age would receive align interests executives shareholders provisions apply options subject less would otherwise contractually entitled aspect policy executives required maintain significant holdings shares performance testing circumstances options accordingly severance payment due dr garnier glaxosmithkline requirements important part notice period calendar months performance share awards made months prior termination company cause resignation aligning interests executives shareholders ceo termination termination notice date lapse executive include years worth pension required hold shares value four times base salary employing company contributions mr coombe remains entitled termination cash equivalent executive directors required build shareholding executive months benefits continuing medical dental committees view balances new pension value three times base salary members cet termination payment x annual salary insurance arrangement contractual entitlement previous required build shareholding value two times base x annual target bonus contract aimed providing fair replacement previous salary requirement build shareholding value one nom itigation required addition dr garnier mr coombe also entitled receive arrangement times base salary applies top executives one years worth pension contributions termination benefits governed benefits policy group result policy review executives new arrangement came effect st january including dr garniers mr coombes contracts executed required continue satisfy shareholding requirements likely effect final accrued benefit rd march take effect st january minimum twelve months following retirement healthcare medical dental transfer value dr garniers pension dr garnier dr garniers contract expire st october company personal financial advice entitlement spouses pension pension increases mr coombes st march last day life assurance contributions reducing initial pension order shares qualify share ownership month reach th birthday vesting longterm rules relevant equity incentive requirements must held personally executives mr coombe participates glaxo wellcome defined benefit incentives plan termination payments made respect part earned deferred one share plan retirement age entitled receive annual notice period extending beyond contract expiry dates programmes operated company unexercised share options pension based existing arrangements pension rds final salary rds widows pension included calculation st december terms relevant pension plan upon dr yamadas appointment board pending finalisation inflation proofing benefits accrued glaxo dr garniers shareholding adss mr coombes noncompete clause months termination new contract previous contractual arrangements wellcome uk pension arrangements augmented shares appointment board notice date superseded letter setting principal terms trustees plans five per cent reflect distribution st january dr yamada held adss holdings appointment available inspection terms surplus augmentation apply element excess share ownership requirements dates drga rniers target bonus per cent salary mr coombes per cent letter expire earlier execution new contract mr coombes pension earnings st march salary termination months notice dr yamadas contract company terminates employment prior retirement remuneration elements imposition month noncompete period executives considered made available inspection shareholders final mr coombe entitled receive pension calculated vitally important company order protect groups intellectual executives participate various legacy glaxo wellcome details confirmed employed months age sooner property light noncompete clause competitor practice smithkline beecham employee share plans either uk committee believes would appropriate provide mitigation usa glaxosmithkline plans replaced contracts reviewing level severance payments committee pensions entitlements considered investor dti guidance however determined line uk plan provides pension based twothirds final addition contractual provisions outlined sharesave plan sharereward plan inland revenue competitive practice appropriate provide payment salary salary age us cash balance plan provides annual event dr garnier mr coombes service agreements approved plans open uk employees terms target bonus termination mr coombes previous contract specified compensation paid event redundancy event notice contribution interest sum accumulated cash terminated employing company would entitled mr coombe member sharesave plan termination given case redundancy mr coombe balance plan contractual promise provide specific contributes month provides option would required mitigate resulting loss earnings special deferred bonus awarded member levels retirement income buy shares end threeyear savings period line cet respect payable th february asap proved shareholders glaxosmithkline glaxo wellcome smithkline opportunity available uk employees mr coombe also beecham appropriate glaxosmithkline makes annual contributions per cent unless terminated cause prior date details contributes per month buy shares share reward dr garniers annual salary bonus fund increases bonus given plan company matches number shares bought dr garnier mr coombe agreed changes interest rate based yield year treasury bonds case awards glaxosmithkline annual month contractual terms without compensation come broadly line company liability beyond making annual investment plan provided agreement terminated new contractual framework including reduction contributions executives also receive benefits including healthcare cause deferred amount income contractual notice period calendar months medical dental personal financial advice life assurance prior us employees including dr garnier moved gains losses automatically distributed soon however order honour certain aspects old contributions cash value benefits received final salary pension arrangement current cash administratively practicable termination resign contractual terms number individual features executive directors shown balance structure employees us cash balance plan retire termination cause deferred retained contributions based combined annual salary annual amount distributed end minimum executive director terms conditions remuneration dr garniers case include entitlement bonus three year deferral period reimbursement excise tax change control related part remuneration review dr garniers pension provisions line policy applicable us senior executives executive director contracts payments life insurance benefit funded company age simplified removing entitlement receive three dr garnier entitled receive continuing medical dental policy regarding executive directors contracts following provisions relating vesting longterm years worth additional pension contributions termination insurance subject extensive review change new incentives also removing entitlement receive payment policy provides framework contracts executive directors following merger participants legacy share pre awards company enables dr garnier purchase annuity appointed future option schemes elected exchange legacy options termination company cause treats three years older new pension options glaxosmithkline shares receive retirement resignation good reason ie resignation arrangement provide simple annual contribution additional cash benefit equal per cent grant price due elected retained director per cent annual salary annual bonus original option additional benefit triggered company merged company result change pension contributions vary performance new option exercised lapses qualify control provided resignation occurs within new annual contribution rate represent additional cash benefit participants retain options days first anniversary change control options enhancement dr garniers pension entitlement designed least second anniversary effective date vest full remain exercisable full option term consolidate previous additional contractual terms single merger performance shares vest end performance annual contribution rate new annual contribution percentage period subject performance timeapportioned ensures long dr garnier continues employment age financial position would prior consolidation contractual pension entitlements glaxosmithkline remuneration report remuneration report glaxosmithkline result remuneration review number changes mr allaire received fees per annum together tsr performance graph also made contracts cet members allocation american depositary shares made following graph sets performance company compensated agreeing changes nonexecutive directors share arrangements relative ftse index company amendments relate following aspects constituent performance comparator group since dr michle barzach sir peter job mr john mcarthur mr merger th december graph prepared termination company poor performance donald mchenry sir ian prosser dr ronaldo schmitz accordance regulations indication notice period related severance payments reduced dr lucy shapiro likely vesting awards granted companys months letters appointment nonexecutive incentive plans entitlement postnotice longterm incentive grants directors dated th june cases agreed removed serve company nonexecutive directors conclusion annual general meeting agm following termination company performance share awards third anniversary appointment cases sir peter job made months prior termination notice date lapse sir ian prosser dr schmitz dr shapiro appointments may new cet members standard contractual terms extended term three years mutual outlined executive directors apply agreement dr barzach mr mcarthur mr mchenry announced retire board conclusion nonexecutive directors terms conditions fees agm th may glaxosmithkline total return ftse total return index mr mcarthur succeeded mr allaire chairman nonexecutive directors glaxosmithkline service glaxosmithkline performance comparator group remuneration committee th june fees contracts instead letters appointment company increased per annum date mr mchenry aims provide nonexecutive directors fees directors senior management remuneration succeeded sir christopher chairman corporate social competitive companies equivalent size following tables set directors glaxosmithkline responsibility committee corporate responsibility complexity nonexecutive directors entitled plc remuneration earned interests shares committee th february fees increased compensation appointment terminated glaxosmithkline plc interests share options incentive per annum date sir ian prosser succeeded plans pension benefits members cet enhance link directors shareholders sir christopher chairman nominations committee company secretary known senior management also set table glaxosmithkline requires nonexecutive th february sir ian stepped chairman participate remuneration plans executive directors receive significant part fees form nominations committee effect st january directors aggregate remuneration interests shares allocated share account offers opportunity succeeded sir christopher directors senior management also provided invest part balance fees share account shares paid directors retirement fees payable share allocations nonexecutive board later date paid basis dividends directors share arrangements directors reinvested interim follows chairman chairmen board committees receive nonexecutive annual shares allocated directors fees annually higher fees dr barzach ordinary shares sir peter job ordinary shares terms conditions mr j mcarthur adss mr mchenry adss sir christopher hogg sir ian prosser ordinary shares sir christopher hoggs letter appointment board dr r schmitz ordinary shares dated th june agreed serve dr l shapiro adss company nonexecutive director conclusion annual general meeting following third anniversary appointment may extended term three mr h lawrence culp mr crispin davis sir robert wilson years mutual agreement letters appointment nonexecutive directors dated th june cases agreed sir christophers letter appointment amended serve company nonexecutive directors st september record appointment nonexecutive conclusion annual general meeting following third chairman effect th may receives anniversary appointment cases may per annum plus allocation shares per annum extended term three years mutual agreement mr culp mr davis joined board st july sir roger hurn mr paul allaire sir robert joined board effect st november sir roger hurn retired deputy chairman nonexecutive fees payable share allocations nonexecutive director mr allaire retired nonexecutive director directors share arrangements directors effect th june sir rogers mr allaires letters follows appointment dated th june cases nonexecutive annual shares allocated agreed serve company nonexecutive directors fees annually directors conclusion annual general meeting mr l culp adss following third anniversary appointment cases mr c davis ordinary shares could extended term three years sir robert wilson ordinary shares mutual agreement sir roger received fees per annum together allocation ordinary shares nonexecutive directors share arrangements glaxosmithkline remuneration report remuneration report glaxosmithkline annual remuneration nonexecutive directors remuneration total cash allocated elected total cash allocated elected total total fees salary fees annual annual fees annual annual salary benefits bonus remuneration salary benefits bonus remuneration footnote current nonexecutive directors sir christopher hogg executive directors dr barzach dr j p garnier abc mr l culp mr j coombe bc mr c davis total sir peter job mr j h mcarthur current nonexecutive directors mr f mchenry sir christopher hogg sir ian prosser dr barzach e dr r schmitz mr l culp dr l shapiro mr c davis sir robert wilson sir peter job mr j h mcarthur former nonexecutive directors mr f mchenry sir richard sykes sir ian prosser sir roger hurn dr r schmitz sir peter walters dr l shapiro f mr p allaire sir robert wilson mr j young total former nonexecutive directors table sets remuneration received nonexecutive directors glaxosmithkline accordingly include sir richard sykes ad dr barzachs fees received glaxosmithkline france healthcare consultancy provided dr shapiros fees received member sir roger hurn glaxosmithklines scientific advisory board see sir peter walters mr p allaire nonexecutive directors required receive part fees form shares adss balance received cash mr c bonham may elect receive either part cash payment form shares adss total value shares mr j young adss date award together cash payment forms total fees included within annual remuneration table fees salary table sets value fees received form cash shares adss total nonexecutive directors shares adss notionally awarded nonexecutive directors allocated interest accounts included within total remuneration directors interests tables accumulated balance shares adss together notional dividends subsequently reinvested paid nonexecutive directors retirement upon retirement nonexecutive directors following merger participants legacy share option schemes elected exchange legacy options options receive either shares adss cash amount equal value shares adss date retirement glaxosmithkline shares granted additional cash benefit equal per cent grant price original option additional benefit known exchange offer incentive eoi payable new option exercised lapses market value qualify additional table sets accumulated number shares adss held nonexecutive director st december cash benefit participants retain options least second anniversary effective date merger year dr garnier together movements account year received relating options exercised sir richard sykes received result options lapsing market value amounts included benefits table number shares adss dividends b dr garnier nonexecutive director united technologies corporation respect dr garnier received form deferred nonexecutive directors share arrangements allocated elected reinvested paid stock units stock options grant price mr coombe member supervisory board siemens ag respect mr coombe received stock appreciation rights grant price amounts excluded table current nonexecutive directors retained executive directors sir christopher hogg c dr garnier mr coombe received special deferred bonus awarded members cet amount awarded equivalent dr barzach salary st december notionally invested glaxosmithkline shares adss th february bonus paid mr l culp adss th february amount equivalent value shares adss notionally acquired february plus dividends reinvested mr c davis period st december value shares adss notionally acquired respect dr garnier increase sir peter job per cent year includes dividends reinvested year shares notionally acquired respect mr coombe mr j h mcarthur adss valued st december increase per cent year includes dividends reinvested year mr f mchenry adss addition remuneration received former director set sir richard sykes received relating appointment senior sir ian prosser advisor st june dr r schmitz dr l shapiro shares e dr barzach received fees subsidiary company healthcare consultancy provided included within adss fees salary sir robert wilson f dr shapiro member glaxosmithklines scientific advisory board received fees form adss included within fees salary former nonexecutive directors sir roger hurn directors received part remuneration currencies sterling average rates exchange year mr p allaire adss used none directors received expenses year requiring separate disclosure required regulations mr j young shares adss glaxosmithkline remuneration report remuneration report glaxosmithkline th june sir roger hurn mr allaire retired board following retirement received value shares share options adss awarded nonexecutive directors share arrangements equivalent smithkline beecham arrangements granted th june awarded shares adss total value date award indicated sir roger hurn weighted average mr allaire th june value shares adss due sir roger hurn options adss date grant grant price number exercised mr allaire change value attributable dividends reinvested change share price dates awards dr j p garnier th june sir roger elected receive value shares th june quarterly instalments years accordingly received mr allaire elected receive adss due retirement mr young elected granted receive value shares th may three annual instalments accordingly received weighted average options shares date grant grant price number lapsed directors interests mr j coombe following beneficial interests directors company shown register maintained company accordance companies act options outstanding st december earliest latest vesting lapse dates market price glaxosmithkline share year end given table shares adss th february st december st december th february st december st december vesting date lapse date footnote weighted average dr j p garnier grant price number earliest latest earliest latest dr j p garnier market price underwater year end vested options mr j coombe ab unvested options sir christopher hogg dr barzach mr l culp market price year end vested options mr c davis unvested options sir peter job mr j h mcarthur total ads options st december mr f mchenry cd sir ian prosser vesting date lapse date dr r schmitz weighted average dr l shapiro mr j coombe grant price number earliest latest earliest latest sir robert wilson market price underwater year end vested options unvested options one glaxosmithkline ads represents two glaxosmithkline shares includes shares purchased glaxosmithkline sharereward plan totalling shares st december shares market price year end unvested options th february total share options st december b includes nonbeneficial interest trusts hold nil shares st december nil shares th february c addition interests shown mr mchenry interests deferred fees plan relating period mr mchenry director glaxosmithkline grants share options executive directors senior managers annual basis generally november initial smithkline beckman prior merger beecham group deferred fees indexed total return glaxosmithkline grant made following completion merger march measurement period options granted march shares payable seven years following mr mchenrys retirement nonexecutive director glaxosmithkline total accumulated value commenced st january measurement periods options granted november commenced deferred fees st december restated reflect merger fully provided equivalent glaxosmithkline adss st january respectively directors hold options various share option plans referred includes shares adss received part fees described nonexecutive directors share arrangements dividends received note financial statements employee share schemes none directors interest option shares adss converted shares adss st december also included directors interests companys shares interests abovementioned directors th february reflect changes end financial year date following merger directors elected exchange outstanding options legacy share option plans options glaxosmithkline shares directors participants legacy schemes made election receive additional benefit cash sum equal per cent grant price original option additional benefit given new option exercised lapses provided exercise lapse second anniversary effective date merger case sir richard sykes cessation executive employment earlier grant market options exercised date number price price gain gain dr j p garnier average exchange rate year gain made dr garnier amounted th february dr garnier exercised options exercise price giving rise gain dr garnier also received respect exchange offer incentive benefit arising exercise options mr coombe exercise share options highest lowest closing prices year ended st december glaxosmithkline shares respectively highest lowest prices glaxosmithkline adss year ended st december respectively market price glaxosmithkline share st december st december glaxosmithkline ads st december share price th february per glaxosmithkline share per glaxosmithkline ads glaxosmithkline remuneration report remuneration report glaxosmithkline incentive plans pensions granted accrued annual pension benefits transfer values executive directors retirement set adss market adss performance share plan adss number price regulations require disclosure accrued benefit end year change accrued benefit year transfer dr j p garnier award value beginning end year change transfer value year listing rules require additional award disclosure change accrued benefit net inflation transfer value change award change award change change accrued transfer value accrued accrued accrued transfer transfer year benefit change benefit benefit benefit value value transfer year net accrued granted year value inflation benefit shares market shares pa pa pa pa performance share plan shares number price dr j p garnier mr j coombe award mr j coombe award change transfer value shown net contributions made individual award award dr garnier member employee us cash balance pension plan glaxosmithkline makes annual contributions calculated percentage employees base salary bonus fund increases interest rate set annually advance based performance share plan psp mediumterm incentive scheme introduced psp replaces longterm incentive year treasury bond rate provide cash sum retirement cash sum used purchase pension retirement based plan midterm incentive plan operated respectively glaxo wellcome smithkline beecham annuity rates applicable time dr garnier entitlement spouses pension pension increases reducing terms psp number shares actually vesting determined following end relevant three year measurement initial pension period dependent glaxosmithklines performance period described pages share awards normal retirement age plan years age dr garniers pension arrangements bought line terms granted annually november december measurement period commences following st january ending three years service agreement assumed retirement age reduced effect reduce dr garniers accrued benefit per annum per annum excluding effects inflation cash balance available dr garniers plan st december three year measurement period award ended st december based performance required purchase annuity five years previously assumed glaxosmithkline period per cent award vested february shares exercised transfer value cash sum dr garniers plan increased year result phased transfers froma market average money previous scheme accumulation interest contributions paid company five per cent base salary plus bonus price market price value shares award exercise exercise dr garniers accrued benefit transfer value translated yearend exchange rate us us longterm incentive plan shares number change accrued benefit transfer value translated average exchange rate us us mr j coombe accordingly changes accrued benefit transfer value stated exclude exchange losses follows change accrued benefit year change accrued benefit year net inflation change year transfer value longterm incentive plan ltip share award scheme operated glaxo wellcome plan closed new entrants upon completion merger grants made award made mr coombe february vested february dr garnier also member us retirement savings plan money purchase scheme open us employees contributions completion measurement period connection merger performance conditions respect grant made invested range funds value accumulated funds paid retirement contributions february waived paid scheme company respect dr garnier invested glaxosmithkline shares stock ownership account shares held account included within directors interests tables vested vested unvested participations unvested deferred participations dividends deferred mr coombes transfer value calculated basis actuarial advice accordance actuarial guidance note gnthe participations vesting participations participations vested reinvested participations midterm incentive plan adss transfer value represents present value future payments made pension plan whilst mr coombes annual accrued dr j p garnier benefit increased excluding effects inflation transfer value increased million year increase arisen primarily result following factors midterm incentive plan mtip share award scheme operated smithkline beecham plan closed new entrants upon completion merger participations granted connection merger performance conditions method calculating transfer value reviewed following completion formal valuation pension scheme respect grants made waived measurement period ended st december ensure assumptions used continue reasonable following st december valuation various assumptions updated including increasing allowance life expectancy members retirement led increase transfer participations vested awarded dr garnier th november ads price ads values pension fund members assumptions used continue reviewed following valuation adjusted price time vesting final award adss made receipt award may deferred director appropriate dr garnier deferred receipt full amounts awarded deferred awards together additional adss subsequently received dividend reinvestment included directors interests table annual increases transfer values become larger closer individual retirement terms mr coombes service since technically retained mtip paid agreement retire age mr coombe approaches retirement transfer value pension increase average reflect level funds required meet annual accrued benefit payments stock appreciation rights sars adss grant price yield gilts underlying assets linked declined therefore leading increase market value dr l shapiro gilts required meet annual accrued benefit sars held dr l shapiro grant price market price glaxosmithkline ads year end dr shapiro member glaxosmithklines scientific advisory board sab dr shapiro member smithkline beechams sab completion merger glaxo wellcome along members sab received annual grants smithkline beecham sars general vested three years date grant expire years date grant grants sars sab members ceased sars entitle holder cash sum future date based share price growth date grant date exercise full provision made financial statements accrued gains sars date grant connection merger previously granted sars became immediately exercisable glaxosmithkline remuneration report glaxosmithkline operating financial review prospects directors senior management operating financial review prospects discusses us reporting purposes necessary provide information compensation interests directors senior management operating financial performance group financial group group purposes disclosure group defined directors members cet company outlook financial resources group secretary respect financial year total compensation paid members group periods following headings served capacity aggregate decrease accrued pension benefits aggregate payment financial trends ratios defined contribution schemes members group granted options shares adss awarded shares adss performance share plan th february year results year st december compared thencurrent members group comprising persons owned shares adss constituting less one per cent year st december issued share capital company group also held date options purchase shares financial position resources st december adss shares adss awarded performance share plan including shares adss vested deferred shares adss legacy smithkline beecham midterm incentive plan including outlook risk factors shares adss vested deferred adss awarded legacy smithkline beecham stock appreciation rights additionally accordance us requirements holdings issued various executive share option plans described note financial statements employee share schemes year results year st december compared year st december directors interests contracts selected financial data ukus gaap except described note financial statements related party transactions end financial year results year compared primarily results director connected person material interest contract significance relation groups business group preceding year reference made also quarterly company halfyearly trends within results appropriate directors remuneration report approved board directors signed behalf exchange group multinational business operates many countries earns revenues incurs costs many currencies results group reported sterling therefore affected movements exchange rates sterling overseas currencies sir christopher hogg group uses average exchange rates prevailing chairman period translate results cash flows overseas group rd march subsidiary associated undertakings joint ventures sterling period end rates translate net assets undertakings currencies influence translations us dollar euro japanese yen average sterling exchange rates stronger us dollar japanese yen nine per cent two per cent respectively weaker euro nine per cent compared giving overall adverse currency impact results year business performance constant exchange rates business performance primary performance measure used management presented excluding merger items integration restructuring costs disposal businesses management believes exclusion items provides better reflection way business managed gives indication performance group terms elements revenue expenditure local management able influence information provided addition statutory results prepared uk gaap appear pages given assist shareholders gain clearer understanding underlying performance business increase comparability periods presented order illustrate underlying performance groups practice discuss results terms constant exchange rate cer growth represents growth calculated exchange rates used determine results overseas companies sterling remained unchanged used previous year cer represents growth constant exchange rates represents growth actual exchange rates glaxosmithkline operating financial review prospects operating financial review prospects glaxosmithkline financial trends ratios year statutory results growth growth world economy world market pharmaceuticals cer cer fears terrorism sars war iraq including global pharmaceutical sales increased almost nine per cent turnover pharmaceuticals uncertainties wars aftermath held headlines billion consumer healthcare rising unemployment number major world economies total collapse world trade organisation talks mexico world market value growth little underpin fragile global economic situation however geographic region bn total cer cost sales optimism recovery global economy settled usa selling general administration economic climate emerged latter part year though europe research development remained little confidence significant improvement germany trading profit long term france uk profit taxation usa dominated areas recovery vigorous italy earnings resilient economic performance particularly consumer japan basic earnings per share pence p p p sector growth rate four per cent achieved despite asia pacific concerns growing budget deficit possible impact latin america merger restructuring disposal subsidiaries interest rates taxes middle east africa cost sales uk growth also stronger expected although still canada selling general administration subdued per cent effects first increase uk total research development interest rates four years autumn followed trading profit increase february led predictions uk rates us market although less buoyant maintained increase next months double digit growth represents per cent global profit taxation prescription pharmaceutical market compared per cent earnings euro zone germanys economy continued weak decade ago growth countries france italy improved business performance results although improvements welcomed general th september glaxosmithkline held second position turnover agreement indicate longterm trend world pharmaceutical market market share cost sales european central bank expressed confidence zones per cent behind pfizer market share per cent selling general administration economic situation maintained interest rates two per glaxosmithkline seven products worlds top research development cent middle year impact accession pharmaceutical products augmentin avandia ten new countries european union likely imigranimitrex seretideadvair seroxatpaxil wellbutrin trading profit subsequent changes labour force may slow future economic zofran growth europe profit taxation world market value growth adjusted earnings towards end year industrialised nations followed top five therapeutic classes bn total cer adjusted earnings per share pence p p p usa reporting signs recovery chinas growth healthy cardiovascular per cent projections cautious research development statutory central nervous system seven per cent however japans economy showed slower alimentary tract metabolic pharmaceuticals expected growth reflecting continued weakness business antiinfectives bacterial consumer healthcare investment despite optimism stronger growth viral fungal excluding vaccines total alongside signs slow recovery global economy respiratory share price indices improved halted threeyear decline interest indicating reduced risks recession deflation note data based months th september net interest payable momentum achieved latter stages year pharmaceutical turnover interest cover times times times particularly economies asia usa uk growth rates included review turnover constant indicates renewed strength world economy interest cover calculated statutory profit interest divided net interest payable exchange rates cer unless otherwise stated sterling growth likely led usa followed albeit less steeply rates may found tables pharmaceutical turnover tax rate slowly europe therapeutic area geographic region business performance statutory results exchange total pharmaceutical turnover million currencies influence groups results us borrowings compared million increase five per dollar euro japanese yen net debt cent approximately one per cent overall growth came gearing pound hit highest level dollar price increases remainder volume growth growth three years climbing yearend euro gained sterling terms one per cent significantly impacted gearing ratio calculated net debt percentage shareholders funds net debt minority interests per cent dollar first year dollar weakness us dollar currencies fallen value euro investors weighed within groups portfolio turnover new products launched impact continued unrest iraq tension elsewhere world major market within last five years accounted per concerns us economy cent total turnover grew per cent million turnover established franchise products amounted million representing per cent total turnover grew one per cent compared last year turnover older products less actively promoted million decline eight per cent representing per cent total turnover glaxosmithkline operating financial review prospects operating financial review prospects glaxosmithkline global pharmaceutical turnover fourth quarter respiratory pharmaceutical turnover therapeutic area declined two per cent reflecting us turnover decline glaxosmithkline continues global leader respiratory total usa europe international six per cent million whereas europe turnover grew pharmaceuticals sales three key products two per cent million international turnover seretideadvair flixotideflovent serevent amounting therapeutic area growth growth growth growth major products total cer cer cer cer grew four per cent million turnover us declined billion per cent sales seretideadvair groups due generic competition paxil began september largest product grew per cent billion although cns depression contributed declines serevent flixotide constituent seroxatpaxil products seretideadvair one top ten pharmaceutical wellbutrin pharmaceutical turnover therapeutic area brands world usa sales grew per cent million migraine glaxosmithklines ability continue deliver pharmaceutical imigranimitrex turnover growth despite generic competition several seretide also continued perform strongly europe naramigamerge products primarily due exceptionally broad product per cent international markets per cent lamictal portfolio fastgrowing highvalue products growth prospects advair strengthened requip fda approval use treatment chronic obstructive zyban include respiratory product seretideadvair billion pulmonary disease copd fourth quarter per cent diabetes treatment avandiaavandamet respiratory billion per cent wellbutrin depression older respiratory products ventolin becotide continued flixotideflovent serevent seretideadvair billion per cent emesis treatment zofran decline patients converted newer products seretideadvair billion per cent lamictal epilepsy billion flixotideflovent per cent trizivir hiv billion per cent antivirals serevent valtrex herpes billion per cent coreg heart hiv medicines grew across regions totalled billion flixonaseflonase ventolin disease billion per cent pediatric vaccine sales six per cent sales trizivir glaxosmithklines triple becotide infanrixpediarix billion per cent combination therapy grew per cent million lexiva hiv launched december initial sales antivirals central nervous system cns million hiv trizivir cns sales grew four per cent million sales us global sales valtrex received fda approval august combivir europe grew three per cent international sales grew reduce risk transmission genital herpes rose epivir per cent retrovir per cent million ziagen sales seroxatpaxil glaxosmithklines leading product agenerase depression anxiety disorders declined four per cent antibacterials herpes million us sales declined nine per cent million antibacterial sales declined per cent worldwide valtrex following launch generic paroxetine september per cent usa augmentins us sales zovirax january glaxosmithkline 's innovative new product paxil per cent year result generic competition cr increased share total paxil prescriptions branded began third quarter zeffix generic since generic launch per cent per cent usa glaxosmithklines two new antibiotics augmentin es antibacterials paxil cr sales million europe paxil sales children augmentin xr adults recorded combined augmentin declined eight per cent million reflecting competition zinnatceftin sales million spite generic competition pricing pressures international sales grew per cent fortum million led continued strong growth japan amoxil metabolic sales wellbutrin depression grew per cent worldwide sales metabolic category billion metabolic avandiaavandamet million reflecting increased physician awareness per cent avandia franchise avandia avandamet products outstanding efficacy favourable sideeffect profile grew per cent year us sales per cent vaccines new oncedaily formulation wellbutrin xl launched million hepatitis september formulation accounted per cent infanrix avandamet combination avandia metformin hci branded wellbutrin prescriptions early february expanded avandia metabolic franchise us launch oncology emesis seven per cent sales fourth quarter europe avandia benefited zofran hycamtin limited generic competition wellbutrin began usa increasing physician acceptance sales million january mg dose generic competition across per cent franchise benefit eu cardiovascular dose forms wellbutrin sr expected time approval avandamet december avandia also urogenital coreg glaxosmithklines medicine epilepsy lamictal continued well international markets sales million levitra per cent avodart grow across regions achieving sales million per cent june fda approved lamictal long vaccines term maintenance treatment bipolar disorder sales vaccines grew two per cent billion supported zantac infanrixpediarix franchise per cent million hepatitis franchise declined per cent million reflecting competitive pressure usa europe usa glaxosmithklines new pediarix vaccine launched cer represents turnover growth constant exchange rates represents growth actual exchange rates analysis turnover quarter given financial record pages january pediarix adds protection hepatitis b poliomyelitis infanrix combination results six fewer injections infants glaxosmithkline operating financial review prospects operating financial review prospects glaxosmithkline cardiovascular urogenital result management believes within european region usa international coreg sales grew per cent million benefiting turnover market invoiced basis presented usa reported five per cent turnover growth year eight per cent turnover growth international region recent data showed highly significant statistical properly represent consumption products within business represents per cent total pharmaceutical reflected mixture good growth middle east africa difference survival coreg metopropol patients market glaxosmithkline staff based market turnover canada japan asia pacific latin america also grew strongly heart failure instrumental promotion groups products within mexico rebounded following poor economic conditions advair maintained strong growth sales million market thereby creating product sale final consumption realignment wholesaler stock levels levitra vardenafil new agent treatment erectile driving overall respiratory growth per cent however market table gives adjustments made order dysfunction launched usa august adversely affected sales constituent products flovent overall international growth driven seretide seroxatpaxil restate turnover markets within europe turnover europe first half year levitra researched serevent showed declines flonase indicated avandia partly offset declines zantac zovirax created basis adjustments glaxosmithkline estimates developed bayer ag copromoted glaxosmithkline treatment perennial rhinitis grew strongly per cent based recent data independent external sources asia pacific area grew due performance seretide valued sterling relevant exchange rates management believes sales growth three per cent central nervous system avandia strong growth number markets partly oncology emesis turnover created basis reporting turnover market products included sales wellbutrin per cent reflecting offset decline one per cent largest market australia sales zofran grew per cent million driven provides better reflection performance businesses performance new day formulation wellbutrin xl reflecting reduced sales zyban zantac older antibiotics strong us performance per cent million market within europe paxil sales declined nine per cent due launch generic growth japan reflected strong growth paxil serevent paroxetine september january glaxosmithkline 's therapeutic areas total turnover europe region unaffected valtrex partly offset declines zovirax zantac innovative new product paxil cr increased share total paxil sales zantac fell per cent million declines restatement government price reductions prescriptions branded generic since generic launch regions parallel trade occurs occasionally elsewhere world per cent per cent paxil cr sales middle east africa area followed trends sufficiently material affect significantly turnover data million markets growth seretide avandia vaccines regional analysis market presented invoiced basis canada growth driven seretide avandia sales antivirals therapeutic area grew four per cent turnover reported table represents sales invoiced hiv led strong performance trizivir per cent glaxosmithklines local entity customers local consumer healthcare sales pharmaceutical turnover europe region partially drew sales constituent products valtrex market plus copromotion income within market reconciliation adjustment parallel trade growth herpes grew per cent driven fda approval cer pharmaceutical turnover geographic region reduced risk transmission genital herpes otc medicines invoiced basis region invoiced adjustment created invoiced adjustment created major markets sales avandia increased per cent benefiting analgesics r ag joio rn arkets af l c eg rr ow th europe launch avandamet november antibacterial sales dermatological france declined per cent result generic competition began gastrointestinal usa uk third quarter coreg sales increased per cent respiratory tract europe italy reflecting benefit recent data showed highly smoking control germany france spain significant statistical difference survival coreg natural wellness support uk italy central metopropol patients heart failure oral care eastern europe germany spain europe europe nutritional healthcare central turnover market within europe adjusted effects discussion individual market performance europe eastern europe europe parallel trade show turnover basis country region turnover created basis rather turnover product finally consumed product invoiced basis growth consumer healthcare sales four per cent international sold glaxosmithkline million comprised otc medicines sales increase asia pacific europe region contributed per cent pharmaceutical turnover two per cent nutritional healthcare sales increase nine per japan although overall turnover growth region two cent oral care sales increase three per cent l din la e eae sr tic frica pharmaceutical turnover geographic region per cent good growth recorded italy central canada turnover created basis eastern europe government healthcare reforms including otc medicines region growth pricing reimbursement restrictions adversely affected turnover overthecounter medicine sales billion two per cent major markets total cer france spain germany seretide glaxosmithklines largest sales smoking control gastrointestinal products cer represents turnover growth constant exchange rates represents growth usa selling product europe reported notable growth france italy significantly usa primarily due flat market conditions actual exchange rates analysis turnover quarter given financial record uk although partly offset expected declines pages europe private label competition growth smoking control serevent flixotide trizivir showed strong growth france products recently launched europe sales dermatological individual governments determine pricing medicines uk major markets region decline sales herpes products acquired earlier year helped offset declines countries within europe result wide price variations italy franchise mainly result generic competition zovirax product parallel trade occurs third parties germany partially offset patients switching newer valtrex product spain oral care exploit price differential purchasing products market central oral care sales billion three per cent low prices enforced selling governments eastern europe glaxosmithkline 's sensodyne brand continues grow purchasers markets higher prices europe regions agreed parallel trade permitted single international market rules european union glaxosmithkline asia pacific nutritional healthcare derive benefit profit resale higher price japan nutritional healthcare products grew nine per cent latin america billion lucozade sport lucozade hydroactive continued middle east africa canada drive growth category cer represents turnover growth constant exchange rates represents growth actual exchange rates analysis turnover quarter given financial record pages glaxosmithkline operating financial review prospects operating financial review prospects glaxosmithkline trading profit statutory results profit taxation statutory results trading profit business performance profit taxation business performance statutory results include merger items integration analysis discussion profit taxation relates illustrate glaxosmithkline business performance analysis discussion profit taxation relates restructuring costs disposal subsidiaries statutory performance analysis trading profit subsequent discussion business performance excludes merger items integration restructuring costs growth cer operating incomeexpense disposal businesses management believes exclusion operating incomeexpense turnover royalties income items provides better reflection way royalties income operating expense business managed accordingly information provided operating expense cost sales supplement contained consolidated statement selling general profit loss pages prepared accordance administration income equity investments income equity investments uk gaap research disposals disposals development growth trading profit cer operating incomeexpense includes litigation costs operating incomeexpense includes litigation costs turnover provisions relating legal claims withdrawn products provisions relating legal claims withdrawn products product cost sales product withdrawals antitrust matters equity investment cost sales withdrawals antitrust matters equity investment carrying cost sales reduced percentage turnover result carrying value adjustments arising stock market price selling general value adjustments arising stock market price changes royalty benefits arising merger manufacturing restructuring changes royalty income product disposals equity administration income product disposals equity investment sales savings favourable product mix small pricing benefit investment sales research offset adverse exchange impact merger development operating expenses million year compared manufacturing costs incurred million million operating expenses million year trading profit million yearonyear movement reflects lower compared million year year higher provisions product liability antitrust movement reflects higher provisions product liability claims partially offset higher proceeds product selling general administration antitrust claims partially offset higher cost sales disposals equity investment sales selling general administration sga costs declined two per proceeds product disposals equity investment sales cost sales reduced percentage turnover result c e ine x cn c ret e l alr ee sn efl c de e c c ein llg nt gr se ad cv ou sc tge sd oim n se uir pg pe ivr oe ri sn nte ehg wera et pi rw de c ureo c tpt la ra utn l nyd c h f efp sse e r ca hbt ai yo r gn ea sl b thhu ees fipn nre fi l st ed ti n ts l ep mo iss epa nol ts sa rl eo gf b rdu nin ge ts hs ee sp al f f h e lm thi cll aio ren reflects b thne ne fi f fs f sva eor ti u brin yg b lef nr p r v dm eu sc er tg ee xr c x hm aaa n n gsmu ef ia mlc l ppu arr ci cn ti ng g r e bs etr nu ec fit tu r win ag mav oi rn eg u thh n ea r e se hr ao rf ek p onr fgo psfi r ots fi sl os fs ae ss cf ia j esin r iv see sn pu rir ne cs ip llyd fa ross mo c ti ha et e gd r oups relating cost saving programmes increased pension costs services businesses selling general administration holding quest diagnostics inc without merger integration costs sga grew four per cent selling general administration sga costs grew four per driven selling cost increases accounted three share profitslosses joint ventures associated cent reflecting increased selling costs support new product net interest payable percentage point increase charges relating operational undertakings launches charges relating operational excellence cost saving interest payable excellence pension cost increases individually added one share profits associates arises principally programmes increased pension costs partly offset cost investment income percentage point cost savings reduced growth one groups holding quest diagnostics inc saving initiatives cost saving initiatives relatively small percentage point together produced reduction percentage points relative expenses expressed net interest payable restructuring activities estimated share interest payable associate without operational excellence charges sga would percentage turnover interest payable grown three per cent driven principally selling cost increases investment income pension cost increases added one percentage point net interest payable increased compared largely research development offset cost saving initiatives together produced result unwinding discounts provisions long rd declined one per cent reflecting reduced merger integration share interest payable associate reduction percentage points expressed percentage term receivables costs partly offset increased clinical trial inlicensing activity turnover reinvestment merger synergies pharmaceuticals rd profit ordinary activities taxation business expenditure represented per cent pharmaceutical turnover net interest payable increased compared largely research development performance year result unwinding discounts provisions research development rd increased four per cent reflecting taking account net operating incomeexpense longterm receivables increased clinical trial inlicensing activity reinvestment contribution associates net interest payable business trading profit merger synergies pharmaceuticals rd expenditure represented performance profit tax million compared statutory trading profit million growth profit ordinary activities taxation statutory per cent pharmaceutical turnover year million increase eight per cent per cent stronger turnover growth five per cent results demonstrating improved trading margin percentage taking account net operating incomeexpenses trading profit merger items restructuring costs disposal businesses points principally due lower merger integration costs contribution associates business disposals net interest business performance trading profit million cost savings derived merger integration manufacturing merger manufacturing restructuring payable statutory profit tax million compared growth nine per cent stronger turnover growth five per initiatives partly offset charges relating operational glaxosmithkline made good progress merger million increase per cent cent demonstrating improved trading margin points excellence cost saving programmes higher pension costs manufacturing restructuring plans merger programmes per cent compared principally due cost substantially complete end combined savings derived merger integration manufacturing programmes produced annual savings exceeded initiatives partly offset charges relating operational excellence published target billion cost saving programmes higher pension costs costs million incurred year respect focus operational excellence value creation merger manufacturing restructuring tax relief elimination waste bureaucracy programme become million net charge million costs integral part way business managed include severance asset writedowns professional fees site charges booked business performance closure glaxosmithkline operating financial review prospects operating financial review prospects glaxosmithkline block drug company inc glaxosmithkline uses best advice determining transfer critical accounting policies impairment fixed assets glaxosmithkline acquired block drug january costs pricing methodology seeking manage transfer pricing carrying values fixed assets subject depreciation consolidated financial statements prepared accordance incurred integrating business million issues satisfactory conclusion basis external amortisation reviewed impairment uk generally accepted accounting principles following including redundancies asset writedowns site closures professional advice continues believe made adequate indication values assets might impaired accounting policies approved board described provision liabilities likely arise open assessments impairment determined reference higher net note financial statements accounting policies disposal businesses however continues wide difference views realisable value value use measured reference management required make estimates assumptions profit disposal businesses million reflects group irs ultimate liability riskadjusted future cashflows discounted using appropriate risk affect amounts assets liabilities revenue expenses final settlements regarding disposal healthcare matters may vary significantly amounts provided free interest rates future cashflows based business reported financial statements actual amounts results services businesses dependent upon outcome litigation proceedings forecasts therefore inherently judgemental future events could differ estimates following considered negotiations relevant tax authorities could cause assumptions used impairment reviews critical accounting policies adopted taxation change consequent adverse effect future results credit taxation merger restructuring items group amounting million reflects actual tax rate applicable turnover business performance transactions territories arise gross turnover reduced discounts allowances vary investment shares merger restructuring disposal product arrangements buying groups arrangements subsidiaries earnings growth purchasing organisations dependent upon submission glaxosmithkline invested shares employee cer share ownership trusts order meet obligations arising claims time initial recognition sale total statutory earnings certain companys employee share option schemes provision made time sale estimated discount basic earnings per share p p shares held cost less provision recognise shortfall allowance payable based historical experience amounts integrated nature groups worldwide operations basic earnings per ads proceeds receivable employee exercise unless subject change dependent upon amongst things involving significant investment research strategic management believes permanent impairment types buying group product sales mix level provision manufacture limited number locations consequential adjusted earnings value relation period time related reviewed regularly light historical experience actual crossborder supply routes numerous endmarkets gives rise adjusted earnings per share p p share options may exercised impairment would discounts allowances given changes arrangements complexity delay negotiations revenue authorities adjusted earnings per ads adverse effect results group accounting future events could cause assumptions discounts profits individual group companies liable weighted average number based change could affect future results period following change uk accounting tax disagreements revenue authorities shares millions group requirements shares shown deduction intragroup transactions particular price goods equity shareholders funds longer subject transferred group companies different tax adjusted earnings adjusted earnings per share presented potential impairment legal disputes jurisdictions produce conflicting claims revenue order illustrate business performance glaxosmithkline provides anticipated settlement costs authorities profits fall taxed individual primary measure used management adjusted earnings pensions postretirement benefits associated expenses arising asserted claims group territories resolution issues continuing fact life increased eight per cent adjusted earnings per share increased costs providing pensions postretirement benefits reasonable estimate may made likely outcome glaxosmithkline group open issues revenue per cent reflecting reduction weighted average charged profit loss account accordance dispute companys directors taken legal advice authorities usa uk japan canada far number shares resulting groups share buyback ssap period benefit derived established provisions taking account insurance largest relates glaxo heritage products usa programme interest cost programme also impacts employees services costs assessed accordance agreements regard relevant facts groups earnings advice received independent actuaries basis usa number years glaxosmithkline circumstances matter accordance accounting assumptions selected management assumptions include significant open issues relating transfer pricing glaxosmithkline actual rates exchange adjusted earnings per share increased requirements provisions made unasserted claims future earnings pension increases discount rates expected attempted settle dispute first direct discussion five per cent sterling terms compared per cent cer claims reasonable estimate likely long term rates return assets disclosed note us internal revenue service irs subsequently terms adverse currency impact eps five per cent outcome yet made ultimate liability pending financial statements employee costs expected long discussions usa uk authorities year reflected significant weakening us dollar relative unasserted claims may vary amounts provided term rates return assets determined based long term terms double tax convention two countries compares four per cent adverse currency dependent upon outcome litigation proceedings government bond rates adjusted risk current market glaxosmithkline understands views two tax impact turnover difference principally arises investigations possible settlement negotiations expectations note also gives additional disclosures authorities different unable reach different mix currencies profits compared turnover required frs retirement benefits selection different agreement discussions terminated july intangible assets taken together expenses taxation business assumptions could affect future results group intangible assets acquired glaxosmithkline group received claim additional taxes disposals resulted basic eps pence compared third parties costs acquisition capitalised licences irs asserts legacy company glaxo wellcome owes years pence diluted eps pence compared product rights goodwill compounds development amortised estimated statutory notice deficiency billion pence merger manufacturing restructuring addition critical accounting policies outlined useful lives exceeding years estimated useful lives billion tax principally relates allocation profits costs lower result sterling accounting policy product rights goodwill deemed reviewed annually impairment reviews undertaken glaxo heritage products usa countries based growth basic eps per cent significantly higher important respect balance sheet prepared events occur call question carrying values extent irs successful claim interest cer based growth adjusted eps despite overall accordance us accounting principles us gaap assets brands acquired businesses capitalised would payable glaxosmithkline estimates interest negative impact currencies merger glaxo wellcome smithkline beecham independently separable longterm full claim date would approximately billion billion accounted acquisition gave rise product rights value group brands amortised estimated net federal tax relief similar tax issues remain open dividend billion goodwill billion recognised useful lives exceeding years except end date glaxosmithkline expects receive claims board declared fourth interim dividend pence per goodwill product rights determined indefinite useful economic life foreseen brands irs years share making total year pence per share lives amortised rather reviewed annually amortised subject annual impairment reviews compares total dividend pence per share impairment impairment reviews assess business projections since glaxosmithkline exhausted administrative remedies impairment reviews based riskadjusted future cash flows prepared part groups annual budgeting planning open company plans contest claim additional glaxosmithkline expects similar increase total discounted using appropriate riskfree interest rates future process determine whether impairment value taxes filing petition us tax court trial dividend declared allocation cash flows based business forecasts therefore goodwill occurred business projections include expected sometime quarterly dividends rebalanced glaxosmithkline inherently judgemental future events could cause values assumptions future events changes future events could intends increase first three interim dividends nine intangible assets impaired would glaxosmithkline continues believe profits reported cause assumptions business projections change pence pence remainder total dividend adverse effect future results group us subsidiaries period date consequent adverse effect future results group year allocated fourth quarter dividend paid taxes usa sufficient reflect reported us gaap activities us operations glaxosmithkline operating financial review prospects operating financial review prospects glaxosmithkline financial position resources financial position debtors commitments contingent liabilities groups policy provide settlement costs debtors increased reflecting timing yearend financial commitments summarised note financial asserted claims environmental disputes reasonable receipts higher deferred tax asset insurance receivables statements commitments contingent liabilities estimate may made prior point liability recorded goodwill additional cash contributions uk pension plan obligations respect short longterm debt set legal environmental costs discussed risk factors intangible fixed assets note financial statements contingent liabilities pages tangible fixed assets provisions note financial statements net debt glaxosmithkline uses best advice determining transfer investments group carried provisions million st december amounts provided pensions postretirement benefits pricing methodology basis external professional respect estimated future liabilities fixed assets restructuring integration plans legal environmental advice continues believe made adequate provision million related legal disputes million disputes set note financial statements liabilities likely arise open taxation assessments equity investments related pensions postretirement benefits provisions liabilities charges ultimate liability matters may vary significantly stocks employees provision made tax legal amounts provided dependent upon outcome litigation debtors disputes indemnified disposal liabilities costs contractual obligations commitments proceedings negotiations relevant tax authorities liquid investments manufacturing restructuring merger integration extent following table sets groups contractual obligations discussed note financial statements cash bank balance sheet date actual constructive obligation commitments fall due payment taxation existed could reasonably estimated current assets loans overdrafts net debt mal myr mrs mrs rs cash flow creditors group net debt st december comprised loans summary consolidated cash flow statement set creditors amounts due within one year finance lease obligations net current assets operating lease cash liquid investments commitments total assets less current liabilities borrowings repayable within one year intangible fixed assets net cash inflow operating activities loans borrowings repayable one year tangible fixed assets dividends joint ventures creditors net debt commitments associated undertakings returns investment servicing creditors amounts due one year total net debt decreased million primarily due finance provisions liabilities charges lower purchases shares company cancellation partly group entered number research collaborations taxation paid net assets offset increase working capital develop new compounds pharmaceutical companies capital expenditure financial investment terms arrangements include upfront fees equity acquisitions disposals called share capital pensions investments loans commitments fund specified levels equity dividends paid share premium account group continues account pension arrangements research addition group often agree make net cash inflowoutflow management reserves accordance ssap transitional provisions payments future milestones achieved liquid resources financing profit loss account frs disclosed pension assets liabilities group agreements relate compounds early stages management liquid resources equity shareholders funds st december show net deficit allowing deferred development milestone payments continue number financing taxation million million fourth years compounds move successfully nonequity minority interests quarter special cash contributions million development process generally closer product decreaseincrease cash year equity minority interests made reduce funding deficit marketing approval greater possibility success capital employed company review position annually make payments shown represent maximum would reconciliation net cash flow movement net debt contributions appropriate paid milestones achieved number commitments investments made licensing agreements glaxosmithkline investments excluding shares principally neurosearch ranbaxy laboratories ltd net debt beginning year shareholders funds st december carrying value million pozen inc pension commitments provided note decreaseincrease cash year summary movements equity shareholders funds set million market value st december financial statements employee costs cash inflowoutflow management million million investments liquid resources include associates joint ventures mainly equity contingent liabilities net increase longterm loans shares holding derives directly groups following table sets contingent liabilities comprising net repayment shortterm loans business investments include stakes companies beginning year discounted bills performance guarantees items arising exchange movements group research collaborations provide access profit year normal course business expected net debt end year biotechnology developments potential interest interests dividends expire companies arise business divestments shares issued exercise share options net cash inflow operating activities million total yr yrs yrs yrs shares purchased cancelled decrease million arising timing shares exchange movements guarantees trade receipts yearend period higher st december esots held million uk tax exchange movements contingent liabilities payments legal provisionable items partly offset glaxosmithkline shares carrying value million unrealised gains reduced restructuring integration payments market value million future exercise unrealised gain equity investments total capital expenditure tangible intangible fixed assets share options share awards valuation shortfall end year normal course business group provided various amounted million million disposals considered represent permanent diminution value indemnification guarantees respect business disposals realised million million equity investments context length future period related equity shareholders funds increased million legal disputes subsequently arisen costing million million purchased share options may exercised accordingly provision st december million st december provision made reasonable estimate made year sales equity investments realised million made increase arises retained earnings positive exchange likely outcome dispute included note million movements overseas net assets partly offset shares financial statements provisions liabilities charges purchased cancelled glaxosmithkline operating financial review prospects operating financial review prospects glaxosmithkline shares glaxosmithkline plc purchased esots liquidity funding maturity counterparty risk group uses limited number interest rate swaps satisfy future exercises options awards group operates globally primarily subsidiary companies group invests centrally managed liquid assets government redenominate external borrowings interest rate coupon employee share incentive schemes nil total established markets group trades due bonds shortterm corporate debt instruments minimum required group purposes duration swaps matches million million received employees nature groups business patent protection many shortterm credit rating ap money market funds duration principal instruments interest rate derivative exercise share options option exercises satisfied products groups portfolio groups products credit rating aaaaaa preference share investments fully instruments accounted hedges relevant assets shares previously purchased esots yielded million compete largely product efficacy rather price selling collateralised highly rated bonds credit ratings shown liabilities possible million option exercises satisfied issue margins sufficient cover normal operating costs standard poors moodys investors services group manages centrally shortterm cash surpluses new shares yielded million million groups operating subsidiaries substantially cash generative respectively borrowing requirements subsidiary companies uses forward group purchased shares market cancellation operating cash flow used fund investment research group manages net borrowing requirements contracts hedge future repayments back originating amounting million million period development new products well routine outflows portfolio long mediumterm borrowings including bonds currency st january th february million capital expenditure tax dividends repayment maturing together shortterm finance us dollar commercial sensitivity analysis considers sensitivity groups net debt shares purchased cancelled cost million debt group time time additional demands paper programme billion per cent coupon hypothetical changes market rates assumes finance share purchases acquisitions bond million per cent coupon bond issued variables remain constant based composition net debt future cash flow european medium term note programme glaxosmithkline operates relatively low levels net debt st december one percentage point basis points group expects future operating cash flow addition strong positive cash flow normal trading groups mediumterm borrowings mature dates increase decrease average interest rates would result sufficient fund operating debt service costs satisfy activities additional liquidity readily available via commercial private financing matures negligible change groups annual interest expense normal levels capital expenditure meet obligations paper programme longdated sterling bond matures private financing existing licensing agreements meet routine may redeemed glaxosmithkline time equity risk management commitments including tax dividends subject risk group also uncommitted euro medium term note particular occurrence event would increase equity investments classified current assets available sale factors discussed pages group may time programme billion million issue cost funding group group also group manages disposals meet overall business time additional demands finance st december million flexible auction market preferred stock flex requirements arise group regularly monitors value acquisitions group access sources liquidity amps million auction rate preference stock arps equity investments enters hedges selectively banks financial institutions addition treasury operations originally issued notice redeem flex amps approval board cash flow operations needs objective treasury activity manage posttax net arps given february redemption expected costincome financial operations benefit group completed march april financial assets liabilities payment policies earnings corporate treasury operate profit centre analysis net debt given note financial glaxosmithklines longterm debt rating aa standard group companies responsible monitoring managing glaxosmithkline uses variety financial instruments including statements net debt analysis financial assets liabilities poors aa moodys investors services agencies working capital terms sales collections supplier derivatives finance operations manage market risks carrying value fair value reconciliation net debt shortterm rating paper issued groups commercial payments reflect local commercial practice operations financial instruments comprise cash given note financial statements financial paper programme p respectively liquid resources borrowings spot foreign exchange contracts instruments related disclosures together discussion uk company uk subsidiaries derivative financial instruments quantitative disclosures policies ensure suppliers paid time particular number derivative financial instruments used manage foreign exchange risk management market risk accordance requirements financial uk companies seek market risks treasury operations derivative instruments glaxosmithkline foreign currency transaction exposure arising reporting standard principally comprising forward foreign currency contracts interest normal trade flows respect external intragroup settle terms payment suppliers agreeing rate currency swaps used swap borrowings liquid trade hedged glaxosmithklines policy minimise group continues benefit strong positive cash flow terms transaction assets currencies required group purposes exposure overseas operating subsidiaries transaction risk group net debt would decreased significantly year ensure suppliers made aware agreed terms manage exposure funding risks changes foreign matching local currency income local currency costs st december groups purchase payment exchange rates interest rates purpose intragroup trading transactions matched shares market million abide terms payment centrally intragroup payment terms managed reduce glaxosmithkline balances use borrowings liquid assets financial assets liabilities st december policy includes arrangements accelerated payment small risk exceptional foreign currency cash flows hedged selectively regard cash flow operating activities representative treasury policies strategies suppliers management corporate treasury currencies earned tax cost intragroup glaxosmithkline applied consistently year distributions currencies business assets significant proportion group borrowings including significant changes policies throughout year payment performance denominated posttax cost borrowings compared commercial paper programme us dollars benefit st december average number days purchases posttax return liquid assets liquidity us dollar denominated capital markets certain esot share purchases shares purchased cancellation represented trade fixed asset creditors company borrowings swapped currencies shares held trusts satisfy future exercises options nil days nil days respect company liquid assets surplus immediate operating requirements required group purposes group seeks denominate awards group share option award schemes uk subsidiaries aggregate days days group companies invested managed centrally borrowings currencies principal overseas assets proportion shares held trusts respect corporate treasury requirements group companies awards rules scheme require company treasury policies operating finance met whenever possible central borrowings denominated swapped foreign currencies satisfy exercises market purchases rather issue resources match investments overseas group assets treated glaxosmithkline plc uk based business reporting sterling new shares shares held trusts matched hedge relevant net assets paying dividends sterling profits role corporate external borrowings mainly managed centrally corporate options awards granted diminish dilutive effect treasury glaxosmithkline manage monitor groups treasury comprise portfolio long mediumterm based composition net debt st december new share issues shareholders ' capital earnings external internal funding requirements financial risks instruments shortterm finance per cent appreciation sterling major currencies would annual general meeting shareholders renewed support group corporate objectives treasury activities result reduction groups net debt approximately glaxosmithkline hold issue derivative financial approval glaxosmithkline make market purchases governed policies procedures approved board million per cent weakening sterling major instruments trading purposes groups treasury policies shares rd october glaxosmithkline announced monitored treasury management group glaxosmithkline currencies would result increase groups net debt specifically prohibit activity transactions financial second share repurchase programme billion exact maintains treasury control systems procedures monitor approximately million instruments undertaken manage risks arising amount timing future purchases following changes foreign exchange interest rate liquidity credit financial underlying business activities speculation uk company law whether repurchased shares held risks interest rate risk management treasury shares rather cancelled depend glaxosmithklines policy interest rate risk management requires market conditions factors amount net borrowings fixed rates increases ratio forecast net interest payable trading profit glaxosmithkline operating financial review prospects operating financial review prospects glaxosmithkline outlook risk factors outlook risk loss expiration patents marketing exclusivity risk substantial adverse outcome litigation continued consolidation pharmaceutical industry could patent infringement litigation government investigations adversely affect groups competitive position continued pharmaceutical sales growth existing products key driver efforts generic manufacturers may involve challenges see note financial statements legal proceedings consolidation among groups customers may increase pricing glaxosmithklines current business performance validity patent assertions products discussion proceedings governmental investigations pressures year transition glaxosmithkline first nine months infringe groups patents group successful group currently involved unfavourable resolution challenging group absorbs full erosion group eight products million billion patent protection period maintaining exclusive rights similar future proceedings investigations may generics however starting fourth quarter expected annual global sales among products market one major products particularly usa material groups financial results group made return growth impact generics paxilseroxat augmentin respect group group highest margins sales material provisions related legal proceedings diminishes underlying business strength shows faces generic competition wellbutrin sr zofran imitrex country groups revenues margins would adversely investigations reduced earnings group may avandia respect group currently glaxosmithkline engaged legal proceedings regarding validity affected see note financial statements legal also make material provisions related legal proceedings defending intellectual property rights usa infringement groups patents relating many proceedings discussion patentrelated proceedings investigations future would reduce earnings products particular relating paxilseroxat group involved many cases practice plaintiff bar claim damages groups major products wellbutrin discussed risk factors compensatory punitive statutory amounts bear become subject problem loss patent protection generic drug manufacturers seeking market generic versions note financial statements legal proceedings relationship underlying harm accordingly potentially unexpected side effects regulatory proceedings publicity affecting many groups important products including misleading quantify potential exposure claims doctor patient confidence pressure competitive glaxosmithklines published earnings guidance wellbutrin seretideadvair avandia imitrex valtrex lamictal proceedings investigations type described note products new effective treatment deliver eps constant exchange rates least line zofran prior expiration groups patents introduced impact groups revenues operating business performance eps impact generics exhibited readiness products future recent insurance loss experience including pharmaceutical results could significant particular group faces intense becomes less significant group looks forward return generic products competitive augmentin paxil product liability exposures increased cost insurance competition manufacturers generic pharmaceutical eps growth launched usa respectively coverage pharmaceutical companies generally including products major markets significant adverse impact groups overall sales group order contain insurance costs group net debt billion low relative earnings group adjusted coverage profile accepting greater generic products often enter market upon expiration market capitalisation positions take advantage degree uninsured exposure patents data exclusivity periods groups products opportunities might arise build business following patent expiry ability generic manufacturers introduction generic products typically leads dramatic loss obtain regulatory approval generic versions groups risks uncertainties inherent business product liability litigation sales reduces groups revenues margins products also relevant example one manufacturer may affect future performance including expected earnings group currently defendant number product liability proprietary products expiration dates patents indicated expects approval generic version flonase growth discussed risk factors lawsuits including class actions involve substantial claims groups major products set following patent expiry usa mid approved damages related groups pharmaceutical products generic launch could adversely affect groups sales risk factors governmental payer controls earnings litigation particularly usa inherently unpredictable pharmaceutical products subject price controls pressures risks uncertainties relevant groups business excessive verdicts justified evidence occur restrictions many markets including japan germany factors listed among group thinks weakness intellectual property protection certain class actions sweep together persons prescribed france italy governments intervene directly setting could cause groups actual results differ materially countries groups products inflate potential liability force prices addition markets major purchasers expected historical results countries group operates patent numbers claims pain suffering punitive damages pharmaceutical products whether governmental agencies protection may significantly weaker usa frequently asserted product liability actions allowed private health care providers economic power exert risk rd deliver commercially successful new european union addition effort control public health represent potentially openended exposure substantial pressure prices terms access formularies products crises developing countries south africa brazil continued development commercially viable new products considered plans substantial reductions scope antitrust litigation group predict whether existing controls increase critical groups ability replace sales older products patent protection pharmaceutical products particular usa become increasingly common following new controls introduced reduce groups decline upon expiration exclusive rights increase overall countries could facilitate competition within markets adverse outcome prosecution patent infringement actions margins affect adversely ability introduce new products sales developing new products costly lengthy uncertain generic manufacturers would otherwise unable defendants direct indirect purchasers payers profitably process new product candidate fail stage introduce competing products number years loss initiate antitrust actions well claims direct indirect example usa group highest margins process one latestage product candidates could fail patent protection including abrogation patent rights purchasers payers typically filed class actions sales country pricing pressures could significantly receive regulatory approval compulsory licensing likely affect adversely groups relief sought may include treble damage restitution claims increase upon implementation pharmaceutical benefit operating results national markets expected new product candidates may appear promising development medicare event state programmes control material group overall absence adequate patent governmental investigations significant investments fail reach market cost pharmaceuticals adopted medicare protection could limit opportunity look markets group responding federal state governmental limited commercial success result efficacy safety programme initiates outpatient pharmaceutical coverage future sales growth investigations usa pricing marketing concerns inability obtain necessary regulatory approvals beneficiaries us government private insurers reimbursement number prescription drug products difficulty excessive costs manufacture infringement offer coverage enormous purchasing power investigations could result related restitution civil false claims patents intellectual property rights others inability programme could demand discounts may implicitly create act litigation behalf federal state governments differentiate product adequately price controls prescription drugs additionally number related proceedings initiated glaxosmithkline competes successful development groups research states proposed implemented various schemes control behalf consumers private payers development pipeline particular importance light prices senior citizens drug programmes including recent anticipated expiration patent data exclusivity importation countries bulk purchasing drugs risks competition price controls limitations sales number groups largest selling products growth number patients covered large third party competition managed care institutions usa would likely group operates highly competitive businesses increase implementation medicare amendments also pharmaceuticals business faces competition increases pricing pressures groups products trends proprietary products large international manufacturers may adversely affect groups revenues margins sales producers generic pharmaceuticals significant product usa terms implementation medicare innovations technical advances intensification price pharmaceutical benefit finalised possible competition competitors could adversely affect groups quantify impact benefit groups financial results operating results glaxosmithkline operating financial review prospects operating financial review prospects glaxosmithkline year regulatory controls global political economic conditions accordance us sec disclosure requirements following sales wellbutrin depression grew per cent group must comply broad range regulatory controls group conducts substantial portion operations outside discussion compares results year st december million reflecting increased physician awareness testing approval manufacturing marketing many uk fluctuations exchange rates sterling results year st december products outstanding efficacy favourable side effect profile pharmaceutical consumer healthcare products currencies especially us dollar euro japanese yen application approval oncedaily formulation growth rates included review turnover constant particularly usa countries european union materially affect groups financial results wellbutrin xl submitted fda exchange rates cer unless otherwise stated sterling growth affect cost product development also time group control changes inflation interest rates may found table pharmaceutical sales glaxosmithklines medicine epilepsy lamictal continued required reach market uncertainty successfully rates foreign currency exchange rates controls therapeutic area grow across regions achieving sales million economic factors affecting businesses possibility per cent group filed snda lamictal seeking strict regulatory controls also heighten risk withdrawal political unrest legal regulatory changes nationalisation exchange firstever indication longterm management depressive regulators approval previously granted would reduce jurisdictions group operates factors could episodes bipolar disorder currencies influence groups results us revenues result product recalls product liability materially affect groups future results operations dollar euro japanese yen lawsuits addition cases group may voluntarily respiratory cease marketing product example withdrawal accounting standards pound hit highest level dollar glaxosmithkline continued global leader respiratory lotronex shortly initial launch usa face declining new revised accounting standards rules promulgated twoandahalf years climbing euro gained pharmaceuticals sales three key products sales based concerns efficacy safety whether time time uk us international accounting standard per cent dollar first year seretideadvair flixotideflovent serevent amounting scientifically justified even absence regulatory action setting boards could material adverse impact dollar fallen value euro investors weighed nearly billion per cent developments postapproval adverse event profile groups reported financial results group believes impact possible war iraq tensions north korea sales seretideadvair glaxosmithklines second largest product product product class may major impact complies appropriate regulatory requirements concerning fears us economy grew per cent billion although contributed marketing sale product financial statements disclosures however companies pharmaceutical sales declines serevent flixotide constituent products advair experienced investigations potential noncompliance became us asthma market leader new prescriptions concentration sales wholesalers accounting disclosure requirements resulted total pharmaceutical sales million compared less two years market seretide also continued usa line pharmaceutical companies significant penalties million increase eight per cent perform strongly europe per cent international group sells products small number wholesalers less one per cent overall growth came price markets per cent december glaxosmithkline addition hospitals pharmacies physicians groups increases growth sterling terms five per cent significantly filed nda ariflo copd group exposed concentration credit risk impacted weakness us dollar currencies wholesalers affected financial difficulty could materially within groups portfolio sales new products antivirals adversely affect groups financial results launched major market within last five years accounted hiv medicines grew across regions totalled billion per cent total sales grew per cent sales per cent sales trizivir glaxosmithklines triple environmental liabilities million sales established franchise products combination therapy grew per cent million environmental laws various jurisdictions impose actual amounted million representing per cent total sales potential obligations group remediate contaminated valtrex herpes continued benefit convenient grew six per cent compared last year sales older sites group also identified potentially oncedaily dosing suppressive therapy achieved strong products less actively promoted million responsible party us comprehensive environmental sales growth per cent worldwide per cent decline per cent representing per cent total sales response compensation liability act number sites usa october glaxosmithkline filed snda valtrex remediation costs relating groups use ownership global pharmaceutical sales fourth quarter grew seeking firstever indication reduce risk transmission sites failure properly manage environmental risks seven per cent reflecting us sales growth per cent genital herpes december glaxosmithkline filed could result additional remedial costs could materially million whereas europe sales growth weaker nda protease inhibitor treatment hiv adversely affect groups operations see note one per cent sales million international decline zovirax sales reflected transfers newer valtrex financial statements legal proceedings discussion sales flat million generic competition environmentalrelated proceedings group involved pharmaceutical sales therapeutic area antibacterials reliance information technology antibacterial sales declined per cent worldwide per across groups portfolio products six major therapeutic group increasingly dependent information technology cent usa augmentins us sales per cent areas experienced good growth year including fast systems including internet based systems internal year result generic competition began growing franchises cns billion per cent respiratory communication well communication customers third quarter four generic versions augmentin billion per cent antivirals billion per cent suppliers significant disruption systems whether introduced usa following decision us district vaccines billion per cent due computer viruses outside incursions could court eastern virginia held invalid glaxosmithklines materially adversely affect groups operations patents augmentin expiring us central nervous system sales ceftin declined per cent due generic competition sales seroxatpaxil glaxosmithklines leading product taxation began first quarter depression anxiety disorders driver growth effective tax rate groups earnings benefits cns therapy area sales billion per cent globally fact portion earnings taxed favourable per cent usa international sales paxil grew rates jurisdictions outside united kingdom changes per cent million led continued strong growth tax laws application respect matters japan launched april paxil cr continued gain transfer pricing risk double taxation relate acceptance due strong tolerability profile portion groups earnings taxed favourable rates could increase groups effective tax rate adversely affect financial results group involved significant dispute us internal revenue service transfer pricing matters discussed note financial statements taxation glaxosmithkline operating financial review prospects operating financial review prospects glaxosmithkline pharmaceutical sales therapeutic area metabolic sales antivirals therapeutic area grew per cent led worldwide sales metabolic category million strong performance trizivir per cent partially total usa europe international avandia franchise avandia avandamet grew per cent drew sales constituent products valtrex therapeutic area growth growth growth growth year us sales per cent million per cent major products total cer cer cer cer cns avandamet combination avandia metformin hci sales avandia increased per cent benefiting depression expanded avandia metabolic franchise us launch launch avandamet november antibacterial sales seroxatpaxil fourth quarter avandamet treatment type declined augmentin started experience generic competition wellbutrin diabetes first medicine targets insulin resistance second half year cardiovascular franchise migraine decreases glucose production one convenient pill since coreg sales increased million reflecting improved market imigranimitrex approval fda may avandia used share naramigamerge four million patients worldwide europe lamictal requip vaccines europe region contributed per cent pharmaceutical sales zyban sales vaccines grew per cent billion supported although overall sales growth region two per cent hepatitis franchise per cent million total good growth recorded several markets including spain respiratory vaccine sales europe grew per cent us sales grew central eastern europe government healthcare reforms flixotideflovent serevent seretideadvair per cent launch twinrix continued growth including pricing reimbursement restrictions adversely seretideadvair havrix driven new state mandates requiring hepatitis affected sales italy flixotideflovent vaccination school age children infanrix glaxosmithklines serevent dtpa range combination vaccines grew eight per cent international flixonaseflonase ventolin million four per cent sales growth international region reflected becotide mixture good growth middle east africa canada cardiovascular urogenital asia pacific decline sales latin america principally antivirals coreg sales grew per cent million benefiting poor economic conditions mexico brazil hiv trizivir throughout year new indication treatment addition mexico suffered realignment wholesaler stock combivir severe heart failure levels epivir retrovir november levitra vardenafil new agent overall international growth driven seretide seroxatpaxil ziagen treatment erectile dysfunction received positive opinion avandia vaccines partly offset declines zantac agenerase european cpmp fda issued approvable letter zovirax herpes levitra levitra researched developed bayer ag asia pacific area grew due performance seretide valtrex copromoted glaxosmithkline zovirax vaccines strong growth number markets partly offset lower growth largest market australia reflecting oncology emesis zeffix reduced sales zyban zantac sales zofran grew per cent million driven antibacterials strong us performance per cent million market growth japan reflected strong growth paxil augmentin flixotideflovent partly offset decline older product zinnatceftin therapeutic areas zantac government price reductions fortum amoxil sales relafen arthritis fell reflecting generic competition middle east africa area followed trends usa metabolic markets growth seretide avandia vaccines hiv avandia regional analysis canada growth driven seretide paxil avandia vaccines antivirals partly offset lower sales antibacterials usa hepatitis infanrix usa reported per cent sales growth year consumer healthcare sales business currently represents per cent total pharmaceutical growth oncology emesis sales sales growth central nervous system products cer zofran per cent driven wellbutrin reflecting increased otc medicines hycamtin prescribing primary care physicians psychiatrists paxil analgesics cardiovascular following launch cr formulation april lamictal dermatological urogenital indicated epilepsy recorded sales growth per cent gastrointestinal coreg advair maintained strong growth sales million respiratory tract driving overall respiratory sales growth per cent smoking control zantac however adversely affected sales constituent products natural wellness support flovent serevent showed declines flonase oral care indicated treatment perennial rhinitis grew strongly nutritional healthcare per cent cer represents sales growth constant exchange rates actual exchange rates certain products reclassified different therapeutic areas comparative purposes glaxosmithkline operating financial review prospects operating financial review prospects glaxosmithkline otc medicines trading profit profit ordinary activities taxation statutory results profit taxation business performance smoking control sales growth driven performance statutory trading profit million growth taking account net operating expense net analysis discussion profit taxation relates nicodermniquitinnicabate usa nicoderm grew strongly per cent stronger sales growth seven per cent operating income contribution associates business performance despite competition private label launch demonstrating improved trading margin percentage business disposals net interest payable statutory profit competitor patches niquitin lozenge commit points per cent compared principally tax million compared million operating incomeexpense launched usa november clinical studies show due cost savings derived merger integration increase per cent royalties income commit help smokers tried quit manufacturing initiatives lower costs operating expense analgesics panadol recorded good sales growth five per cent implementing initiatives trading profit business performance cer two per cent sterling partly offset declines number illustrate glaxosmithklines business performance brands abreva usa zovirax europe profit taxation statutory results income equity investments analysis trading profit subsequent discussion treatment cold sores drove dermatological sales disposals excludes merger items integration restructuring costs growth five per cent cer one per cent sterling decline operating incomeexpense disposal businesses management believes exclusion gastrointestinal sales citrucel rose per cent cer royalties income items provides better reflection way per cent sterling offset declines tums operating expense operating incomeexpense includes litigation costs business managed accordingly information provided tagamet provisions relating legal claims withdrawn products product supplement contained consolidated statement withdrawals antitrust matters equity investment carrying income equity investments profit loss pages prepared accordance oral care value adjustment arising stock market price changes royalty disposals uk gaap oral care sales grew marginally europe declined income product disposals equity investment sales highly competitive us market overall oral care sales declined growth operating expenses million year compared two per cent principally result reduced aquafresh sales cer million income year year movement reflects operating incomeexpense includes litigation costs although increase sensodyne sales partially offset sales higher provisions product liability claims provisions relating legal claims withdrawn products cost sales lower proceeds disposals equity investment sales product withdrawals antitrust matters equity investment nutritional healthcare selling general carrying value adjustments arising stock market price nutritional healthcare lucozade ribena reported strong administration profit disposal interest associate changes royalty income product disposals equity growth europe driven increased availability promotion research disposals interest associates investment sales horlicks sales declined primarily international markets development group sold million shares quest diagnostics inc operating expenses million year realising gain million trading profit trading profit statutory results compared million income year year movement reflects higher provisions product liability share profitslosses joint ventures associated analysis discussion relates statutory cost sales claims lower proceeds disposals undertakings performance statutory results include merger items integration cost sales reduced percentage sales result benefits equity investment sales share profits associates arises principally groups restructuring costs disposal subsidiaries arising merger manufacturing restructuring savings holding quest diagnostics inc growth profit disposal interest associate movements stock provisions favourable regional mix cer disposals interest associates net interest payable sales group sold million shares quest diagnostics inc selling general administration interest payable selling general administration costs benefited cost savings cost sales realising gain million investment income arising merger integration implementation cost saving selling general programmes including local restructuring europe international administration share profitslosses joint ventures associated share interest payable associate regions research undertakings development share profits associates arises principally research development groups holding quest diagnostics inc trading profit research development rd increased nine per cent net interest payable increased compared largely reflecting increased clinical trial inlicensing activity result higher average level net debt driven use cash cost sales disposal business reinvestment merger synergies pharmaceuticals rd fund groups share buyback programme benefit cost sales reduced percentage sales result benefits profit product divestments disposal business expenditure represented per cent pharmaceutical sales smaller number shares issue reflected earnings per share arising merger manufacturing restructuring savings million reflects final settlements regarding merger year movements stock provisions favourable regional mix related product disposals disposal healthcare profit ordinary activities taxation business services business trading profit performance see inin gg g g ee nn ere ar la al na dn ad md inm isi tn ri tt iora nt co st benefited lower net interest payable b gu ros win te hs p f e r fo prm era cn ec ne r sa td roin ng g ep rr thfi nw sa l e g ro w tm h olli fo sn e vw ei nth path rte fo tp er inti tn eg sn tc io nm ae n ae sx sp oe cn iase te g et h e r rw edit uh c eth de p rois fip bsa yl merger integration costs cost saving programmes merger interest payable per cent demonstrating improved trading margin million added million profit integration implementation initiatives including local investment income percentage points per cent compared taking account contribution associates net interest restructuring europe international regions principally due cost savings derived merger integration payable business performance profit tax million share interest payable associate manufacturing initiatives compared million increase per cent research development research development rd increased per cent reflecting increased merger integration costs higher clinical trial inlicensing activity reinvestment merger synergies pharmaceuticals rd expenditure represented per cent pharmaceutical sales year glaxosmithkline operating financial review prospects operating financial review prospects glaxosmithkline selected financial data ukus gaap merger items restructuring costs disposal businesses earnings growth profit loss account cer merger integration items represent items earnings arisen result merger glaxo wellcome smithkline amounts accordance uk gaap basic earnings per share p p beecham acquisition block drug restructuring costs turnover basic earnings per ads arise merger acquisition manufacturing operating profit restructuring programmes already agreed glaxo adjusted earnings profit taxation wellcome smithkline beecham date merger adjusted earnings per share p p earnings items nature considered outside adjusted earnings per ads basic earnings per share p p p p p normal business expenditure glaxosmithkline expected diluted earnings per share p p p p p weighted average number occur regular basis shares millions weighted average number shares issue key items discussed basic adjusted earnings adjusted earnings per share presented diluted merger manufacturing restructuring order illustrate business performance dividends per glaxosmithkline share pence glaxosmithkline made good progress merger primary performance measure used management adjusted glaxosmithkline shareholder p p p manufacturing restructuring plans remains track deliver earnings increased per cent adjusted earnings per share glaxo wellcome shareholder p p forecast total annual merger manufacturing restructuring increased per cent reflecting reduction weighted smithkline beecham shareholder p p savings billion excluding benefits block average number shares resulting groups share drug acquisition estimated cost achieving remains buyback programme interest cost programme also dividends expressed terms glaxosmithkline share around billion billion charged impacts groups earnings amounts accordance us gaap st december actual rates exchange business performance eps increased turnover costs million incurred year respect eight per cent compared per cent cer terms net incomeloss merger manufacturing restructuring tax relief adverse currency impact eps five per cent year basic net incomeloss per share pence p p p p p million net charge million costs reflected significant weakening us dollar relative diluted net incomeloss per share pence p p p p p include severance asset writedowns professional fees site compares three per cent adverse currency impact closure sales difference principally arises different mix information presents us gaap net incomeloss net incomeloss per share results years ended currencies profits compared sales st december adjusted reverse amortisation expense goodwill indefinitelived intangible assets block drug company inc sfas also applied years taken together expenses taxation product glaxosmithkline acquired block drug january costs divestments resulted eps pence compared adjusted net incomeloss incurred integrating business million pence diluted eps pence compared adjusted basic net incomeloss per share pence p p p including redundancies asset writedowns site closures pence merger manufacturing restructuring adjusted diluted net incomeloss per share pence p p p costs lower result sterling disposal businesses based growth eps per cent significantly higher balance sheet profit disposal businesses million reflects cer based growth business performance eps despite final settlements regarding merger related product disposals overall negative impact currencies amounts accordance uk gaap disposal healthcare services businesses total assets taxation dividend net assets board declared fourth interim dividend pence per equity shareholders funds share making total year pence per share business performance amounts accordance us gaap compares dividend pence per share merger restructuring disposal total assets subsidiaries net assets shareholders equity total exchange rates charge taxation business performance profit million represents effective tax rate per cent guide holders adrs following tables set periods indicated information exchange rate us dollars represents increase compared effective rate sterling reported federal reserve bank new york noon buying rate per cent restated implementation average frs deferred tax credit taxation merger restructuring items average rate year calculated average noon buying rates last day month year amounting million reflects estimated actual tax rate feb jan dec nov oct sept applicable transactions territories arise high low noon buying rate th february us glaxosmithkline glaxosmithkline financial statements section comprises directors statements responsibility independent auditors report financial statements financial statements consisting principal financial statements supporting notes directors statements responsibility independent auditors report financial statements consolidated statement profit loss consolidated statement total recognised gains losses consolidated statement cash flow consolidated balance sheet reconciliation movements equity shareholders funds company balance sheet notes financial statements presentation financial statements accounting policies new accounting policies future requirements exchange rates merger glaxo wellcome smithkline beecham segment information merger items restructuring costs divested businesses operating incomeexpense operating profit joint ventures associated undertakings net interest payable taxation earnings per share dividends goodwill intangible assets tangible fixed assets fixed asset investments equity investments stocks debtors creditors provisions liabilities charges contingent liabilities net debt commitments share capital share premium account nonequity minority interests reserves legal proceedings acquisitions disposals financial instruments related disclosures employee costs employee share schemes related party transactions reconciliation us accounting principles principal group companies glaxosmithkline glaxosmithkline directors statements responsibility independent auditors report members glaxosmithkline plc directors statement responsibility relation internal control audited financial statements comprise basis audit opinion financial statements consolidated statement profit loss consolidated statement board audit committee reviewed conducted audit accordance auditing standards total recognised gains losses consolidated statement directors assessment risks internal control framework issued united kingdom auditing practices board audit cash flow consolidated company balance sheets operates glaxosmithkline considered effectiveness includes examination test basis evidence relevant responsible ensuring maintenance proper accounting related notes prepared historical cost system internal control operation group amounts disclosures financial statements records disclose reasonable accuracy financial convention accounting policies set statement year covered report date approval auditable part directors remuneration report also position group time financial accounting policies also audited disclosures board directors includes assessment significant estimates judgements statements prepared comply companies required part schedule companies act made directors preparation financial act contained directors remuneration report auditable combined code statements whether accounting policies appropriate part required law prepare financial statements companys groups circumstances consistently applied board considers glaxosmithkline plc applies principles financial period give true fair view state adequately disclosed combined code described corporate respective responsibilities directors auditors affairs company group end governance pages complied planned performed audit obtain financial period profit loss period directors responsibilities preparing annual report requirements combined code exception information explanations considered necessary directors remuneration report financial statements responsible also ensuring operation systems senior independent director companys position order provide us sufficient evidence give reasonable accordance applicable united kingdom law accounting internal control taking reasonable steps safeguard described corporate governance provisions assurance financial statements auditable part standards set statement directors responsibility assets group preventing detecting relating executive directors service contracts pension directors remuneration report free material fraud irregularities arrangements companys position described responsibility audit financial statements misstatement whether caused fraud irregularity remuneration report auditable part directors remuneration report accordance error forming opinion also evaluated overall financial statements year ended st december relevant legal regulatory requirements united adequacy presentation information financial comprising principal statements supporting notes set required listing rules financial services authority kingdom auditing standards issued auditing practices statements financial statements pages report auditors considered directors statement board report including opinion prepared compliance relation points combined directors confirm suitable accounting policies companys members body accordance opinion code specified review consistently applied preparation financial statements section companies act purpose opinion supported reasonable prudent judgements estimates giving opinion accept assume responsibility annual report necessary applicable accounting standards followed purpose person report financial statements give true fair view state financial statements prepared going annual report year ended st december shown whose hands may come save expressly affairs company group st december concern basis comprising report directors remuneration report agreed prior consent writing profit cash flows group financial statements additional information investors year ended responsibilities auditors relation financial report opinion whether financial approved board directors signed financial statements properly prepared statements set independent auditors report statements give true fair view whether financial behalf accordance companies act opposite statements auditable part directors remuneration parts remuneration report required part report properly prepared accordance financial statements year ended st december schedule companies act properly companies act also report opinion included annual report published prepared accordance companies act report directors consistent financial hardcopy printed form website directors statements company kept proper accounting responsible maintenance integrity annual records received information report website accordance uk legislation governing explanations require audit information specified preparation dissemination financial statements access sir christopher hogg law regarding directors remuneration transactions website available outside uk comparable chairman disclosed legislation may different rd march read information contained annual report pricewaterhousecoopers llp directors remuneration consider implications report become aware chartered accountants registered auditors apparent misstatements material inconsistencies embankment place remuneration report pages report sets financial statements information comprises london england remuneration policies operated glaxosmithkline financial summary description business unauditable part rd march disclosures directors remuneration disclosable directors remuneration report joint statement chairman information relating directors officers interests chief executive officer operating financial review prepared accordance companies act prospects corporate governance statement amended directors remuneration report regulations review whether corporate governance statement reflects complies section b combined code companys compliance seven provisions combined code issued june specified review going concern basis listing rules financial services authority report making enquiries directors reasonable required consider whether boards expectation group company adequate resources statements internal control cover risks controls continue operational existence foreseeable future form opinion effectiveness companys groups reason continue adopt going concern basis corporate governance procedures risk control preparing financial statements procedures glaxosmithkline consolidated statement profit loss glaxosmithkline consolidated statement profit loss year ended st december merger merger merger restructuring restructuring restructuring business disposal business disposal business disposal performance subsidiaries statutory performance subsidiaries statutory performance subsidiaries statutory notes turnover cost sales gross profit selling general administrative expenditure research development expenditure trading profit operating incomeexpense operating profit share profitslosses joint ventures associated undertakings profit disposal interest associate product divestments profitloss disposal businesses profit interest net interest payable profit ordinary activities taxation taxation profit ordinary activities taxation equity minority interests preference share dividends earnings profit attributable shareholders basic earnings per share p p p adjusted earnings per share p p p diluted earnings per share p p p profit attributable shareholders dividends retained profit consolidated statement total recognised gains losses year ended st december profit attributable shareholders exchange movements overseas net assets unrealised gains equity investments tax exchange movements unrealised gains total recognised gains losses glaxosmithkline consolidated statement cash flow glaxosmithkline consolidated statement cash flow year ended st december reconciliation operating profit operating cash flows analysis cash flows notes notes operating profit returns investment servicing finance depreciation interest received impairment assets written interest paid amortisation goodwill intangible fixed assets dividends paid minority shareholders loss sale tangible fixed assets dividends paid preference shares profit sale equity investments increasedecrease stocks increase trade debtors capital expenditure financial investment decreaseincrease trade creditors purchase tangible fixed assets increase provisions sale tangible fixed assets purchase intangible assets merger transaction costs paid sale intangible assets net cash inflow operating activities product divestments purchase shares employee share options awards proceeds shares employee share options cash flow statement purchase equity investments sale equity investments net cash inflow operating activities dividends joint ventures associated undertakings returns investment servicing finance acquisitions disposals taxation paid purchase businesses capital expenditure financial investment cash acquired subsidiary acquisitions disposals disposal businesses equity dividends paid investment joint ventures associated undertakings net cash inflowoutflow management liquid resources financing disposal interests associates management liquid resources financing decreaseincrease cash year financing issue share capital reconciliation net cash flow movement net debt redemption preference shares issued subsidiary share capital purchased cancellation net debt beginning year financing cash flows decreaseincrease cash year increase longterm loans cash inflowoutflow management liquid resources repayment longterm loans net increase longterm loans net repayment shortterm loans net repayment shortterm loans net repayment obligations finance leases net repayment obligations finance leases net noncash funds subsidiary undertakings acquired exchange adjustments analysis changes net debt cash flow exchange noncash movements movement net debt cash bank overdrafts net debt end year debt due within one year commercial paper eurobonds mediumterm notes debt due one year eurobonds mediumterm notes private financing management liquid resources liquid investments net debt information significant changes net debt see note net debt glaxosmithkline glaxosmithkline consolidated balance sheet company balance sheet st december st december notes notes shares subsidiary companies cost goodwill fixed assets intangible assets amounts owed group undertakings tangible assets taxation investments cash bank fixed assets current assets equity investments dividends payable stocks amounts owed group undertakings debtors creditors amounts due within one year liquid investments net current liabilities cash bank net assets current assets loans overdrafts capital reserves creditors called share capital creditors amounts due within one year share premium account net current assets reserves total assets less current liabilities profit loss account loans equity shareholders funds creditors creditors amounts due one year provisions liabilities charges approved board net assets sir christopher hogg capital reserves chairman called share capital rd march share premium account reserves profit loss account equity shareholders funds nonequity minority interests equity minority interests capital employed approved board sir christopher hogg chairman rd march reconciliation movements equity shareholders funds year ended st december notes equity shareholders funds beginning year total recognised gains losses year dividends share capital issued share capital purchased cancelled exchange movements goodwill written reserves equity shareholders funds end year glaxosmithkline notes financial statements glaxosmithkline notes financial statements presentation financial statements additional information accordance requirements accounting policies foreign currency transactions us generally accepted accounting principles us gaap included foreign currency transactions group companies booked description business consolidation notes financial statements note statement local currency exchange rate ruling date glaxosmithkline major global healthcare group consolidated financial statements include differences reconciliations net income shareholders transaction forward rate hedged forward engaged creation discovery development manufacture equity uk us gaap provided assets liabilities results cash flow exchange contract foreign currency assets liabilities marketing pharmaceutical products including vaccines company subsidiary undertakings including employee translated local currency rates exchange ruling overthecounter otc medicines healthrelated consumer presentation statement profit loss share ownership trusts esots balance sheet date forward rate exchange differences products glaxosmithklines principal pharmaceutical products columnar presentation adopted statement groups share net assets results joint ventures included trading profit include medicines following therapeutic areas profit loss order illustrate underlying business associated undertakings central nervous system respiratory antivirals antibacterials performance primary measure used management revenue vaccines oncology emesis metabolic cardiovascular financial statements undertakings consolidated made purpose certain items identified separately revenue recognised profit loss account goods urogenital st december excluded business performance comprise merger supplied external customers orders received integration items including product divestments costs relating undertakings group material interest certain limited cases customer collects goods revenue financial period previously announced manufacturing restructuring accounted subsidiaries group exercises dominant recognised title risk loss passes turnover represents financial statements cover financial year effect disposals subsidiaries management believes influence joint ventures group exercises joint control net invoice value deduction discounts given st january st december comparative figures exclusion items provides better reflection way associates group exercise significant point sale accruals estimated future rebates financial years st january st december business managed gives indication influence returns methodology assumptions used estimate st january st december performance group terms elements revenue rebates returns monitored regularly light interests acquired undertakings consolidated expenditure local management able influence historical information past experience turnover also includes composition group effective date acquisition interests sold consolidated copromotion income group records share list subsidiary associated undertakings trading profit reflects turnover less cost sales comprising date disposal revenue related cost sales value added tax opinion directors principally affected amount profit costs manufacture external royalties selling general transactions balances subsidiary undertakings sales taxes excluded revenue net assets group given principal group administrative expenditure comprising costs selling eliminated profit taken sales subsidiary companies note distribution medical support currently marketed products undertakings sales joint ventures associated undertakings expenditure costs administration costs research products sold customers outside group expenditure recognised respect goods services received composition financial statements development create future products sale supplied accordance contractual terms provision consolidated financial statements drawn accordance goodwill arising acquisition interests subsidiary made obligation exists future liability respect uk generally accepted accounting principles uk gaap accounting convention undertakings joint ventures associated undertakings past event amount obligation reliably uk accounting presentation financial statements prepared using historical representing excess purchase consideration estimated advertising promotion expenditure charged cost convention groups share separable net assets acquired capitalised financial statements comprise profit loss account incurred shipment costs inter separate item case subsidiary undertakings company transfers charged cost sales distribution costs consolidated statement profit loss accounting standards part cost investment case joint ventures sales customers included selling general consolidated statement total recognised gains losses financial statements comply applicable uk accounting associated undertakings goodwill denominated currency administrative expenditure restructuring costs recognised consolidated statement cash flow standards acquisition made financed case respect direct expenditures business reorganisation consolidated balance sheet acquisitions prior goodwill written plans sufficiently detailed well advanced reconciliation movements equity shareholders funds accounting principles policies reserves subsequent disposal assets acquisitions appropriate communication affected company balance sheet preparation financial statements conformity related goodwill removed consolidated reserves undertaken balance sheet date notes financial statements generally accepted accounting principles requires management charged consolidated profit loss account make estimates assumptions affect reported amounts permitted section companies act groups interests joint ventures accounted using research development assets liabilities disclosure contingent assets profit loss account company presented gross equity method groups interests associated research development expenditure charged profit liabilities date financial statements reported undertakings accounted using equity method loss account period incurred tangible consolidated statement total recognised gains losses amounts revenues expenses reporting period fixed assets used research development depreciated includes actual results could differ estimates deferred taxation relief unrealised intragroup profit accordance groups policy accounted extent considered recoverable realised profit attributable shareholders reflected financial statements prepared accordance consolidated statement profit loss companys accounting policies approved board assets liabilities overseas subsidiary associated environmental expenditure unrealised gain loss value groups described note undertakings joint ventures including related goodwill environmental expenditure related existing conditions resulting overseas net assets less related foreign currency borrowings translated sterling rates exchange ruling balance past current operations current attributable currency movements period sheet date results cash flows overseas subsidiary future benefit discernible charged profit loss tax items associated undertakings joint ventures translated account group determines liability sitebysite basis sterling using average rates exchange exchange adjustments records liability time probable reconciliation movements equity shareholders funds arising opening net assets profits year reasonably estimated liability includes groups comprises items contributing increase decrease retained overseas subsidiary associated undertakings portion costs also portion potentially period shareholders funds items include joint ventures translated sterling less exchange differences responsible parties costs probable total recognised gains losses period arising related foreign currency borrowings taken directly able satisfy respective shares cleanup obligation dividends paid proposed reserves reported statement total recognised recoveries reimbursements virtually certain proceeds shares issued period gains losses recorded assets cost shares purchased cancellation translating sterling assets liabilities results cash flows share buyback programme pensions postretirement benefits overseas subsidiary associated undertakings joint changes goodwill arising acquisitions prior cost providing pensions employee postretirement ventures reported currencies hyperinflationary economies st january set directly reserves benefits charged consolidated profit loss account adjustments made reflect current price levels loss systematic rational basis based actuarial assumptions net monetary assets charged consolidated profit loss period benefit derived employees services account difference charge contributions paid included asset liability consolidated balance sheet glaxosmithkline notes financial statements notes financial statements glaxosmithkline accounting policies continued prior acquired minor brands similar intangibles accounting policies continued gains losses foreign exchange contracts designated eliminated group balance sheet reserves year hedges forecast foreign exchange transactions deferred legal disputes investments joint ventures associates acquisition included measurement related foreign currency provision made anticipated settlement costs legal investments joint ventures associated undertakings transactions period occur gains losses balance expenses associated claims received legal carried consolidated balance sheet groups share tangible fixed assets sheet hedges accrued taken directly reserves except disputes group reasonable estimate net assets date acquisition post tangible fixed assets stated cost less provisions forward premiumdiscounts recognised interest made likely outcome dispute provision acquisition retained profits losses together goodwill depreciation impairment costs acquiring developing life contracts made unasserted claims obligation exists arising acquisition net amortisation computer software internal use internet sites external dispute possible make reasonable estimate costs interest differentials interest swap agreements recognised use capitalised tangible fixed asset software associated claims made group third parties stocks profit loss account adjustment interest expense site supports significant business system expenditure charged profit loss account incurred stocks included financial statements lower cost life agreement leads creation durable asset including manufacturing overheads appropriate net employee share plans depreciation calculated write cost tangible fixed realisable value cost generally determined first first debt instruments incentives form shares provided employees assets excluding freehold land equal annual instalments basis debt instruments stated amount net proceeds share option share award schemes respect award expected useful lives normal expected useful lives adjusted amortise issue cost debt evenly term schemes certain share option grants company provides major categories tangible fixed assets reviewed annually taxation debt finance esots purchase company shares open market group accounts taxation deferred accelerated meet companys obligation provide shares reason timing differences originated new accounting policies future requirements employees exercise option award excess freehold buildings years reversed balance sheet date deferred tax assets december urgent issues task force issued abstract purchase price shares exercise price options leasehold land shorter lease term recognised extent considered recoverable amended abstract relating accounting awards charged profit loss account buildings years future taxable profits deferred tax retained presentation esots requirements mandatory periods service respect options awards plant machinery years earnings overseas subsidiaries provided reporting require shares held esots granted respect share option grants share options fixtures equipment years binding commitment distribute past earnings future periods shown deduction arriving shareholders funds exercised accounted share issues exercise price erp systems software years deferred tax measured average tax rates expected charge profit loss account employee share options additional employer costs respect options awards computer software years apply periods timing differences restricted intrinsic loss difference charged profit loss account periods service erp systems software generally involves significant customisation expected reverse deferred tax liabilities assets market price exercise price date grant assets liabilities esots included group prior implementation expected useful economic discounted june council european union adopted balance sheet costs running esots charged profit life seven years rather maximum five years regulation requiring listed companies member states loss account shares held esots accounted computer software disposal tangible fixed asset cost current asset investments prepare consolidated financial statements accordance fixed asset investments held cost less provision recognise related accumulated depreciation removed current asset investments stated lower cost net international financial reporting standards ifrs shortfall proceeds receivable employees exercise financial statements net amount less proceeds realisable value first glaxosmithkline annual report prepared ifrs unless deemed permanent impairment value taken consolidated profit loss account case securities acquired significant premium year ending st december first financial discount maturity value intended held redemption results announcement prepared accordance ifrs goodwill leases cost adjusted amortise premium discount life first quarter goodwill stated cost less provision amortisation leasing agreements transfer group substantially maturity security floating rate bonds stated cost amortisation calculated write cost equal annual benefits risks ownership asset treated groups project convert financial reporting uk interest income taken profit loss account instalments expected useful life useful life finance leases asset purchased outright gaap ifrs progressing well training programme receivable basis normally expected exceed years assets included tangible fixed assets capital element rolled finance staff worldwide preparations leasing commitments shown obligations finance equity investments included current assets regarded collection historical data provide comparative intangible fixed assets leases assets held finance leases depreciated available sale information ifrs well advanced intangible assets stated cost less provision amortisation shorter lease terms useful lives assets interest element lease rental charged profit derivative financial instruments exchange rates acquired licences patents knowhow marketing rights leases operating leases annual rentals group hold issue derivative financial instruments amortised estimated useful lives equal instalments group uses average exchange rates prevailing charged profit straightline basis lease term trading purposes longer years items capitalised restricted period translate results cash flows overseas related specific compounds products derivative financial instruments used manage exposure subsidiaries joint ventures associated undertakings impairment fixed assets developed commercial applications estimated useful lives market risks treasury operations principal derivative sterling period end rates translate net assets carrying values fixed assets reviewed impairment determining amortisation charge reviewed annually instruments currency swaps forward exchange contracts undertakings currencies influence indication assets might impaired take account estimated time takes bring interest rate swaps derivative contracts treated translations relevant exchange rates provision impairment charged profit year compounds products market marketable products inception economic hedge underlying financial concerned first year impairment reviews conducted development costs incurred group instrument matching accounting treatment cash flows acquired goodwill intangible assets certain intangibles associated acquired licence patent knowhow derivative contracts high correlation specific average rates considered indefinite life therefore marketing rights written profit loss account financial instrument hedged inception us amortised intangibles subject annual impairment tests incurred throughout hedge period derivative instruments longer euro impairment determined reference higher net designated hedges restated market value future yen brands valued independently part fair value realisable value value use measured reference changes value taken directly profit loss account period end rates businesses acquired third parties brand discounted future cash flows value shares held us value substantial longterm brands esots reviewed quarterly determine permanent currency swaps forward exchange contracts used fix euro sold separately rest businesses acquired impairment value related asset liability contract currency yen brands amortised estimated useful lives longer contract rate accrued profit loss account years except end useful economic life life contract brand foreseen glaxosmithkline notes financial statements notes financial statements glaxosmithkline merger glaxo wellcome smithkline beecham segment information continued combination glaxo wellcome plc smithkline beecham plc treated merger th december uk gaap merger accounting shares issued glaxosmithkline plc acquire glaxo wellcome smithkline beecham accounted turnover location subsidiary undertaking par share premium arose shares acquired glaxosmithkline glaxo wellcome smithkline beecham similarly usa accounted nominal value shares issued consolidated financial statements glaxosmithkline results net europe assets glaxo wellcome smithkline beecham combined book amounts subject alignment adjustments international turnover including intersegment turnover segment information usa analysis turnover profit taxation total assets net assets tangible fixed assets business geographical sector set europe business sectors consist pharmaceuticals prescription pharmaceuticals vaccines consumer healthcare oral care international otc medicines nutritional healthcare geographical sectors reflect groups significant regional markets intersegment turnover consistent groups regional market management reporting structure business sector data includes allocation corporate costs sector sales business sectors usa europe groups activities organised global basis geographical sector figures therefore influenced location international groups operating resources particular manufacturing research variations time intragroup trading funding external turnover arrangements group copromotes product third party records sale group records share revenue copromotion statutory profit tax location subsidiary undertaking income within turnover nature copromotion activities group records costs sales pharmaceutical turnover usa includes copromotion income million nil nil europe international operating profit turnover business sector share profits joint ventures associated undertakings pharmaceuticals profit disposal interest associate consumer healthcare profit disposal businesses external turnover product divestments net interest payable statutory profit tax business sector profit taxation pharmaceuticals profit taxation consumer healthcare taxation operating profit minority interests share profits joint ventures associated undertakings preference share dividends profit disposal interest associate statutory earnings profit disposal businesses product divestments total assets location subsidiary undertaking net interest payable usa profit taxation europe profit taxation international taxation total operating assets minority interests cash bank liquid investments preference share dividends total assets statutory earnings net assets location subsidiary undertaking total assets business sector usa pharmaceuticals europe consumer healthcare international total assets net operating assets net debt net assets business sector net assets pharmaceuticals consumer healthcare net assets glaxosmithkline notes financial statements notes financial statements glaxosmithkline segment information continued merger items restructuring costs divested businesses continued plant disposal land equipment computer assets merger restructuring block drug subsidiaries total tangible fixed assets location subsidiary undertaking buildin g ms vehic le ms softw mre construct io mn mal mal manufacturing restructuring usa merger integration costs europe block drug integration costs international total effect operating profit profit disposal businesses effect profit tax turnover location customer usa effect taxation operating items europe effect taxation nonoperating items international effect taxation external turnover effect earnings uk segment disposal merger restructuring block drug subsidiaries total information given separately respect uk although included groups europe market region considered groups home segment purposes segmental reporting manufacturing restructuring merger integration costs block drug integration costs turnover location customer effect operating profit product divestments turnover including intersegment turnover profit disposal businesses intersegment turnover effect profit tax turnover location subsidiary effect taxation operating items operating profit effect taxation nonoperating items total assets effect taxation net operating assets effect earnings disposal merger items restructuring costs divested businesses merger restructuring block drug subsidiaries total manufacturing restructuring costs incurred glaxosmithkline implementation manufacturing restructuring previously announced plans restructuring manufacturing activities merger integration costs merger integration costs relate integration glaxo wellcome smithkline beecham unified glaxosmithkline business block drug integration costs costs include consultancy fees respect integration planning severance costs asset writeoffs costs related early vesting effect operating profit lapse performance conditions share options share incentive awards costs programme encourage staff convert loss disposal businesses glaxo wellcome smithkline beecham share options glaxosmithkline share options integration costs incurred effect profit tax relating integration block drug businesses costs include professional fees severance costs asset writeoffs product divestment income arising related finalisation disposals famvir kytril products required effect taxation operating items order obtain regulatory approval merger effect taxation nonoperating items effect taxation disposal businesses related finalisation disposals clinical laboratories healthcare services disposal businesses primarily arose sale affymax included million write goodwill effect earnings previously eliminated group reserves operating incomeexpense royalties income operating expense income equity investments disposals royalties income principally core recurring income form royalties outlicensing intellectual property operating expense includes litigation costs provisions relating legal claims withdrawn products product withdrawals antitrust matters income equity investments disposals includes equity investment carrying value adjustments arising stock market changes product disposals equity investment sales glaxosmithkline notes financial statements notes financial statements glaxosmithkline operating profit net interest payable following items charged operating profit interest payable employee costs note bank loans overdrafts advertising loans distribution costs respect finance leases depreciation tangible fixed assets unwinding discount provisions owned assets leased assets share interest payable associate amortisation goodwill amortisation intangible fixed assets exchange losses foreign currency depositsloans investment income operating lease rentals interest income plant realised gains land buildings unwinding discount assets audit fees fees auditors work auditors uk firm auditors overseas firms analysis fees auditors work taxation assurance auditrelated services tax services taxation charge based profits period merger glaxo wellcome smithkline beecham uk corporation tax uk statutory rate services less double taxation relief included within audit fees fee relating company audit overseas taxation glaxosmithkline plc included assurance services amounts related groups preparation adoption deferred taxation international financial reporting standards preparation section sarbanesoxley act tax services relates fees paid corporate tax compliance tax planning advice services include human resources advisory compliance treasury related services included within fees auditors work million paid auditors management share taxation charge associates consulting practice sold group started apply discounting certain longterm assets liabilities using riskfree rates return reconciliation current taxation rate group profits joint ventures associated undertakings uk statutory rate taxation overseas taxes associated undertakings average group tax rate share profits quest diagnostics inc effect special tax status manufacturing locations share losses associated undertakings share option deductions usa amortisation goodwill merger restructuring costs rd credits share losses joint ventures permanent differences capital allowances excess depreciation intragroup profit reversing timing differences tax losses share turnover joint ventures timing differences sales joint ventures associated undertakings prior year items current tax rate ordinary activities capital allowances excess depreciation intragroup profit reversing timing differences tax losses timing differences share taxation charge associates prior year items tax rate ordinary activities group operates countries tax rate differs uk tax rate average group tax rate determined aggregating local standard tax rates weighting proportion accounting profits profits arising manufacturing operations singapore puerto rico ireland taxed reduced rates effect reduction taxation charge increased earnings per share p p p glaxosmithkline notes financial statements notes financial statements glaxosmithkline taxation continued earnings per share integrated nature groups worldwide operations involving significant investment research strategic manufacture p p p limited number locations consequential crossborder supply routes numerous endmarkets gives rise complexity delay negotiations revenue authorities profits individual group companies liable tax disagreements basic earnings per share revenue authorities intragroup transactions particular price goods transferred group adjustment merger items restructuring costs disposal subsidiaries companies different tax jurisdictions produce conflicting claims revenue authorities profits fall taxed merger integration transaction costs individual territories resolution issues continuing fact life glaxosmithkline group open issues revenue restructuring costs authorities usa uk japan canada far largest relates glaxo heritage products usa block drug integration costs disposal businesses glaxosmithkline attempted settle us dispute first direct discussion us internal revenue service irs adjusted earnings per share subsequently discussions us uk authorities terms double tax convention two countries glaxosmithkline understands views two tax authorities different unable reach diluted earnings per share agreement discussions terminated july basic adjusted earnings per share calculated dividing profit attributable shareholders weighted average group received claim additional taxes irs asserts legacy company glaxo wellcome owes years number shares issue period numbers used calculating basic diluted earnings per share reconciled statutory notice deficiency billion billion tax principally relates allocation profits glaxo heritage products usa countries extent irs successful claim interest would payable adjusted earnings per share calculated using business performance earnings business performance primary performance glaxosmithkline estimates interest full claim date would approximately billion billion net federal tax relief measure used management presented excluding merger items integration restructuring costs disposal businesses similar tax issues remain open date glaxosmithkline expects receive claims irs years management believes exclusion items provides better reflection way business managed gives indication performance group terms elements revenue expenditure local management able since glaxosmithkline exhausted administrative remedies open group plans contest claim additional taxes influence information provided addition statutory results prepared uk gaap given assist shareholders filing petition us tax court trial expected sometime gain clearer understanding underlying performance business increase comparability periods presented glaxosmithkline continues believe profits reported us subsidiaries period date paid taxes usa sufficient reflect activities us operations net profit period attributable shareholders earnings basic diluted glaxosmithkline uses best advice determining transfer pricing methodology seeking manage transfer pricing issues adjustments merger items restructuring costs disposal subsidiaries satisfactory conclusion basis external professional advice continues believe made adequate provision liabilities likely arise open assessments however continues wide difference views group irs adjusted earnings ultimate liability matters may vary amounts provided dependent upon outcome litigation proceedings negotiations relevant tax authorities weighted average number shares issue millions millions millions except shown financial statements provision made taxation would arise distribution profits basic adjusted retained overseas subsidiary associated undertakings grounds remittance profit retained st december dilution share options required way incremental tax arise diluted st december group income tax losses approximately million million capital losses estimated excess billion excess billion recognised deferred tax assets insufficient shares held employee share ownership trusts esots excluded trustees waived rights dividends shares evidence losses used held esots current deferred deferred tax creditor tax debtor tax provision dividends tax balances st january first interim exchange adjustments second interim charge profit loss account third interim cash paid fourth interim movements st december dividends per share p p p deferred taxation assetliability first interim accelerated capital allowances second interim stock valuation adjustment third interim intragroup profit fourth interim product business disposals pensions postretirement benefits tax losses legal disputes merger integration manufacturing restructuring net timing differences deferred taxation provided stock valuation adjustments intragroup profit timing differences shown current deferred taxation movements arise origination reversal timing differences net timing differences include accrued expenses provisions glaxosmithkline notes financial statements notes financial statements glaxosmithkline plant land equipment computer assets goodwill total tangible fixed assets buildings vehicles software construction total cost st january cost st january exchange adjustments exchange adjustments additions note additions disposals cost st december reclassifications amortisation st january cost st december exchange adjustments provision year depreciation st january exchange adjustments amortisation st december provision year net book value st january disposals reclassifications net book value st december depreciation st december impairment st january licences exchange intangible assets patents etc brands total impairment loss cost st january disposals exchange adjustments impairment st december additions assets written total depreciation impairment st december cost st december net book value st january net book value st december amortisation st january exchange adjustments net book value st december groups land buildings comprises freehold properties million provision year st january million properties leases years million st january million assets written properties leases less years million st january million included plant equipment vehicles amortisation st december st december leased assets cost million st january million accumulated depreciation million st january million net book value million st january million impairment st january impairment loss principally arises decisions rationalise facilities calculated based either net realisable value value exchange adjustments use typically using recorded sga discount rate eight per cent impairment loss assets written joint associated equity fixed asset investments ventures undertakings investments shares total impairment st december total amortisation impairment st december st january exchange adjustments net book value st january additions charge year net book value st december impairment licences patents acquired year relate acquisition various compound rights research based agreements transfers see note disposals retained profit year brands largely comprise portfolio products acquired acquisition sterling winthrop inc panadol solpadeine goodwill amortisation hedex products acquired acquisition block drug company sensodyne polident poligrip st december considered indefinite life given strength durability brand level marketing support accordingly amortised valuation sterling brand reviewed annually using year cash flow forecast investments joint ventures comprise million share gross assets million million share gross liabilities million basis original independent assessment acquired posttax discount rate eight per cent valuation block drug brand also reviewed annually using five year cash flow forecast posttax discount rate principal associated undertaking quest diagnostics inc us clinical laboratory business listed new york stock exchange eight per cent investment book value st december million million market value million million st december group owned per cent quest per cent book value includes goodwill amortised years amortisation charge million goodwill st december amounts million million goodwill million relates continuing group interest clinical laboratories assets attributed quest remains eliminated group reserves equity investments comprise listed investments million million unlisted investments million million market value listed investments st december million million investments shares consist shares held employee share ownership trusts see note market value shares st december million million valuation shortfall considered represent permanent diminution value context length future period related share options may exercised accordingly provision made glaxosmithkline notes financial statements notes financial statements glaxosmithkline equity investments provisions pensions legal postretirement manufacturing merger deferred total liabilities charges benefits restructuring integration disputes taxation provisions total st january st january exchange adjustments exchange adjustments additions charge year impairments unwinding discount disposals applied st december reclassifications movements st december equity investments include listed investments million million market value listed investments million million group made special cash contributions totalling million uk us pension schemes contribution relating us pension scheme included within amounts applied provision contributions relating uk pension scheme increased pension prepayment amount shown debtors note stocks group recognised costs respect plans manufacturing restructuring initiated raw materials consumables following merger glaxo wellcome smithkline beecham acquisition block drug plans largely completed costs work progress recognised provision principally respect identified severances sites announced manufacturing activities finished goods cease expected incurred mainly costs asset writedowns recognised impairment fixed assets group recognised costs respect plans integration glaxo wellcome smithkline beecham businesses implementation integration following merger substantially complete costs recognised provision respect identified severances expected incurred respect programme encourage staff convert glaxo wellcome smithkline beecham share options glaxosmithkline share options employees exercise options debtors latter provision discounted million using riskfree rates return provisions legal disputes matters include amounts relating us antitrust product liability contract terminations amounts due within one year selfinsurance environmental cleanup property rental companys directors taken legal advice established provisions trade debtors taking account insurance agreements regard relevant facts circumstances matter debtors accordance accounting requirements provisions discounted million using riskfree rates return prepaid pension contributions reclassifications include amounts receivable insurance contracts shown within debtors note prepayments accrued income provisions made unasserted claims ultimate liability matters may vary amounts provided amounts due one year dependent upon outcome litigation proceedings investigations possible settlement negotiations debtors prepayments accrued income glaxosmithkline involved number legal disputes including notification possible claims early deferred taxation note stage matter reliable estimate outcome made accordingly provision recorded matters unasserted claims nature groups business number matters may subject negotiation litigation several debtors include trading balances million nil due joint ventures associated undertakings debtors due years largest individual amounts provided expected settled within three years one year include insurance recovery receivables discounted using riskfree rate return discussion legal issues refer note legal proceedings creditors contingent liabilities st december contingent liabilities comprising guarantees discounted bills items arising normal course amounts due within one year business amounted million million discussion tax issues refer note taxation legal issues trade creditors refer note legal proceedings taxation note social security creditors accruals deferred income dividends payable amounts due one year creditors accruals deferred income accruals include obligations wages salaries million million glaxosmithkline notes financial statements notes financial statements glaxosmithkline net debt net debt continued secured loans liquid investments loans amounting million million secured charges fixed current assets cash bank finance lease obligations loans overdrafts due within one year rental payments due within one year bank loans overdrafts rental payments due one two years commercial paper rental payments due two three years eurobonds mediumterm notes rental payments due three four years obligations finance leases rental payments due four five years loans rental payments due five years total finance lease obligations loans due one year bank loans financial instruments eurobonds mediumterm notes private financing information given note loan stock obligations finance leases commitments loans capital commitments contracted provided financial statements net debt intangible fixed assets tangible fixed assets balance sheet date groups liquid investments aggregate market value million million liquid investments include redeemable preference shares fully collateralised highly rated bonds billion nil group entered number research collaborations develop new compounds pharmaceutical companies loans overdrafts due within one year terms arrangements include upfront fees equity investments loans commitments fund specified levels research commercial paper comprises us billion programme million issue st december future addition group often agree make payments future milestones achieved st december million backed committed facilities days duration million million agreements relate compounds early stages development milestone payments continue number years million renewable annually liquid investments million million million compounds move successfully development process generally closer product marketing approval greater possibility success weighted average interest rate commercial paper borrowings st december per cent per cent group also commitments million million relating revenue payments made licences loans due one year alliances principally exelixis inc two bonds issued european medium term note programme billion per cent coupon bond number commitments made licensing agreements principally neurosearch ranbaxy million per cent coupon bond laboratories ltd pozen inc loans due one year repayable various periods follows commitments operating leases pay rentals next year operating leases land buildings expire one two years one year less two three years one five years three four years five years four five years five years operating leases plant equipment vehicles expire one year less loans repayable five years carry interest effective rates per cent per cent repayment dates range one five years five years commitments operating leases pay rentals future years thereafter glaxosmithkline notes financial statements notes financial statements glaxosmithkline profit share reserves reserves loss account total share capital share premium account ordinary shares p p ccm oi uu nm number st december goodwill written back share capital authorised exchange movements st december shares purchased cancellation st december profit attributable shareholders share capital issued fully paid dividends st january revaluation goodwill due exchange share capital issued share option schemes st december share capital purchased cancelled exchange movements st december uk tax exchange movements share capital issued share option schemes shares purchased cancellation share capital purchased cancelled profit attributable shareholders dividends st december unrealised gains equity investments st december number exchange movements number shares issuable outstanding options note tax exchange movements unrealised gains st december shares purchased cancellation st december profit attributable shareholders dividends number unissued shares option unrealised gains equity investments st december revaluation goodwill due exchange st december st december october glaxosmithkline commenced new billion share buyback programme follows completion billion buyback programme announced total million spent new share buyback programme goodwill arising acquisitions st january written reserves amounts million million spent exact amount timing future purchases whether repurchased shares held including goodwill million previously held goodwill reserve offset reserves goodwill treasury shares rather cancelled determined company dependent market conditions factors written back relates primarily disposals affymax part groups holding quest diagnostics inc goodwill period st january th february million shares purchased cancelled cost denominated local currencies subject revaluation amounted million st december million goodwill acquisitions st january capitalised accordance accounting policy set note details substantial shareholdings refer substantial shareholdings exchange movements taken reserves include losses million losses million losses million foreign currency loans less deposits gains million gains million losses million nonequity minority interests retranslation net assets million nil losses million goodwill eliminated reserves smithkline beecham holdings corporation sbh corp subsidiary incorporated delaware usa issue million flexible tax exchange movements unrealised gains year million million nil relates taxable auction market preferred stock flex amps comprising shares issued six series dividend shares element foreign currency loans less deposits unrealised gains taken reserves fixed issuance sevenyear period ended july half shares five year period ended half dividend shares varies predominately prevailing interest rates exchange adjustments debited reserves cumulatively amount million million million set every seven weeks auction shares also traded reserves include merger reserve created merger glaxo wellcome smithkline beecham amounting million sbh corp also issue million auction rate preference stock arps comprising shares issued st december million million reserves also include capital redemption reserve created five series dividend also varies conditions similar flex amps described result share buyback programme amounting million st december million million together arps flex amps constitute preference shares represent nonequity minority interests notice total reserves amounted million st december million million million redeem eleven series given february redemption expected completed march april million million relates company million million million relates joint ventures associated undertakings smithkline beecham plc certain circumstances guaranteed payment dividends declared preference shares smithkline beecham plc also agreed sbh corp certain circumstances provide support sbh corp relation principal profit glaxosmithkline plc year million million million dividends however guarantee support limited circumstances could holder preference shares favourable million million million gave retained loss million profit million position holder preference share smithkline beecham plc preference shares represent longterm profit million cost shares purchased cancellation million million nonequity minority interest group balance sheet accordance frs capital instruments uitf obligations capital million unrealised profit capital reduction subsidiary nil million nil profit instruments loss account reserve st december stood million million million million unrealised million nil glaxosmithkline notes financial statements notes financial statements glaxosmithkline legal proceedings group continues pursue patent infringement claims legal proceedings continued case still discovery phase june group litigation eastern district pennsylvania apotex commenced action us district court district group involved numerous legal administrative actions also filed watson pharmaceuticals geneva alphapharm andrx teva pharmaceuticals zenith new jersey faulding pharmaceutical company alleging proceedings principally product liability intellectual property us district court southern district ohio eon labs bulk suppliers basf sumika fine chemicals apotex infringement two method use patents ondansetron antitrust governmental investigations related private manufacturing us district court southern district alphapharm basf sumika filed counterclaims faulding challenge compound patent case litigation significant matters described new york impax laboratories us district court actions alleging group violated antitrust unfair date report stayed pending decisions northern district california excel pharmaceuticals competition laws teva reddy kali cases us district court district new jersey us intellectual property february cafc heard apotexs appeal decision district court eastern district virginia watson case lamictal usa us district court district columbia denying settled terms involving supply agreement referred august group commenced action us district apotexs request fda required delist certain court district new jersey teva pharmaceuticals paxil groups patents paxil orange book october usa inc alleging infringement groups compound patent usa number distributors generic drugs filed judges granted summary judgement noninfringement cafc affirmed district court decision dismissed lamotrigine active ingredient lamictal oral tablets applications fda market generic versions impax excel cases group appealed case patent expires july defendant filed anda paxilseroxat paroxetine hydrochloride prior expiration decisions cafc january cafc ruled favour fda certification invalidity groups patent groups patent paroxetine hydrochloride march glaxosmithkline filed action pentech impax affirmed district court ruling impaxs fda approval anda stayed earlier january hemihydrate apotex launched generic version paxil pharmaceuticals us district court northern district generic version infringe groups patents fda resolution patent infringement litigation trial september distributors looking bring illinois infringement groups patents paroxetine earlier granted tentative approval impax generic version date set case market anhydrate versions paroxetine hydrochloride hydrochloride pentech filed anda capsule version cafc yet ruled groups appeal summary one case paroxetine mesylate response group filed paxil asserting compound presentation infringe judgement noninfringement excel case eons motion levitra actions distributors infringement various groups patents patents invalid april summary judgement noninfringement denied district october pfizer inc filed action bayer ag groups patents cases complex group believes group reached settlement pentech par court trial eon case concluded december glaxosmithkline us district court district generic anhydrate versions infringe pharmaceuticals pentech granted rights date report decision yet announced delaware alleging manufacture sale levitra contain andor convert hemihydrate form andor pentechs anda paroxetine hydrochloride capsules vardenafil would infringe patent newly issued pfizer january cafc granted eons motion stay infringe group patents settlement allowed par distribute puerto rico substitutable asking bayer glaxosmithkline permanently enjoined preliminary injunction launch eons mg generic generic paroxetine hydrochloride immediate release tablets september us patent trademark office initiated july glaxosmithkline filed action apotex version entered trial court conclusion supplied licensed group royalty payable reexamination pfizer patent based questions us district court northern district illinois trial terms supply agreement group par became entitled distribute product patentability light prior art pfizer action including infringement groups patent paroxetine hydrochloride glaxosmithkline watson pharmaceuticals began shipping us market apotexs generic version paxil became available additional suit filed court following launch hemihydrate apotex filed abbreviated new drug second mg generic version day eon began september settlement par pentech levitra usa predicated validity patent application anda fda seeking approval introduce shipment generic version january acknowledge glaxosmithkline patent covering stayed pending outcome reexamination generic form paxil following trial february judge hemihydrate form paroxetine hydrochloride valid zofran ruled glaxosmithklines patent valid infringed imitrex enforceable would infringed pentechs proposed capsule august group commenced action us district apotexs product glaxosmithkline appealed ruling non december group commenced action us product bureau competition us federal trade court district new jersey reddycheminor infringement us court appeals federal circuit district court southern district new york commission reviewed settlement review voluntary dr reddys laboratories dr reddy certified invalidity three cafc hears appeals us district courts dr reddys laboratories alleging infringement one two conducted request group par pentech patents ondansetron active ingredient zofran tablets intellectual property matters cafc heard appeal primary compound patents sumatriptan active ingredient pentechs former supplier asahi glass co filed claims alleging including compound patent expires july two january date report decision yet imitrex patent expires defendant filed settlement violated antitrust laws us district court method use patents later expires december announced anda fda certification invalidity northern district illinois dismissed claims instances taking account expected extension compound patent certify invalidity noninfringement june glaxosmithkline filed action geneva october asahi appealed decision cafc paediatric exclusivity reddy case scheduled trial second compound patent expires december pharmaceuticals subsidiary novartis pharmaceuticals similar claims brought apotex sumika pending may july group filed action dr case early stages us district court eastern district pennsylvania us district court eastern district pennsylvania reddys laboratories district court infringement infringement groups patents paroxetine hydrochloride groups patents related orally disintegrating tablet valtrex october glaxosmithkline filed action synthon following notice genevas anda filing case presentation zofran october group filed action may group commenced action us district pharmaceuticals us district court middle district consolidated similar infringement actions westward pharmaceuticals inc district court court district new jersey ranbaxy laboratories north carolina infringement groups patents generic companies subsequently filed andas additional infringement groups patents related injectable alleging infringement groups compound patent paroxetine hydrochloride paroxetine mesylate synthon infringement actions brought based patents issued presentation zofran dr reddy disintegrating tablet valaciclovir active ingredient valtrex patent expires filed b application paper nda fda using subsequent original filing apotex northern case westward case consolidated defendant filed anda fda paroxetine mesylate different salt form paroxetine district illinois group also filed action apotex earlier dr reddy case scheduled trial may certification invalidity groups compound patent used marketed form paxil december relating new patents eastern district noninfringement two patents expiring glaxosmithkline synthon reached settlement pursuant march group filed similar action teva pennsylvania december judge granted part listed orange book fda approval anda stayed group granted synthon royaltybearing license pharmaceuticals usa inc us district court district denied part summary judgement motions filed apotex earlier october resolution patent market paroxetine mesylate product usa delaware alleging infringement two method use patents result issues validity infringement three infringement litigation discovery underway case ondansetron teva certified invalidity noninfringement four new patents move toward trial group petitioned wellbutrin two method use patents teva challenge avandia district court permit interim appeal cafc june five distributors generic pharmaceutical products filed compound patent trial teva case concluded january august group filed action us district court group requested us food drug administration andas sustained release bupropion hydrochloride tablets date report decision district new jersey teva pharmaceuticals usa inc fda remove three patents related paxil register wellbutrin sr zyban accompanied case announced september november january infringement groups patent relating maleate salt pharmaceutical patents maintained fda orange book certification invalidity andor infringement groups group filed actions teva court form rosiglitazone active ingredient avandia delisting affect validity patents patents group brought suit patent infringement infringement groups patents related injectable expires september group filed comparable related patent litigation following fda approval anda filing parties group filed suit orally disintegrating tablet presentations zofran action court dr reddys laboratories alleging apotex subsequently launched generic version paxil andrx pharmaceuticals first file anda us district infringement patent maleate salt form september earlier ondansetron case involving orally disintegrating zofran court southern district florida february tablets commenced group january kali district court judge granted andrxs summary judgement motion laboratories us district court district new jersey ruled product infringe groups patents september cafc reversed decision remanded case district court trial glaxosmithkline notes financial statements notes financial statements glaxosmithkline legal proceedings continued uk europe legal proceedings continued baycol august bayer ag withdrew baycol cerivastatin sodium dr reddys laboratories teva filed andas fda seroxat patent set expire including supplementary worldwide light reports adverse events including deaths certifications invalidity groups maleate salt patent following expiration data exclusivity period europe protection certificate protection relates combination involving rhabdomyolosis glaxosmithkline participated fda approval andas stayed earlier marketing authorisation issued synthon bvgenthon active ingredients salmeterol fluticasone propionate marketing baycol usa pursuant copromotion november resolution respective patent infringement october regulatory authorities denmark paroxetine separate patents exist challenged providing agreement bayer license holder actions teva subsequently filed additional certification mesylate different salt form paroxetine used patent protection uk late manufacturer product challenging validity groups basic compound patent marketed form seroxatpaxil marketing authorisations subsequently generics uk ivax arrow generics filed rosiglitazone january group commenced since granted number european countries following withdrawal bayer glaxosmithkline revocation actions respect patent trial action teva court infringement majority based original danish approval named defendants thousands lawsuits filed state revocation actions completed january patent basic compound patent currently expires mutual recognition process generic products containing federal courts usa behalf individuals judges decision expected shortly several uk seretide although expiry expected extended us paroxetine mesylate launched austria denmark putative classes former baycol users number suits patents example relating diskus device patent trademark office granted patent term restoration france germany ireland italy netherlands sweden allege plaintiffs suffered personal injuries including cfcfree mdi device expire respectively although product austria denmark withdrawn rhabdomyolosis use baycol others claim persons augmentin challenged following award patent interim injunctions group took baycol although injured may risk future august group commenced proceedings initiated litigation challenging approval danish injury may suffered economic damages purchasing geneva pharmaceuticals biochemie gmbh biochemie spa product liability medicines agency grounds authorisation using baycol plaintiffs seek remedies including compensatory parent novartis ag us international trade paxil granted abridged procedure paroxetine punitive statutory damages creation funds medical commission colorado state court alleging group received purported class action individual mesylate essentially similar seroxat questions monitoring glaxosmithkline bayer corporation principal manufacture sale usa genevas generic augmentin lawsuits filed state federal courts usa alleging case referred european court justice us subsidiary bayer ag signed allocation agreement product using production strain stolen earlier paroxetine active ingredient paxil addictive causes february bayer corporation agreed pay per cent glaxosmithkline constitutes misappropriation groups trade dependency withdrawal reactions plaintiffs seek remedies settlements compensatory damages judgements secrets unfair competition proceedings sought marketing authorisations also issued eleven european including compensatory punitive statutory damages party retaining responsibility attorneys fees prevent importation sale usa generic augmentin countries products containing paroxetine hydrochloride cost fund medical monitoring federal judge punitive damages federal cases consolidated containing clavulanate made using stolen glaxosmithkline anhydrate another variant groups product generic us district court central district california denied multidistrict litigation proceeding us district court production strain colorado action sought damages well products containing anhydrate market class action certifications nationwide class california district minnesota numerous cases scheduled trial additional action brought lek pharmaceuticals austria denmark finland france germany italy netherlands statewide class cases filed federal court district state federal courts date one class action another novartis affiliate october north carolina state portugal spain sweden uk glaxosmithkline believes subsequently petition plaintiffs counsel federal court glaxosmithkline named defendant court july group reached settlement agreement marketing either paroxetine hydrochloride anhydrate product cases transferred district court consolidation certified oklahoma september plaintiffs class novartis affiliate companies named groups paroxetine mesylate product third parties european multidistrict litigation mdl remaining lawsuits action certification motion consolidated federal multidistrict complaints itc complaint related state court countries infringes patents litigating position actions early stages although certain state court trials litigation denied actions terms agreement group receive many european countries outside usa june scheduled start may determination singledigit percentage royalties us sales generic versions european patent office opposition division rejected whether lawsuits pending mdl state fenphen augmentin sold novartis affiliate companies july opposition filed synthon groups european patent courts permitted proceed class actions fda became aware reports cardiac valvular june similar state court actions covering crystal form paroxetine mesylate used problems individuals fenfluramine dexfenfluramine last decade litigation initiated teva pharmaceuticals usa inc ranbaxy synthons product decision appeal alone combination phentermine prescribed part manufacturers prozac selective serotonin reuptake pharmaceuticals inc august philadelphia county regimen weight reduction requested voluntary uk following revocation action initiated synthon inhibitor ssri products paxil homicidal suicidal court common pleas affected novartis withdrawal fenfluramine dexfenfluramine market court appeal upheld validity corresponding uk behaviour exhibited users products group settlement november cafc affirmed decision reports cardiac valvular problems subsequent patent decision overturned first instance decision received number claims lawsuits respect us district court eastern district virginia holding withdrawal products market spawned numerous held patent invalid synthons petition leave paxil none purport class actions groups patents covering augmentin invalid product liability lawsuits filed manufacturers appeal house lords accepted february phenylpropanolamine distributors fenfluramine dexfenfluramine phentermine ceftin dutch court revoked corresponding dutch patent following report yale haemorrhagic stroke project one number manufacturers phentermine group group filed action infringement patents decision appealed found suggestion association first use defendant thousands lawsuits various state federal cefuroxime axetil active ingredient groups ceftin anti response challenge basf groups uk patent phenylpropanolamine ppa decongestant haemorrhagic district courts usa lawsuits seek relief including infective product ranbaxy pharmaceuticals us paroxetine hydrochloride anhydrate uk high court july stroke group manufacturers voluntarily combination compensatory punitive damages district court new jersey preliminary injunction granted judge decided patent partly valid partly withdrew consumer healthcare products ppa medical monitoring refunds purchases drugs favour group cafc subsequently vacated invalid claims held valid asserted apotex neolab active ingredient since ppa product withdrawal group judicial panel multidistrict litigation issued order injunction remanded case district court full waymade healthcare interim injunction preventing sale named defendant numerous personal injury consolidating transferring federal actions district trial merits thereafter ranbaxy launched generic version version product granted november class action lawsuits filed state federal courts alleging court eastern district pennsylvania court approved march trial concluded august june uk court appeal upheld first instance personal injury increased risk injury use products global settlement proposed defendant wyeth sold date report decision announced since decision held process claims patent valid containing ppa unfair deceptive business practices fenfluramine dexfenfluramine settlement subsequently patent group claims infringement expired may infringement action apotex continued plaintiffs seek remedies including compensatory punitive confirmed third circuit court appeals include group seeks monetary damages based patent uk high court ruled december favour damages refunds federal cases consolidated phentermine defendants including group ranbaxys sales group filed similar action apotex held patent infringed also invalid multidistrict litigation proceeding us district court individual plaintiffs may elect opt class settlement apotex second distributor generic pharmaceutical products glaxosmithkline filed appeal decision district washington judge responsible pursue claims individually tens thousands us district court northern district illinois hearing scheduled ndrd march proceedings denied class certification struck class plaintiffs elected wyeth continues settle preliminary injunction granted favour group june interim apotex launched generic version seroxat uk allegations federal personal injury consumer refund individual state court cases trial group continues apotex subsequently obtained fda approval january class actions limited number cases group dismissed lawsuits settled wyeth generic product trial judge ruled apotex willfully manufacturers defendants reaching trial state infringed groups patent awarded attorney fees seretide courts class certification denied california state court glaxosmithkline january cipla neolab filed action uk high pennsylvania state court putative class action court seeking revocation one groups uk patents dismissed leaving putative class actions pending relating asthma treatment seretideadvair group litigation glaxosmithkline notes financial statements notes financial statements glaxosmithkline legal proceedings continued civil suits filed state court state attorneys general legal proceedings continued commercial matters class action plaintiffs initially removed federal court otsuka pharmaceutical co ltd initiated arbitration proceedings thimerosal august cafc issued decision affirming district conditionally transferred federal court december concerning groups unilateral withdrawal glaxosmithkline along number pharmaceutical courts judgement invalidity declining rule massachusetts three attorney general cases new york grepafloxacin raxarvaxar october safety reasons companies named defendant numerous individual judgement inequitable conduct nevada connecticut one private payer class action otsuka alleges product withdrawal simultaneous personal injury lawsuits purported class actions state cases since remanded respective state courts following district court decision antitrust claims alleging public announcement constituted material breaches license federal district courts usa courts canada alleging remand motions pending actions competitive injury overcharges filed teva eon supply agreements thimerosal preservative used vaccines causes early stages pharmaceuticals generic manufacturers nabumetone neurodevelopmental disorders injuries plaintiffs seek group believes underlying product withdrawal purported classes direct indirect purchasers payers remedies including compensatory punitive statutory damages cidra puerto rico manufacturing site consistent terms agreements valid individual retail chains cost fund medical monitoring research october fda began investigation groups defences exist claims uk arbitration panel concluded lawsuits early stages manufacturing facility cidra puerto rico cidra site plaintiffs claims based allegations fraudulent hearing liability december date yet determination whether purported class actions engaged tableting packaging range procurement patent wrongful listing patent issued determination event panel finds favour permitted proceed class actions glaxosmithkline products primarily us market including fda orange book prosecution sham patent infringement otsuka liability separate hearing would held later paxil paxil cr coreg avandia avandamet subsequently litigation cases originally filed us district determine damages lotronex fda issued two forms observations possible courts district massachusetts eastern district following voluntary withdrawal lotronex usa deficiencies manufacturing practices group pennsylvania transferred district massachusetts environmental matters november number lawsuits filed group settled cases filed teva eon group glaxosmithkline notified potential responsibility group state federal district courts including individual fda observations relate certain aspects production major retail pharmacy chains january group reached relating past operations past waste disposal practices personal injury actions purported class actions asserting controls process validation laboratory investigations primarily settlement class direct purchasers pursuant certain sites primarily usa matters product liability consumer fraud claims plaintiffs seek remedies respect activities occurred group agreed pay million settlement subject litigation including proceedings initiated us including compensatory punitive statutory damages group responded observations contained forms subject approval us district court litigation continues federal state governments waste disposal site remediation substantial number claims settled date fda advised group whether class indirect purchasers court trial costs tort actions brought private parties remaining actions early stages although tentative trial action indicated group continues work set june dates cases set summer fall closely fda address concerns implement glaxosmithkline advised may responsible date class certified one class actions changes required agency arising forms augmentin party approximately sites appear matter west virginia state court rejected plaintiffs request fda investigation group received indication us district court eastern district virginia national priority list created comprehensive environmental certify national refund class certify class west ongoing supply site affected found various patents covering augmentin invalid holding response compensation liability act superfund virginia consumers suffered economic injury resulting subsequently affirmed cafc immediately following proceedings seek require operators hazardous individual purchase lotronex noted damages antitrust adverse trial court decision purported antitrust class actions waste facilities transporters waste sites generators proven would limited cost medication paxil filed behalf consumers third party payers various hazardous waste disposed sites clean sites november us federal trade commission ftc staff federal courts transferred consolidated reimburse government cleanup costs government investigations advised group conducting nonpublic us district court eastern district virginia plaintiffs instances glaxosmithkline involved alleged generator colorado us attorney subpoena investigation determine whether group violating allege group knowingly obtained invalid patents hazardous waste although sites february glaxosmithkline received subpoena section federal trade commission act monopolizing engaged anticompetitive conduct prevent entry glaxosmithkline involved current former operator us attorneys office colorado regarding groups sales attempting monopolize market paroxetine generic products violation monopolization section facility although superfund provides defendants promotional practices relating number largest selling hydrochloride preventing generic competition paxil us antitrust laws plaintiffs seek declaratory injunctive relief jointly severally liable cleanup costs proceedings products period january present group requested group submit certain information connection well treble damages alleged overcharges frequently resolved basis nature quantity cooperating investigation early stages investigation october ftc closed determination whether putative class actions waste disposed site generator glaxosmithklines investigation basis finding action permitted proceed class actions two new complaints average wholesale price proportionate liability cleanup costs substantially warranted filed shortly cafc decision first complaint filed glaxosmithkline responded subpoenas office determined sites referred december us district court eastern district inspector general us department health human following public reference ftc investigation regarding paxil virginia lek pharmaceuticals whollyowned subsidiary glaxosmithklines potential liability varies greatly site site services us department justice states texas purported class actions filed us district court novartis seeking lost profits treble damages injunctive relief cost investigation study remediation sites california connection allegations pharmaceutical eastern district pennsylvania behalf indirect attorneys fees second purported class action filed could time substantial glaxosmithkline routinely accrues companies including glaxosmithkline violated federal fraud purchasers including consumers third party payers direct court behalf direct purchasers primarily wholesalers amounts related share liability matters abuse laws federal false claims act purchasers plaintiffs claim group monopolized respect texas california comparable state laws result market paxil bringing allegedly sham patent litigation wellbutrin legal charges provisions way certain drugs priced based average allegedly abusing regulatory procedures listing separately group prosecuted patent infringement suits legal expenses incurred relating defence groups wholesale price awp way medicare medicaid patents fda orange book treble damages sought four companies filed andas seeking permission intellectual property litigation costs provisions related programmes reimburse drugs alleged overcharges flowing conduct cases sell generic bupropion wellbutrin srzyban usa three product liability claims existing products charged selling scheduled trial december motions certifications cases summary judgement entered subsequently states nevada montana new york general administration costs litigation costs provisions classes direct indirect purchasers yet group following adverse rulings patent litigation connecticut respective attorneys general several relating legal claims withdrawn products antitrust decided patent infringement litigation glaxosmithkline eight purported class actions initially filed behalf counties new york state filed civil lawsuits state matters charged operating incomeexpense provisions several generic drug companies filed antitrust counterclaims purchasers third party payers us district court federal court glaxosmithkline several drug made taking appropriate legal advice reasonable based allegations october antitrust claims eastern district pennsylvania alleging group engaged companies actions claim behalf states payers estimate made likely outcome dispute filed asahi glass co dismissed us district court anticompetitive conduct including prosecution sham patent behalf instate patients consumers damages information provisions taken payments northern district illinois asahi appealed decision infringement litigation prevent entry generic products restitution based defendants awpbased pricing provisions set note cafc glaxosmithklines motions dismiss portions seeking declaratory injunctive relief well treble damages undefined set pharmaceutical products covered states counterclaims filed apotex sumika us district court alleged overcharges cases subsequently ultimate liability legal claims may vary amounts medicaid programmes addition private payer class action eastern district pennsylvania yet decided consolidated single action district court plaintiffs provided dependent upon outcome litigation lawsuits filed glaxosmithkline several federal group entered agreement plaintiffs proceedings investigations possible settlement negotiations district state courts federal cases relafen dismiss consolidated case without prejudice refiling consolidated multidistrict litigation proceeding us august us district court district dismissal papers pending court tax matters district court district massachusetts massachusetts ruled groups patent nabumetone relafen pending tax matters described note invalid anticipatory art unenforceable grounds inequitable conduct glaxosmithkline notes financial statements notes financial statements glaxosmithkline acquisitions disposals acquisitions disposals continued details acquisition disposal subsidiary associated undertakings joint ventures given book fair value net assets goodwill cost book fair value net assets goodwill cost acquisitions valu e ms adjustme n mts acqui md capitalis e md acquisit io mn values adjustments acquired capitalised acquisition acquisitions block drug europharm shionogi joint venture europharm group completed buyout minority interests europharm holdings sa group subsidiary located romania million giving rise goodwill million capitalised block drug company inc iterfi sterilyo january group acquired block drug cash consideration million represented fair value assets payment million made pursuant acquisition agreement based financial performance acquired acquired company amount included deferred compensation shionogi joint venture disposals group established joint venture shionogi develop commercialise number compounds contributed sb clinical laboratories parties group acquired per cent equity share capital cash consideration million committed additional cash refund million received respect indemnified liabilities arising sb clinical laboratories make contributions certain development milestones achieved disposal occurred refund follows successful outcome case us court appeal disposals iterfi sb clinical sterilyo europharm laboratories total quest diagnostics inc cash flows may group disposed million shares investment quest diagnostics inc cash proceeds million cash consideration paid reducing groups holding st december per cent recognising charge goodwill previously written reserves million profit million recognised net cash proceeds disposals affymax group completed sale affymax business affymax inc new holding company million nonvoting book fair value net assets goodwill cost preference shares affymax inc representing value million million recognising charge goodwill previously values adjustments acquired capitalised acquisition acquisitions written reserves million loss million made disposal costs million incurred completing sale iterfi sterilyo tagamet human kft february group sold tagamet japan sumitomo pharmaceutical co ltd cash consideration million recognising charge goodwill previously written reserves million loss million recognised quest diagnostics affymax tagamet block drug shionogi total iterfi sterilyo cash flows group acquired iterfisterilyo group initial cash consideration million payment paid cash consideration paid million based financial performance acquired company net assets iterfisterilyo cash acquired incorporated financial statements provisional fair values adjustments made values net cash payment acquisitions human kft net cash proceeds disposals group acquired vaccine related assets human kft manufacturing business located hungary cash consideration million disposals sb clinical laboratories cash refund million received respect indemnified liabilities arising sb clinical laboratories disposal occurred refund follows successful outcome case us court appeal sb clinical iterfi human laboratories sterilyo kft total cash flows cash consideration paid net cash proceeds disposals glaxosmithkline notes financial statements notes financial statements glaxosmithkline financial instruments related disclosures group applies boardapproved limits amount credit financial instruments related disclosures continued exposure one counterparty employs strict minimum policies classification fair values financial assets liabilities credit worthiness criteria choice counterparty discussion groups objectives policies following table sets classification financial assets liabilities provides reconciliation group net debt note management financial instruments associated risks shortterm debtors creditors excluded financial assets liabilities provisions included fair value financial assets liabilities included treasury policies operating financial contractual obligation settle cash table presents carrying amounts uk review prospects gaap fair values groups financial assets liabilities st december st december investments carrying fair carrying fair debtors creditors due within one year excluded amount value amount value group holds number equity investments frequently entities group entered research collaborations fair values financial assets liabilities included net debt group seeks realise value investments amount instrument could exchanged liquid investments part research collaboration helps create therefore current transaction willing parties forced cash bank certain investments regarded available sale liquidation sale following methods assumptions current asset financial instruments accounted current asset investments purposes used estimate fair values us gaap current asset investments classified equity investments market value based quoted market available sale sterling notes bonds prices case listed investments market value glaxosmithkline hedged part equity value reference quoted prices similar companies recent holdings largest equity investment quest diagnostics inc financing information case material unlisted us dollar notes bonds private financing series variable sale forward contracts contracts investments notes bonds swapped us dollars equity collar structured five series one cash bank approximates carrying amount currency swaps million quest shares mature liquid investments based quoted market prices similar interest rate swaps companies recent financing information case group liquid investments representing funds surplus marketable securities approximates carrying amount immediate operating requirements accounted notes bonds swapped yen case time deposits short maturity current asset investments purposes us gaap currency swaps shortterm loans overdrafts approximates carrying investments classified available sale proceeds amount short maturity instruments sale investments classified available sale us gaap mediumterm loans market value based quoted market year ended st december million euro notes bonds prices case eurobonds fixed rate proceeds include rollover liquid funds shortterm deposit interest rate swap borrowings approximates carrying amount case us gaap gross gains losses reflected floating rate bank loans loans consolidated profit loss account respect investments forward exchange contracts based market prices classified available sale million million mediumterm borrowings exchange rates balance sheet date respectively shortterm loans overdrafts currency swaps based market valuations balance sheet date total borrowings foreign exchange risk management equity collar fair value determined based option group entered forward foreign exchange contracts interest rate swaps pricing model order swap liquid assets borrowings currencies interest rate instruments based market valuations required group purposes st december group balance sheet date total net debt outstanding contracts sell purchase foreign currency debtors creditors approximates carrying amount total notional principal amount million provisions approximates carrying amount fixed asset equity investments million majority contracts periods auction rate preference stock approximates carrying current asset equity investments months less amount case floating rate instruments debtors due year end group number currency swaps flexible auction market preferred stock based market creditors due year place respect mediumterm debt instruments borrowings valuations balance sheet date provisions denominated swapped foreign currencies match foreign exchange derivatives investments overseas group assets treated hedge fair value investments shares equity collar relevant net assets exchange gains losses group st december investments shares recorded reserves million million fair value auction rate preference stock million million difference flexible auction market preferred stock interest rate risk management carrying amount fair value represents unrealised total nonequity minority interests manage fixedfloating interest rate profile debt group loss million valuation shortfall considered total financial assets liabilities several interest rate swaps outstanding commercial banks represent permanent diminution value context st december length future period related share options total financial assets may exercised accordingly provision made total financial liabilities concentrations credit risk credit exposures investments excluded financial instrument disclosure appropriate currency interest rate swaps presented alongside underlying principal instrument carrying financial instruments fair value market value based quoted market price amounts instruments adjusted effect currency interest rate swaps acting hedges group believe exposed major concentrations shares represent purchases employee share ownership credit risk financial instruments group exposed difference carrying amount fair value equity fixed current assets liquid investments represents gross trusts satisfy future exercises options awards creditrelated losses event nonperformance unrealised gains million million respectively employee incentive schemes purchases matched counterparties financial instruments expect options predetermined exercise prices gain loss counterparties fail meet obligations recognised measured exercise price rather market value glaxosmithkline notes financial statements notes financial statements glaxosmithkline financial instruments related disclosures continued financial instruments related disclosures continued currency interest rate risk profile financial liabilities currency exposure net monetary assetsliabilities financial liabilities taking account currency interest rate swaps analysed groups currency exposures give rise net currency gains losses recognised profit loss account arise principally companies sterling functional currency monetary assets liabilities denominated overseas functional currency total financial liabilities comprise total borrowings million million creditors due one year borrowings designated hedge overseas net assets excluded table million million provisions million million nonequity minority interest preference shares million million creditors due within one year excluded st december benchmark rate determining interest payments floating rate financial liabilities tables libor functional currency group operation net monetary assetsliabilities sterling us euro yen total fixed rate floating rate noninterest bearing held nonfunctional currency weighted weighted sterling average average weighted us dollars st december interest years average rate rate years total euro currency fixed maturity japanese yen us dollars sterling euro japanese yen currencies st december functional currency group operation net monetary assetsliabilities sterling us euro yen total held nonfunctional currency fixed rate floating rate noninterest bearing sterling weighted weighted us dollars average average weighted euro st december interest years average japanese yen rate rate years total currency fixed maturity us dollars sterling euro nonequity japanese yen finance minority total total debt leases interests currencies maturity financial liabilities within one year demand one two years currency interest rate risk profile financial assets two five years total financial assets comprise fixed asset equity investments million million current asset equity investments five years million million liquid investments million million cash bank million million debtors due one year million million exclude foreign exchange derivatives million million benchmark rate determining interest receipts floating rate assets table libor gains losses net st december fixed floating noninterest hedges rate rate bearing total unrecognised gains losses beginning year currency unrecognised gains losses arising year us dollars total unrecognised gains losses end year sterling euro expected recognised within one year japanese yen expected recognised one year currencies total unrecognised gains losses end year unrecognised gains losses represent difference carrying amount fair value currency swaps st december fi rx ae td e float ri tg e non bin et ae rr ie ns gt total interest rate swaps equity collar foreign exchange derivatives currency us dollars committed facilities sterling group committed facilities back commercial paper programme million million days euro duration renewable annually st december undrawn committed facilities totalled million us million japanese yen us million currencies glaxosmithkline notes financial statements notes financial statements glaxosmithkline employee costs employee costs continued pension costs accounting purposes assessed accordance independent actuarial advice generally using projected wages salaries unit method spreading surpluses deficits average expected remaining service lives respective memberships social security costs certain countries pension benefits provided unfunded basis administered trustee companies assets held pension postretirement costs specific purpose matching liabilities unfunded schemes provision included within provisions pensions cost sharebased incentive plans postretirement benefits liabilities generally assessed annually accordance advice independent actuaries severance costs arising integration restructuring activities pension postretirement costs arising integration restructuring activities market value assets groups funded defined benefit pension funds dates latest actuarial valuations date back billion actuarial value assets sufficient cover approximately per cent benefits accrued members allowing future salary pension increases uk defined benefit pension schemes group provides benefits employees commensurate local practice individual countries including markets healthcare account approximately per cent groups plans asset valuation projected benefit terms us defined benefit pension insurance subsidised car schemes personal life assurance schemes account approximately per cent groups plans asset valuation projected benefit terms million credit relation sharebased incentive plans includes benefit introduction discounting provision group made special funding contributions uk us pension schemes totalling million group established cost programme encourage employees convert glaxo wellcome smithkline beecham share options agreed trustees certain pension schemes make additional contributions dependent funding status glaxosmithkline share options see schemes pension costs expected approximately information directors remuneration given remuneration report pages uk uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline average number persons employed group including directors year number number number beecham employees remain separate schemes closed new entrants subsequent uk employees entitled manufacturing join defined contribution scheme relevant assumptions used calculating pension costs former glaxo wellcome selling general administration former smithkline beecham uk defined benefit schemes accounting purposes follows research development pa pa rate increase future earnings average number group employees excludes temporary contract staff discount rate expected longterm rate return investments numbers group employees end financial year given financial record expected pension increases uk equity dividend growth na pension postretirement costs regular cost glaxo wellcome pension arrangements million reduced accounting cost uk pension schemes million allowance made spreading surplus disclosed level percentage salary expected future working us pension schemes lifetime existing members years recent triennial actuarial valuations funding purposes carried overseas pensions schemes st december date assets schemes represented per cent actuarial value benefits accrued unfunded postretirement healthcare schemes members allowing future salary pension increases total market value assets held schemes postemployment costs st december million regular cost smithkline beecham schemes million increased accounting cost million analysed allowance made spreading deficit expected future working lifetime current employees scheme funded defined benefithybrid schemes years latest valuation carried st december date scheme assets represented per cent unfunded defined benefit schemes actuarial value accrued service liabilities based assumptions total market value assets held scheme defined contribution schemes st december million unfunded postretirement healthcare schemes postemployment costs usa usa former glaxo wellcome smithkline beecham defined benefit hybrid schemes merged pension postretirement costs arising integration restructuring relevant assumptions used calculating pension costs accounting purposes follows pa pa pensions group undertakings operate pension arrangements cover groups material obligations provide pensions retired employees rate increase future earnings arrangements developed accordance local practices countries concerned pension benefits provided discount rate state schemes defined contribution schemes whereby retirement benefits determined value funds arising expected longterm rate return investments contributions paid respect employee defined benefit schemes whereby retirement benefits based employee cash balance creditconversion rate pensionable remuneration length service defined benefit schemes also include defined contribution sections us equity dividend growth na described hybrid schemes table regular cost main us scheme million increased accounting cost million allowance majority cases contributions defined benefit schemes determined accordance advice independent made spreading deficit expected future working lifetime current employees schemes latest professionally qualified actuaries formal independent actuarial valuations groups main plans undertaken regularly normally valuation carried st january date actuarial value scheme assets represented per cent actuarial least every three years assets funded schemes generally held separately administered trusts insured assets value accrued service liabilities total market value assets held scheme st january million invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment postretirement healthcare group operates number postretirement healthcare schemes principal one usa cost us scheme assessed using assumptions us pension scheme together assumption future medical inflation per cent reducing one per cent per year five per cent total provision postretirement benefits st december amounted million million glaxosmithkline notes financial statements notes financial statements glaxosmithkline employee costs continued employee costs continued frs disclosures uk usa rest world group group continues account pension arrangements accordance ssap accounting pension costs average st december expected rate fair expected rate fair expected rate fair fair transitional provisions frs retirement benefits certain disclosures required basis valuation methodology adopted return value return value return value value frs defined benefit schemes fair values pension scheme assets st december compared future pension liabilities calculated projected unit method applying following assumptions equities property uk usa rest world bonds assets pa pa pa pa pa pa pa pa pa fair value assets rate increase future earnings present value scheme liabilities discount rate expected pension increases na na na cash balance creditconversion rate na na na na na value schemes surplus inflation rate deferred tax liability expected longterm rates return assets determined based actuarial advice fair values assets liabilities uk us defined benefit schemes together aggregated data defined benefit schemes group follows value schemes deficit deferred tax asset uk usa rest world group average st december expected rate fair expected rate fair expected rate fair fair group total return value return value return value value equities uk defined benefit schemes also defined contribution sections account balances totalling million st december property million million defined benefit sections uk schemes closed new members bonds projected unit method valuing pension scheme liabilities current service cost increase percentage payroll assets members schemes approach retirement deficits frs reflect different basis valuing liabilities compared fair value assets ssap present value scheme liabilities liability frs us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation per cent reducing one per cent per year value schemes surplus five per cent basis liability us scheme assessed million million million deferred tax liability reduced million million million taking account deferred tax defined benefit pension postretirement benefit schemes accounted frs following amounts would value schemes deficit recorded profit loss account statement total recognised gains losses two years ended deferred tax asset st december postretirement group total pensions benefits uk usa rest world group group assets uk schemes include special cash contribution paid december invested equities bonds amounts charged operating profit uk usa rest world group current service cost average past service cost st december expected rate fair expected rate fair expected rate fair fair curtailmentssettlements return value return value return value value equities property amounts creditedcharged net interest bonds expected return pension scheme assets assets interest scheme liabilities fair value assets present value scheme liabilities amounts recorded statement total recognised gains losses value schemes surplus actual return less expected return pension scheme assets deferred tax liability experience lossesgains arising scheme liabilities changes assumptions relating present value scheme liabilities value schemes deficit deferred tax asset group total glaxosmithkline notes financial statements notes financial statements glaxosmithkline employee costs continued employee costs continued postretirement postretirement pensions benefits pensions benefits history experience gains losses uk usa rest world group group uk usa rest world group group amounts charged operating profit difference expected actual current service cost return scheme assets past service cost percentage scheme assets st december curtailmentssettlements experience lossesgains scheme liabilities percentage present value scheme liabilities amounts creditedcharged net interest st december expected return pension scheme assets interest scheme liabilities total amount recognised statement total recognised gains losses percentage present value scheme amounts recorded statement total liabilities st december recognised gains losses actual return less expected return pension scheme assets experience gainslosses arising scheme liabilities difference expected actual changes assumptions relating present return scheme assets value scheme liabilities percentage scheme assets st december experience gainslosses scheme liabilities percentage present value scheme liabilities st december postretirement pensions benefits total amount recognised statement total movements deficits uk usa rest world group group recognised gains losses percentage present value scheme deficits schemes st january liabilities st december exchange adjustments charged operating profit employer contributions frs valuation basis applied financial statements instead ssap valuation basis effect profit finance incomeexpense loss account reserve taking account deferred tax would follows actuarial losses recognised statement total recognised gains losses deficits schemes st december exchange adjustments profit loss account reserve per balance sheet charged operating profit pension liability frs employer contributions pension assetliability ssap per balance sheet finance incomeexpense actuarial lossesgains recognised statement total postretirement healthcare schemes frs recognised gains losses postretirement healthcare schemes provision per balance sheet deficits schemes st december profit loss account reserve including frs pension postretirement healthcare liability glaxosmithkline notes financial statements notes financial statements glaxosmithkline employee share schemes employee share schemes continued company operates share option schemes whereby options granted employees acquire shares adss glaxosmithkline plc options outstanding share option share option savingsrelated grant price share award schemes whereby awards granted employees acquire shares adss glaxosmithkline plc schemes shares schemes adss share option schemes st december cost subject achievement performance targets weighted latest weighted latest weighted latest number exercise exercise number exercise exercise number exercise exercise company operates share option schemes savingsrelated share option schemes grants share option schemes normally year grant price date price date price date exercisable three ten years date grant grants savingsrelated share option schemes normally exercisable three years saving options share option schemes normally granted market price ruling date grant accordance uk practice majority options savingsrelated share option schemes granted price per cent market price ruling date grant accordance exemption granted uitf revised charge profit loss account made relation savingsrelated share option schemes options outstanding share option share option savingsrelated schemes shares schemes adss share option schemes weighted weighted weighted number exercise number exercise number exercise price price price total st december options exercisable except options shares adss granted savingsrelated options granted share options granted options exercised options cancelled change effective exercise price outstanding options year options granted st december st december th february options granted options exercised options exercisable share option share option savingsrelated schemes shares schemes adss share option schemes options cancelled weighted weighted weighted st december number exercise number exercise number exercise options granted price price price options exercised st december options cancelled st december st december range exercise prices st december order encourage employees convert options excluding savingsrelated share options held glaxo wellcome smithkline glaxosmithkline share award schemes beecham shares adss glaxosmithkline shares adss programme established give additional cash benefit group operates performance share plan whereby awards granted directors senior executives cost percentage ten per cent exercise price original option provided employee voluntarily leave group two years award vests based upon performance group three year measurement period performance conditions date merger exercise option earlier six months expiry date original option consist two parts applies per cent award first part condition compares glaxosmithklines total two years date merger cash benefit also paid options expire unexercised market price shareholder return tsr period tsr companies uk ftse index period second part exercise price date expiry performance condition compares glaxosmithklines earnings per share growth increase uk retail prices index three year performance period shares adss number shares adss issuable number number st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december glaxosmithkline notes financial statements notes financial statements glaxosmithkline employee share schemes continued reconciliation us accounting principles additionally group reassesses useful lives existing recognised intangible assets intangible assets deemed employee share ownership trusts analyses reconciliations presented note represent indefinite lives longer amortised instead tested group sponsors employee share ownership trusts acquire hold shares glaxosmithkline plc satisfy awards made financial information prepared basis us generally annually potential impairment separable intangible assets employee incentive plans options granted employee share option schemes trustees employee share ownership accepted accounting principles us gaap rather uk gaap finite lives continue amortised useful lives trusts purchase shares open market finance provided group way loans contributions expected cost obligations deliver shares schemes normally spread periods service respect awards options summary material differences uk us gaap group adopted sfas st january granted accelerated charge made respect outstanding cost providing shares awards options acquisition smithkline beecham implementation sfas resulted impairment became exercisable solely result merger combination glaxo wellcome plc smithkline beecham groups goodwill initial impairment million plc accounted merger pooling interests million net tax indefinitelived assets shown shares held share award schemes accordance uk gaap us gaap business cumulative effect accounting change combination qualify pooling interests accounting number shares uk gaap costs incurred integrating glaxo wellcome determined accounting restructuring wellcome smithkline beecham block drug acquirer purchase business combination businesses following acquisitions nominal value accordingly net assets smithkline beecham fair valued respectively charged profit loss account post cost less provision date acquisition result fair value exercise acquisition us gaap certain costs considered market value increases values smithkline beechams inventory tangible allocation purchase consideration thereby affecting fixed assets investments pension obligations recognised goodwill arising acquisition shares held share option schemes fair market values attributed intangible assets mainly uk gaap certain intangible assets related specific product rights inclusive patents trade marks assembled number shares compounds products purchased third party workforce inprocess research development together developed commercial applications capitalised appropriate deferred taxation effects difference us gaap payments made compounds products cost acquisition fair value assets liabilities nominal value still development yet received regulatory smithkline beecham recorded goodwill cost less provision approval charged directly profit loss time market value capitalised interest receive regulatory approval uk gaap group capitalise interest us gaap trusts also acquire hold shares meet notional dividends reinvested deferred awards smithkline beecham requires interest incurred part cost constructing fixed restructuring costs midterm incentive plan trustees waived rights dividends shares held employee share ownership trusts assets capitalised amortised life asset uk gaap restructuring costs incurred following acquisitions charged profit loss account post acquisition option pricing computer software us gaap purposes certain costs recognised purposes valuing options arrive stockbased compensation adjustment reconciliation us accounting principles uk gaap group capitalises costs incurred acquiring liabilities upon acquisition opening balance sheet note blackscholes option pricing model used assumptions used model follows developing computer software internal use software supports significant business system restructuring costs recorded provision uk expenditure leads creation durable asset us gaap restructuring plan announced us riskfree interest rate gaap group applies sop accounting costs gaap subsequent st december provision may dividend yield computer software developed obtained internal use recognised criteria met liability volatility restricts categories costs capitalised incurred accordingly adjustments made eliminate expected lives options granted uk gaap provisions restructuring costs meet goodwill intangible fixed assets share option schemes years years us gaap requirements uk gaap goodwill arising acquisitions savings related share option schemes years years accounted purchase method eliminated marketable securities shareholders funds additionally uk gaap requires marketable securities consist primarily equity securities subsequent disposal closure business goodwill related party transactions certain liquid investments uk gaap securities previously taken directly shareholders funds charged stated lower cost net realisable value glaxosmithkline held per cent interest quest diagnostics inc throughout group quest diagnostics parties income beginning group changed us gaap securities considered available sale longterm contractual relationship quest diagnostics primary provider clinical laboratory testing support groups accounting policy goodwill intangible assets uk sfas accounting certain investments debt equity clinical trials testing requirements worldwide gaap respect acquisitions uk gaap securities carried fair value unrealised gains goodwill arising acquisitions capitalised group shionogi co ltd entered transactions us joint venture company support losses net tax recorded separate component amortised period exceeding years research development activities conducted joint venture company glaxosmithkline provided services joint shareholders equity venture million million st december balance due glaxosmithkline joint venture million us gaap goodwill arising acquisitions prior equity securities reviewed least annually million june capitalised amortised period temporary impairment factors considered exceeding years july financial accounting dr barzach nonexecutive director glaxosmithkline plc received fees subsidiary company standards board fasb issued statement financial accounting investees current financial performance future healthcare consultancy provided included within annual remuneration remuneration report standard sfas goodwill intangible assets sfas prospects dr shapiro nonexecutive director glaxosmithkline plc received fees requires goodwill longer amortised general market condition geographic industry form adss subsidiary company membership scientific advisory board included within estimated useful life group must instead identify value area investee operates annual remuneration remuneration report reporting units purpose assessing least annually duration extent market value potential impairment goodwill allocated reporting unit available cost gross unrealised gains losses marketable securities million million respectively st december glaxosmithkline notes financial statements notes financial statements glaxosmithkline reconciliation us accounting principles continued requires group recognises measures fair value reconciliation us accounting principles continued recent financial accounting standards board fasb prospective basis certain guarantees issued modified pronouncements pensions postretirement benefits dividends st december uk gaap guarantor obligations january fasb issued fasb staff position fsp key differences uk ssap us gaap uk gaap dividends proposed provided year recognised additional criteria met accounting disclosure requirements related relation defined benefit pension plans respect recommended board liability incurred medicare prescription drug improvement modernization directors approval shareholders us gaap uk gaap effect variations cost act act fsp addresses accounting dividends provided declared board accumulated successive valuations amortised derivative instruments implications act entity sponsors post directors aggregate basis us gaap amortisation sfas accounting derivative instruments hedging retirement health care plan providing prescription drug benefits transition asset costs past service benefit activities amended sfas sfas act introduces usa prescription drug benefit consolidated summary statement cash flows improvements separately tracked experience gainslosses interpreted derivatives implementation group adopted medicare well federal subsidy sponsors certain post us gaap cash flow statement reports changes cash dealt aggregate basis amortised group effect st january sfas retirement health care plans fsp provides election cash equivalents includes shortterm highly liquid outside per cent corridor establishes accounting reporting standards derivative defer accounting implications new law investments original maturities three months less instruments including certain derivative instruments embedded specific authoritative guidance issued address uk gaap allows measurements plan assets liabilities three categories cash flows reported operating contracts collectively referred derivatives accounting treatment result current absence based result latest actuarial valuation activities including tax interest investing activities including hedging activities uk gaap derivative instruments guidance accounting treatment measures us gaap requires measurement plan assets liabilities capital expenditure acquisitions disposals together used hedging recognised balance sheet accumulated postretirement benefit obligation net periodic made date financial statements cash flows available sale current asset investments matching principle used match gain loss postretirement benefit cost included reconciliation us three months prior date financing activities including dividends paid summary hedging contracts foreign currency transaction profits accounting principles accompanying notes reflect statement cash flows presented pension adjustment also includes impact changes relate sfas requires entity recognise effects act authoritative guidance issued could minimum pension liabilities included within accumulated derivatives either assets liabilities consolidated balance require change previously reported information cash cash equivalents comprehensive income sheet measure instruments fair value changes fair uk gaap cash balance includes cash bank january fasb issued interpretation fin value period recorded current earnings unless hedge group decided align measurement date cash balances us gaap cash cash equivalents consolidation variable interest entities december accounting obtained group designate pension postretirement benefit plans st include cash bank certain liquid investments original issued fin r revision interpretation derivatives qualifying hedge instruments sfas december certain groups plans measurement maturities three months less revised interpretation certain entities known variable interest sfas prescribes requirements designation documentation date assets liabilities th september entities vies must consolidated primary beneficiary hedging relationships ongoing assessments effectiveness comprehensive income statement entity primary beneficiary generally defined impact reflected cumulative effect accounting order qualify hedge accounting requirement sfas reporting comprehensive income majority risks rewards arising vie change million credit net tax income group also evaluates contracts embedded derivatives provide comprehensive income statement met additionally vies significant majority considers whether embedded derivatives uk gaap statement total recognised gains losses variable interest held certain disclosures required certain stockbased compensation bifurcated separated host contracts accordance pages measurement principles interpretation relating newly uk gaap share options accounted equity sfas requirements embedded derivatives exist formed vies applicable financial statements exercised valued issuance price us gaap group clearly closely related host contract reclassifications fiscal year ended st december group evaluated applies sfas accounting stockbased compensation accounted separately host contract derivatives certain prior year balances reclassified comparative potential vies newly formed entities related accounting interpretations accounting option plans purposes certain amounts previously presented aggregate identify items would require adjustment require options fair valued grant date gains losses related fair value adjustments reconciliation profit us gaap uk gaap financial statements remaining disclosure requirements included profit loss vesting period options derivative instruments classified consolidated statement presented separately current year presentation provide interpretation effective subsequent financial income cash flows accordance nature group entitled receive tax deduction amount information related adjustments statements beginning glaxosmithkline yet derivative treated compensation us tax rules employee completed assessment remaining relationships stock options exercised us employees fair value book value derivative instruments respect sales incentives could impact disclosures included year uk gaap treated reduction tax financial assets liabilities st december accordance uk gaap certain amounts paid group subsequent financial statements results operations expense whereas us gaap portion amount disclosed classification fair value financial assets customers recorded promotional expense included financial position periods credited equity liabilities table note operating income us gaap items recorded reduction revenue items result net employee share ownership trusts esot valuation derivative instruments impact income statement us gaap amount uk gaap shares groups stock held esots fair value derivative instruments sensitive movements would classified reduction revenue would recorded cost less provision representing difference underlying market rates variables group monitors million cost option exercise price accounted fair value derivative instruments least quarterly basis fixed asset investments projected losses exercise formal review every six months derivatives including options covered shares recorded profit interest rate swaps cross currency swaps valued using loss account life options us gaap standard valuation models counterparty valuations third party shares groups stock purchased esots accounted valuations standard valuation models used group consider within shareholders equity cost gains losses arising relevant discount rates market yield curve valuation subsequent issuance shares employees satisfy share date forward currency exchange rates counterparty risk options recorded adjustments shareholders equity significant rates variables obtained market sources valuations based remaining term maturity guarantor obligations instrument foreign exchange contracts valued using forward group adopted fasbs financial interpretation rates observed quoted prices relevant markets fin guarantors accounting disclosure requirements possible group assumes parties longterm contracts guarantees including indirect guarantees indebtedness economically viable reserves right exercise early others effect st january termination rights economically beneficial rights exist contract glaxosmithkline notes financial statements notes financial statements glaxosmithkline reconciliation us accounting principles continued reconciliation us accounting principles continued following summary material adjustments profit shareholders funds would required us gaap equity shareholders funds notes applied instead uk gaap adjustments reflected income statements balance sheets presented equity shareholders funds uk gaap accordance us gaap us gaap adjustments profit notes goodwill profit attributable shareholders uk gaap product rights b capitalised interest pension intangible asset b computer software tangible fixed assets goodwill amortisation reversalcharge including goodwill associated undertakings capitalised interest amortisation impairment intangible assets b computer software acquisition licences patents etc b marketable securities recognition cost sales fair value stepup inventory investments disposal purchased investment employee share ownership trust product divestments pensions postretirement benefits e equity investments restructuring costs loss disposal subsidiary derivative instruments pensions postretirement benefits e guarantor obligations stockbased compensation dividends provision esot shares deferred taxation derivative instruments shareholders equity us gaap guarantor obligations restructuring certain items year ended st december reclassified comparative purposes tax benefits exercise us stock options c deferred taxation c consolidated statement cash flows us gaap net incomeloss us gaap cumulative effect changes net cash provided operating activities accounting principles net cash used investing activities cumulative effect changes accounting principles net cash used financing activities net incomeloss cumulative effect changes accounting principles net increasedecrease cash cash equivalents exchange rate movements certain items years ended st december st december reclassified comparative purposes cash cash equivalents beginning year cash cash equivalents end year earnings per share us gaap pence pence pence basic net incomeloss per share cumulative effect changes accounting principles us gaap notes profit equity shareholders funds reconciliations cumulative effect changes accounting principles per share goodwill us gaap basic net incomeloss per share cumulative effect changes following tables set uk us gaap adjustments required uk gaap statement profit loss balance sheet accounting principles us gaap respect goodwill diluted net incomeloss per share cumulative effect changes income statement accounting principles us gaap amortisation uk gaap including goodwill respect associated undertakings cumulative effect changes accounting principles per share amortisation us gaap including goodwill respect associated undertakings us gaap diluted net incomeloss per share cumulative effect changes uk us gaap adjustment amortisation including goodwill respect associated undertakings accounting principles us gaap balance sheet earnings per ads us gaap goodwill uk gaap goodwill us gaap basic net incomeloss per ads cumulative effect changes accounting principles us gaap uk us gaap adjustments cumulative effect changes accounting principles per ads us gaap million million us gaap goodwill balance st december million million basic net incomeloss per ads cumulative effect changes respect goodwill arising acquisition smithkline beecham glaxo wellcome accounting principles us gaap diluted net incomeloss per ads cumulative effect changes accounting principles us gaap cumulative effect changes accounting principles per ads us gaap diluted net incomeloss per ads cumulative effect changes accounting principles us gaap glaxosmithkline notes financial statements notes financial statements glaxosmithkline reconciliation us accounting principles continued reconciliation us accounting principles continued following tables present changes goodwill allocated groups reportable segments following intangible assets subject amortisation consumer pharmaceuticals healthcare total product product rights rights st december additions cost exchange adjustments accumulated amortisation impairment st december additions net exchange adjustments following launch usa generic paxil product carrying value product rights relating paxil reviewed st december impairment million recorded carrying values certain product rights also reviewed impairment million recorded impairments million recorded million related augmentin b intangible assets impaired following launch generic augmentin product fair values determined using discounted cash flow model following tables set uk us gaap adjustments required uk gaap statement profit loss balance sheet discussed note legal proceedings number distributors generic drugs filed applications market generic versions respect intangible assets anumber groups products prior expiration groups patents generic versions products launched future periods earlier dates group currently expects impairments carrying value products may arise group income statement continue keep position review amortisation impairment charge uk gaap estimated future amortisation expense next five years intangible assets subject amortisation st december amortisation impairment charge us gaap follows uk us gaap adjustment amortisation impairments cumulative effect change accounting principle year uk us gaap adjustment amortisation impairments period following initial implementation sfas carrying value brands determined indefinite lives reviewed impairment million million net tax recognised recorded cumulative effect change accounting principle total addition adjustment amortisation impairments uk us gaap adjustment arose year million million million respect acquisition licences patents etc capitalised uk intangible assets subject amortisation include pension asset million st december million gaap charged directly profit loss us gaap st december certain product rights intangible assets relating product rights analysed follows balance sheet intangible assets uk gaap intangible assets us gaap cost impairment uk us gaap adjustments less pensions intangible asset net net uk us gaap product rights adjustments impairment charge million million recognised result changes market conditions management forecasts certain brand intangibles intangible assets us gaap analysed follows group accounted goodwill identifiable intangible assets indefinite lives sfas year ended st december impact reported us gaap results would follows acquired products licences patents etc brands net income us gaap pensions amortisation net tax intangible assets us gaap goodwill brands following tables present details groups intangible assets differentiating subject amortisation adjusted net income us gaap subject amortisation adjusted basic net income per share pence adjusted diluted net income per share pence intangible assets subject amortisation intangible assets subject amortisation intangible assets us gaap glaxosmithkline notes financial statements notes financial statements glaxosmithkline reconciliation us accounting principles continued reconciliation us accounting principles continued c taxation e pensions postretirement costs us gaap total tax expense uk pension schemes uk gaap us pension schemes current tax expense overseas pension schemes deferred tax expense unfunded postretirement healthcare schemes total tax expense postemployment costs us gaap current tax expense analysed deferred tax expense period funded defined benefithybrid schemes total tax expense period unfunded defined benefit schemes cumulative effect changes accounting principles defined contribution schemes unfunded postretirement healthcare schemes total tax expense postemployment costs uk us gaap adjustments current tax expense deferred tax expense period contributions estimated approximately million total tax expense period disclosures include additional information required sfas pension costs uk us major overseas cumulative effect changes accounting principles defined benefit pension plans restated following tables accordance us gaap pension costs million total tax expense million million respect minor retirement plans recalculated accordance requirements sfas excluded deferred taxation us gaap net periodic pension costincome major retirement plans comprised classification glaxosmithklines deferred taxation liabilities assets us gaap follows service cost interest cost expected return plan assets liabilities amortisation prior service cost stock valuation adjustment amortisation transition obligation current deferred taxation liabilities amortisation net actuarial lossgain accelerated capital allowances net periodic pension costincome us gaap product rights termination benefits curtailment costs timing differences adjustment change accounting principle total deferred taxation liabilities assets group decided align measurement date pension plans certain groups pension plans intragroup profit measurement date pension assets liabilities th september group elected change measurement date timing differences plans th september st december current deferred taxation assets asset disposal major assumptions used computing pension costincome pa pa pa pensions postretirement benefits rates future pay increases tax losses discount rate manufacturing restructuring expected longterm rates return plan assets legal disputes timing differences aggregate average international plan assumptions vary significantly us assumptions total deferred taxation assets net deferred taxation us gaap net deferred taxation uk gaap uk us gaap adjustment difference uk effective taxation rate us effective taxation rate primarily related fair value adjustments goodwill intangibles related acquisitions wellcome smithkline beecham glaxosmithkline notes financial statements notes financial statements glaxosmithkline reconciliation us accounting principles continued reconciliation us accounting principles continued postretirement healthcare us gaap change benefit obligation postretirement healthcare costs uk us major overseas postretirement healthcare schemes restated benefit obligation beginning year following tables accordance us gaap costs million nil million adjustment change accounting principle recalculated excluded amendments service cost net healthcare cost interest cost service cost plan participants contributions interest cost actuarial loss amortisation prior service cost benefits paid amortisation net actuarial loss termination benefits curtailment costs net healthcare cost exchange benefit obligation end year major assumptions used calculating net healthcare cost pa pa pa benefit obligation end year pension plans accumulated benefit obligations excess plan assets rate future healthcare inflation discount rate accumulated benefit obligation st december million rate future healthcare inflation reflects fact benefits certain groups participants capped change plan assets fair value plan assets beginning year change benefit obligation adjustment change accounting principle benefit obligation beginning year actual return plan assets adjustment change accounting principle employer contribution amendments plan participants contributions service cost benefits paid interest cost termination benefits curtailment costs plan participants contributions exchange actuarial loss benefits paid fair value plan assets end year exchange fair value plan assets end year pension plans accumulated benefit obligations excess plan assets benefit obligation end year plan assets consist primarily investments uk overseas equities fixed interest securities securities linked uk retail prices index property st december uk equities included million glaxosmithkline shares million shares change plan assets market value million million fair value plan assets beginning year employer plan participants contributions funded status benefits paid funded status fair value plan assets end year unrecognised net actuarial loss unrecognised prior service cost funded status unrecognised transition obligation funded status net amount recognised unrecognised net actuarial loss unrecognised prior service cost amounts recognised statement financial position consist accrued postretirement healthcare cost prepaid benefit cost accrued pension liability decrease increase impact one per cent variation rate future healthcare inflation intangible asset effect total service interest cost accumulated comprehensive income effect provision postretirement benefits net amount recognised glaxosmithkline notes financial statements notes financial statements glaxosmithkline principal group companies principal group companies continued following represent principal subsidiary associated undertakings glaxosmithkline group st december europe location subsidiary undertaking segment activity details given principal country operation location headquarters business segment business activities netherlands zeist glaxosmithkline bv ph equity share capital undertakings wholly owned group except percentage interest shown otherwise zeist glaxosmithkline consumer healthcare bv ch companies incorporated principal country operation except stated norway oslo glaxosmithkline ph europe location subsidiary undertaking segment activity poland poznan glaxosmithkline pharmaceuticals sa ph p warsaw glaxosmithkline consumer healthcare sp zoo ch england greenford glaxo group ltd ph h brentford glaxosmithkline holdings one limited phch h portugal lisbon glaxosmithklineprodutos farmaceuticos lda ph brentford glaxosmithkline services unlimited phch republic dublin glaxosmithkline consumer healthcare ireland limited footnote ch brentford smithkline beecham plc phch e h r p ireland carrigaline smithkline beecham cork ltd footnote ph p brentford wellcome limited phch h carrigaline smithkline beecham manufacturing ltd footnote ph p spain burgos glaxo wellcome sa ph r p brentford glaxo operations uk ltd ph p madrid smithkline beecham sa ph brentford glaxo wellcome international bv footnote iii phch h brentford glaxo wellcome investments bv footnote iii phch h sweden mlndal glaxosmithkline ab ph stockley park glaxo wellcome uk ltd ph h p switzerland muenchenbuchsee glaxosmithkline investments switzerland gmbh phch h brentford glaxosmithkline export ltd ph e muenchenbuchsee glaxosmithkline international switzerland gmbh phch h brentford glaxosmithkline research development ltd ph r muenchenbuchsee glaxo wellcome international footnote iiv phch h brentford glaxosmithkline uk ltd ph p muenchenbuchsee glaxosmithkline ag ph brentford smithkline beecham investments ltd phch f zug adechsa gmbh ph e brentford smithkline beecham swg ltd ch e turkey istanbul glaxosmithkline ilaclari sanayi ticaret ph p brentford smithkline beecham research ltd ph brentford staffordmiller ltd ch p usa greenford wellcome foundation ltd ph p usa philadelphia smithkline beecham corporation phch e h r p austria vienna glaxosmithkline pharma gmbh ph pittsburgh glaxosmithkline consumer healthcare lp ch p belgium genval glaxosmithkline sa ph new jersey block drug company inc ch h p rixensart glaxosmithkline biologicals sa ph e r p wilmington glaxosmithkline financial inc phch f rixensart glaxosmithkline biologicals manufacturing sa ph e p wilmington smithkline beecham holdings corporation phch h guernsey st peter port smithkline beecham ltd formerly sb insurance ltd phch wilmington glaxosmithkline holdings americas inc phch h denmark ballerup glaxosmithkline consumer healthcare ch brndby glaxosmithkline pharma ph americas finland espoo glaxosmithkline oy ph bermuda hamilton glaxosmithkline insurance ltd phch france marly le roi groupe glaxosmithkline sas ph h canada mississauga glaxosmithkline inc phch p r marly le roi laboratoire glaxosmithkline sas ch marly le roi glaxo wellcome production sas ph p asia pacific germany buehl glaxosmithkline consumer healthcare gmbh co kg ch p australia boronia glaxo wellcome australia ltd ph p buehl glaxosmithkline healthcare gmbh ph dandenong smithkline beecham australia pty ltd phch formerly smithkline beecham healthcare gmbh china hong kong glaxosmithkline limited ph greece athens glaxosmithkline aebe ph h p tianjin sinoamerican tianjin smith kline french laboratories ltd ph hungary budapest glaxosmithkline kft phch india mumbai glaxosmithkline pharmaceuticals ltd ph p italy verona glaxosmithkline spa ph p r nabha glaxosmithkline consumer healthcare ltd footnote ii ch p milan glaxosmithkline consumer healthcare spa ch h malaysia selangor glaxosmithkline pharmaceutical sdn bhd ph luxembourg mamer glaxosmithkline international luxembourg sa phch f h darul ehsan mamer glaxosmithkline luxembourg sa phch f h new zealand auckland glaxosmithkline nz limited phch pakistan karachi glaxosmithkline pakistan ltd phch p formerly glaxo wellcome pakistan ltd philippines makati glaxosmithkline philippines inc ph formerly glaxo wellcome philippines inc singapore singapore glaxo wellcome manufacturing pte ltd ph p singapore glaxosmithkline pte ltd ph south korea seoul glaxosmithkline korea ph p taiwan taipei glaxo wellcome taiwan ltd ph p glaxosmithkline notes financial statements glaxosmithkline investor information principal group companies continued japan location subsidiary undertaking segment activity japan tokyo glaxosmithkline kk ph p r section includes financial record discusses kobe block drug company japan inc ch shareholder return return shareholders form dividends share price movements provides latin america information shareholders argentina buenos aires glaxosmithkline argentina sa phch p financial record brazil rio de janeiro glaxosmithkline brasil lda phch p quarterly trend colombia bogota glaxosmithkline colombia sa phch five year trend mexico mexico city glaxosmithkline mexico sa de cv phch p puerto rico guaynabo glaxosmithkline puerto rico inc ph shareholder return san juan sb pharmco puerto rico inc ph p shareholder return shareholder information venezuela caracas glaxosmithkline venezuela ca ph p share capital taxation information shareholders middle east africa egypt cairo glaxosmithkline sae formerly glaxo wellcome egypt sae ph p south africa midrand glaxosmithkline south africa pty ltd ph p usa location associated undertaking business usa teterboro quest diagnostics inc clinical testing new jersey footnotes exempt provisions section companies amendment act ireland ii consolidated subsidiary undertaking accordance section companies act grounds significant influence iii incorporated netherlands iv incorporated republic ireland directly held wholly owned subsidiary glaxosmithkline plc business segment ph pharmaceuticals ch consumer healthcare business activity development e exporting f finance h holding company insurance marketing p production r research service full details group subsidiary associated undertakings attached companys annual return filed registrar companies glaxosmithkline financial record glaxosmithkline financial record quarterly trend unaudited analysis provided quarter group results sterling financial year analysis comprises statutory results business performance results pharmaceutical sales therapeutic area profit loss account statutory months q months q months q q cer cer cer cer cer cer cer turnover pharmaceuticals consumer healthcare total turnover cost sales selling general administrative expenditure research development expenditure operating costs trading profit pharmaceuticals consumer healthcare total trading profit operating incomeexpense operating profit share profitslosses joint ventures associated undertakings disposal businesses profit interest net interest payable profit ordinary activities taxation taxation profit ordinary activities taxation equity minority interests preference share dividends earnings profit attributable shareholders basic earnings per share p p p p p p p profit loss account business performance turnover pharmaceuticals consumer healthcare total turnover cost sales selling general administrative expenditure research development expenditure operating costs trading profit pharmaceuticals consumer healthcare total trading profit operating incomeexpense operating profit share profitslosses joint ventures associated undertakings profit interest net interest payable profit ordinary activities taxation taxation profit ordinary activities taxation equity minority interests preference share dividends adjusted earnings profit attributable shareholders adjusted earnings per share p p p p p p p glaxosmithkline financial record financial record glaxosmithkline pharmaceutical turnover total group pharmaceutical turnover usa q q q q q q q q cer cer cer cer cer cer cer cer cns cns depression depression seroxatpaxil seroxatpaxil wellbutrin wellbutrin migraine migraine imigranimitrex imigranimitrex naramigamerge naramigamerge lamictal lamictal requip requip zyban zyban respiratory respiratory flixotide serevent seretide flixotide serevent seretide seretideadvair seretideadvair flixotideflovent flixotideflovent serevent serevent flixonaseflonase flixonaseflonase ventolin ventolin becotide becotide antivirals antivirals hiv hiv combivir combivir trizivir trizivir epivir epivir retrovir retrovir ziagen ziagen agenerase agenerase herpes herpes valtrex valtrex zovirax zovirax zeffix zeffix antibacterials antibacterials augmentin augmentin zinnatceftin zinnatceftin fortum fortum amoxil amoxil metabolic metabolic avandiaavandamet avandiaavandamet vaccines vaccines hepatitis hepatitis infanrix infanrix oncology emesis oncology emesis zofran zofran hycamtin hycamtin cardiovascular urogenital cardiovascular urogenital coreg coreg levitra levitra avodart avodart zantac zantac total total pharmaceutical turnover includes copromotion income pharmaceutical turnover includes copromotion income glaxosmithkline financial record financial record glaxosmithkline pharmaceutical turnover europe q q q q pharmaceutical turnover international q q q q cer cer cer cer cer cer cer cer cns cns depression depression seroxatpaxil seroxatpaxil wellbutrin wellbutrin migraine migraine imigranimitrex imigranimitrex naramigamerge naramigamerge lamictal lamictal requip requip zyban zyban respiratory respiratory flixotide serevent seretide flixotide serevent seretide seretideadvair seretideadvair flixotideflovent flixotideflovent serevent serevent flixonaseflonase flixonaseflonase ventolin ventolin becotide becotide antivirals antivirals hiv hiv combivir combivir trizivir trizivir epivir epivir retrovir retrovir ziagen ziagen agenerase agenerase herpes herpes valtrex valtrex zovirax zovirax zeffix zeffix antibacterials antibacterials augmentin augmentin zinnatceftin zinnatceftin fortum fortum amoxil amoxil metabolic metabolic avandiaavandamet avandiaavandamet vaccines vaccines hepatitis hepatitis infanrix infanrix oncology emesis oncology emesis zofran zofran hycamtin hycamtin cardiovascular urogenital cardiovascular urogenital coreg coreg levitra levitra avodart avodart zantac zantac total total pharmaceutical turnover includes copromotion income pharmaceutical turnover includes copromotion income glaxosmithkline financial record financial record glaxosmithkline five year record record financial performance provided analysed accordance current reporting practice statutory results turnover turnover business segment profit taxation earnings profit attributable shareholders pharmaceuticals dividends consumer healthcare retained profit retained businesses healthcare services return capital employed per cent return capital employed calculated statutory profit taxation percentage average capital employed year pharmaceutical turnover therapeutic area merger restructuring disposal subsidiaries central nervous system manufacturing restructuring respiratory merger costs product divestments antibacterials items antivirals lossprofit taxation metabolic lossprofit attributable shareholders vaccines oncology emesis cardiovascular urogenital business performance results retained businesses others turnover continuing business rd expenditure divested products per cent sales trading profit per cent sales pharmaceutical turnover geographic area net interest payable usa profit taxation europe adjusted earnings profit attributable shareholders international asia pacific business performance primary performance measure used management presented excluding merger items japan integration restructuring costs disposal businesses management believes exclusion items provides better latin america reflection way business managed gives indication performance group terms elements middle east africa revenue expenditure local management able influence information provided addition statutory canada results prepared uk gaap given assist shareholders gain clearer understanding underlying performance business international increase comparability periods presented statutory results include items share statistics pharmaceutical turnover includes copromotion income earnings per share p dividends per glaxosmithkline share p glaxosmithkline shareholder consumer healthcare sales glaxo wellcome shareholder otc medicines smithkline beecham shareholder oral care dividends per glaxosmithkline ads nutritional healthcare glaxosmithkline shareholder continuing business glaxo wellcome shareholder smithkline beecham shareholder divested products dividends expressed terms glaxosmithkline shareads merger glaxo wellcome smithkline beecham th december shareholders adr holders received shares glaxosmithkline following ratios glaxo wellcome share glaxosmithkline share smithkline beecham share glaxosmithkline shares glaxo wellcome ads glaxosmithkline ads smithkline beecham ads glaxosmithkline adss glaxosmithkline ads represents glaxosmithkline shares glaxosmithkline financial record glaxosmithkline shareholder return net assets share price dividends fixed assets glaxosmithkline pays dividends quarterly board declared assets liabilities dividends follows net operating assets st january net debt high year dividends per share pence pence low year first interim paid rd july st december second interim paid nd october increasedecrease third interim paid th january capital employed fourth interim payable th april share capital share premium table sets middle market closing prices total reserves derived london stock exchange daily official list equity shareholders funds companys share price increased seven per cent glaxosmithkline expects similar increase total minority interests price st january dividend declared allocation quarterly st december compares increase ftse dividends rebalanced glaxosmithkline intends index per cent year increase first three interim dividends nine pence capital expenditure tangible fixed assets pence remainder total dividend year market capitalisation allocated fourth quarter dividend number employees market capitalisation glaxosmithkline st december usa billion date glaxosmithkline dividends adss europe fourth largest company market capitalisation ftse guide holders adrs tables set international index dividends paid per ads us dollars last five years asia pacific dividends adjusted uk tax credits less withholding tax japan smithkline beecham plc floating rate unsecured loan stock applicable translated us dollars applicable latin america exchange rates middle east africa loan stock listed exchange holders may since th april claims refunds tax credits canada require smithkline beecham plc redeem loan stock dividends uk tax authorities negligible benefit international par ie every loan stock held first business us shareholders day march june september december holders wishing year gsk gw sb redeem part loan stock complete manufacturing notice back loan stock certificate return selling registrar arrive least days relevant administration redemption date research development taxation dividends paid glaxo wellcome smithkline beecham adr general information concerning uk us tax effects number employees number permanent employed staff end financial period excludes employees holders expressed dividends per glaxosmithkline ads share ownership set 'taxation information employed managed glaxosmithkline contract basis shareholders ' dividend calendar fourth quarter exdividend date th february record date th february payable th april first quarter exdividend date th may record date th may payable st july second quarter exdividend date th august record date th august payable th september third quarter exdividend date rd november record date th november payable th january glaxosmithkline glaxosmithkline shareholder information share capital ordinary shares publications nature trading market glaxo wellcome pence per share company 's shares listed london stock exchange glaxosmithklines corporate responsibility report available ordinary shares company listed london fiscal periods th december high low secretariat companys head office website stock exchange th december shares also registrar wwwgskcom listed new york stock exchange form american company 's share register administered lloyds tsb depositary shares adss date registrars also provide following services annual general meeting us dollars per ads following table sets periods indicated high fiscal periods th december high low glaxosmithkline investment plan low middle market closing quotations pence queen elizabeth ii conference centre th may plan enables shareholders reinvest quarterly dividends shares london stock exchange derived daily broad sanctuary westminster andor make monthly investments company 's ordinary official list high low last reported sales prices us london swp ee shares using special dealing arrangement dollars adss new york stock exchange derived glaxosmithkline individual savings account annual general meeting company 's principal forum new york stock exchange composite tape smithkline beecham pence per share communication private shareholders addition formal glaxosmithkline individual savings account isa information relating share ads prices glaxo fiscal periods th december high low resolutions put meeting presentation taxefficient way invest company 's ordinary shares wellcome smithkline beecham prior date chief executive officer performance business merger also given glaxosmithkline corporate sponsored nominee future development opportunity questions corporate sponsored nominee provides facility board chairmen board 's committees glaxosmithkline pence per share shareholders hold shares without need share take questions matters relating committees fiscal periods th december high low us dollars per ads certificates shareholders ' details held main investors holding shares company nominee service quarter ended st march fiscal periods th december high low share register remain confidential arrange nominee service appointed february shareview service corporate representative proxy respect shareholding january shareview portfolio service provides shareholders order attend vote meeting december information investment company shareholders november adr holders wishing attend meeting must obtain proxy may register service wwwshareviewcouk october bank new york enable attend september meeting vote business transacted adr holders share dealing facility quarter ended st december may instruct bank new york shares hoare govett limited operates postal share dealing service quarter ended th september represented adrs voted completing companys ordinary shares enables investors buy sell quarter ended th june returning voting card provided bank new york shares competitive commission charges transactions quarter ended st march accordance instructions given executed settled pershing securities limited details quarter ended st december service together purchase sale forms may quarter ended th september financial reporting obtained telephoning quarter ended th june financial reporting calendar quarter ended st march smith barney part citigroup also offers share dealing service companys ordinary shares adss details announcement st quarter results th april quarter ended st december quarter ended th september service obtained contacting see contact details announcement nd quarter results th july quarter ended th june inside back cover announcement rd quarter results th october quarter ended st march provision details intended preliminary announcement annual results th february th st december invitation inducement engage investment activity publication annual reportreview march advice share dealing obtained stockbroker us dollars per ads independent financial adviser fiscal periods th december high low results announcements results announcements issued london stock quarter ended st march share price information exchange lse made available lse news service february share price information available company 's website time shortly afterwards issued media january wwwgskcom information also available ceefax teletext made available website usa sent december ft cityline calling securities exchange commission new york stock november calls charged p minute plus vat times exchange october september american depositary shares financial reports quarter ended st december company 's shares listed new york stock exchange company publishes annual report investor quarter ended th september form american depositary shares adss needing full detail report annual review quarter ended th june evidenced american depositary receipts adrs one available date publication quarter ended st march represents two ordinary shares glaxosmithkline website quarter ended st december quarter ended th september annual review sent shareholders date adr programme administrator quarter ended th june publication shareholders may also elect receive report adr programme administered bank new york quarter ended st march also provides following service writing companys registrars alternatively shareholders quarter ended st december may elect receive notification email publication quarter ended th september global buydirect financial reports registering wwwshareviewcouk quarter ended th june global buydirect direct ads purchasesale dividend copies previous financial reports available website quarter ended st march reinvestment plan adr holders printed copies obtained registrar uk th st december customer response center usa th february glaxosmithkline share capital glaxosmithkline taxation information shareholders analysis shareholdings information shareholders stamp duty number total total number uk stamp duty stamp duty reserve tax sdrt subject analysis shareholdings st december accounts accounts shares shares summary main tax consequences holders shares certain exemptions payable purchase shares holding shares adrs citizens residents uk usa rate per cent purchase price minimum set complete analysis possible tax charge stamp duty liability arises consequences purchase ownership securities intended general guide holders advised consult us shareholders advisers respect tax consequences purchase ownership shares adrs following summary certain uk taxation usa consequences state local tax laws usa federal income tax considerations may relevant us totals implications new ukus income tax convention holder shares adrs summary applies held shareholder holds shares adrs capital assets nominee companies statement based upon uk us tax laws practices citizen resident usa domestic corporation investment trust companies date report otherwise subject united states federal income taxation insurance companies new ukus income tax convention came force net income basis respect shares adrs individuals corporate bodies st march provisions new treaty apply uk resident uk uk tax purposes hold shares bny nominees limited tax purposes st april uk corporation tax th april purposes trade profession vocation carried totals uk income tax capital gains tax st may uk branch agency withholding taxes us tax purposes provisions bank new yorks holding held bny nominees limited represents companys adr programme whereby ads new treaty apply st may withholding taxes taxation dividends represents two ordinary shares p nominal value st january us taxes however holders shares gross amount dividends received including amounts th february number holders record shares usa holdings shares adrs ability elect continue use respect associated tax credit uk withholding tax treated number registered holders adrs holdings adrs certain shares adrs provisions previous treaty months following foreign source dividend income us tax purposes held brokers nominees result number holders record registered holders usa representative new treatys entry force election must made eligible dividend received deduction allowed us number beneficial holders residence beneficial holders advance first event new treaty would apply corporations dividends adrs payable us dollars dividends shares payable sterling dividends paid us holders adrs generally treated owners control company underlying shares purposes current usauk pounds sterling included income us dollar amount calculated reference exchange rate day far known company directly indirectly owned controlled one corporations government double taxation conventions relating income gains dividends received holder uk taxes withheld company know arrangements operation might result change control company income tax convention estate gift taxes estate gift dividend distributions eligible credit holders tax convention purposes us internal revenue us federal income tax liability subject generally applicable substantial shareholdings code amended code limitations holder 's tax position determine th february company received notification following interest three per cent shares following analysis deals dividends paid th april whether effective use made special us foreign tax advance corporation tax act abolished credits us tax liability bny nominees limited holds shares representing per cent shares held behalf holders american depositary receipts evidence american depositary shares uk shareholders th april rate tax credits reduced one ninth act abolished claims refunds tax credits legal general investment management limited holds shares representing per cent taxation dividends dividends paid date negligible benefit barclays plc holds shares representing per cent th april rate tax credits reduced one us shareholders ninth result compensating reductions rate tax far known company person owner three per cent shares company dividend income increase tax borne uk taxation capital gains resident individual shareholders tax credits however generally us holders subject uk capital gains tax directors officers longer repayable shareholders tax liability less subject us tax capital gains realised sale associated tax credit disposal shares adrs interests directors officers company defined companies act share options company given remuneration report pages taxation capital gains estate gift taxes uk shareholders may liable uk tax gains estate gift tax convention us shareholder exchange controls limitations affecting security holders disposal shares adrs may also entitled generally subject uk inheritance tax currently uk laws decrees regulations restricting import export capital affecting remittance dividends indexation relief taper relief sales indexation relief payments holders companys shares nonresidents uk limitations relating calculated market value shares st march stamp duty nonresidents uk english law companys memorandum articles association right holder cost subsequent purchases date uk stamp duty sdrt subject certain exemptions vote respect companys shares purchase indexation relief individual shareholders payable issue transfer shares adr custodian ceased th april taper relief available individual depository rate per cent price issued documents display shareholders hold deemed hold shares least amount consideration provided transferred three years sold sale value transferred consideration documents referred annual report available inspection registered office company sdrt would payable transfer adr uk inheritance tax stamp duty payable transfer adr individual shareholders may liable inheritance tax provided instrument transfer executed remains transfer shares adrs tax may charged amount times outside uk stamp duty transfer value shareholder 's estate reduced adr would payable rate per cent result transfer way gift disposal less consideration transfer sale underlying shares full market value gift disposal subject would result liability uk stamp duty case may uk inheritance tax us estate gift tax estate gift sdrt rate per cent minimum charge tax convention would generally provide tax paid usa stamp duty liability arises credited tax payable uk glaxosmithkline glossary terms contact details terms used annual report us equivalent brief description internet accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay information investors company charging payment tax us equivalent tax depreciation available glaxosmithklines corporate website advance corporation tax act advance payment uk tax made dividends paid direct us wwwgskcom equivalent american depositary receipt adr receipt evidencing title ads glaxosmithkline adr represents two ordinary head office registered office shares glaxosmithkline plc american depositary shares adss ordinary shares registered new york stock exchange great west road calledup share capital ordinary shares issued fully paid brentford middlesex tw gs cer growth growth constant exchange rates tel combined code guidelines required listing rules financial services authority address principal aspects corporate governance united kingdom united states america company glaxosmithkline plc investor relations investor relations creditors accounts payable great west road one franklin plaza currency swap exchange two currencies coupled subsequent reexchange currencies brentford po box agreed exchange rates dates middlesex tw gs philadelphia pa debtors accounts receivable tel tel toll free fax tel outside usa defined benefit plan pension plan specific employee benefits often called final salary scheme fax defined contribution plan pension plan specific contributions level pension dependent upon growth registrar pension fund lloyds tsb registrars adr programme administrator causeway bank new york derivative financial instrument financial instrument derives value price rate underlying item worthing shareholder relations diluted earnings per share diluted income per share west sussex bn da po box dividend cover profit attributable shareholdersnet income divided dividends payable shareholders wwwshareviewcouk church street station earnings per share basic income per share new york ny general enquiries annual report orderline wwwadrbnycom employee share ownership trusts trusts established group satisfy share based employee incentive plans corporate nominee service tel toll free equity shareholders funds aggregation shares reserves owned shareholders us equivalent tel inside uk tel outside usa shareholders equity tel outside uk customer response center finance lease capital lease shareholder investment plans tel toll free dividend reinvestment enquiries freehold ownership absolute rights perpetuity tel inside uk corporate share dealing facility gearing ratio net debt percentage shareholders funds net debt minority interests tel outside uk ordinary holders smith barney group glaxosmithkline plc subsidiary undertakings tel outside uk employees attn gsk services hedging reduction risk normally relation foreign currency interest rate movements state street making offsetting commitments monthly savings plan enquiries th floor tel inside uk intangible fixed assets assets without physical substance brands licences patents knowhow boston tel outside uk marketing rights purchased outside parties tel toll free isa enquiries tel outside usa interest cover number times profit interest exceeds net interest payable tel inside uk fax interest payable interest expense tel outside uk thetaylorgroupsmithbarneycom interest receivable interest income glaxo wellcome smithkline beecham corporate peps nonequity minority interest preference shares issued subsidiary outside parties share centre limited preference shares shares issued varying dividend rates treated outside interests oxford house profit income oxford road aylesbury profit loss account reserve retained earnings bucks hp sz profit attributable shareholders net income tel share capital ordinary shares capital stock common stock issued fully paid corporate share dealing facility share option stock option smith barney share premium account additional paidup capital paidin surplus distributable attn gsk services citigroup centre level shares issue shares outstanding canada square canary wharf statement total recognised gains losses statement comprehensive income london e lb stocks inventories tel subsidiary undertaking affiliate glaxosmithkline holds majority shareholding andor exercises control fax thebalaesgroupcitigroupcom tangible fixed assets property plant equipment turnover revenue printed midas press uk paper used production document made pulp harvested sustainable forests also using sawmill residues forest thinnings elemental chlorinefreedo feel better live longer improving performance ever day annual report troper launna enilkhtimsoxalg wwwgskcom annual review